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Summary
Ischaemia-reperfusion injury, sustained when the blood and oxygen supply is removed and 
then reinstated, is a common cause of cardiac tissue damage and therefore a popular area of 
scientific research.
It is commonly thought that the mitochondria play an important role in mediating ischaemia- 
reperfusion injury. Particular attention has been focused on the mitochondrial permeability 
transition pore. This has many times been shown to open only during the reperfusion phase 
disrupting the mitochondrial transmembrane potential and therefore the synthesis of ATP.
This study endeavours to examine the activity of the pore in rat neonatal primary 
cardiomyocytes during cell death. Models of apoptotic and necrotic cell death are established, 
as both have been implicated in ischaemia-reperfusion injury. An in vitro model of ischaemia- 
reperfusion injury is set up and an in vivo model of ischaemia-reperfusion injury is also 
examined.
Many studies have shown that inhibition of cyclophilin D can successfully block the opening of 
the mitochondrial pore. In this study, the cyclophilin inhibitor cyclosporin A is applied to 
determine the importance of cyclophilin D as an attenuator of ischaemia-reperfusion injury. The 
resulting effect on cell viability is analysed by various assays. Changes in the activity of the 
mitochondrial permeability transition pore are also monitored using a fluorescent mitochondrial 
transmembrane potential-sensitive dye.
A kinetic assay is established to measure the peptidyl prolyl cis-trans-isomerase activity of 
cyclophilin D, which is believed to have a role in regulation of the pore. Additionally ATP 
synthesis is measured by a luciferase-based assay and free radical production is monitored 
using a radical-sensitive dye during cell death. The effect of cyclosporin A on all measured 
parameters is examined.
The results presented in this study show that the importance of the mitochondrial permeability 
transition pore can vary widely according to the prevailing conditions. However, the data 
obtained in both isolated cardiomyocytes and cardiac tissue broadly uphold the concept of the 
major impact of mitochondrial permeability transition pore induction during ischaemia- 
reperfusion injury and strongly support the hypothesis of a significant role for cyclophilin D in 
the molecular mechanism of the pore.
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Chapter 1 Introduction
1: Introduction
1.1 Ischaemia-reperfusion injury in the heart -  the clinical problem 
Ischaemia-reperfusion injury is a well-established clinical problem sustained when the supply 
of blood and oxygen to the tissue is suspended (ischaemia) and then reinstated (reperfusion). 
It occurs in situations such as myocardial infarction, open-heart surgery and organ 
transplantation and is therefore a common cause of damage to solid tissues and a popular 
area of scientific research.
Restoration of the oxygen supply would logically be expected to limit tissue damage but it has 
long been recognised that major tissue damage can occur during the initial reperfusion phase 
(1-4). This may present a major problem following situations such as heart surgery or drug- 
induced thrombolysis after a myocardial infarction, as it could potentially result in patient death 
despite the procedure being otherwise successful.
- 12-
Chapter 1 Introduction
1.2 Cell death during ischaemia-reperfusion injury -  apoptosis or necrosis?
The two widely recognised forms of cell death are apoptosis and necrosis. Kerr, Wyllie and 
Currie first described apoptosis, also known as programmed cell death, as a physiological 
process in 1972 (5). Since then it has also gained recognition as a factor in many pathological 
situations, fuelling a vast amount of research into apoptotic inducers and signalling pathways.
Two types of signalling pathway have been identified for apoptosis -  the ‘extrinsic’ and 
‘intrinsic’ pathways. Extrinsic signalling pathways involve the activation of what are termed 
‘death receptors’ on the surface of the cell and allow the cell to respond to its external 
environment (illustrated in Figure 1). These receptors, a subset of the tumour necrosis factor 
(TNF) receptor family, include TNFR1, TNF-related apoptosis-inducing ligand (TRAIL) receptor 
1 and 2 and the Fas receptor. These are activated by binding of the appropriate ligand, which 
induces receptor trimerization and the recruitment and binding of other proteins to the 
intracellular ‘death domain’ (DD) possessed by these receptors. This results in the formation of 
a large complex known as the ‘death-inducing signalling complex’ (DISC) and the recruitment, 
oligomerization and activation of members 8 and 10 of the aspartic acid specific cysteine 
protease family (reviewed in 6), commonly known as caspases and the most important 
effectors of apoptosis discovered to date.
- 13-
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Death
Pro-caspase 8/10
Activated caspase 8/10
Proteolytic caspase cascade
1
Cleavage of caspase substrates
Figure 1: Extrinsic signalling through death receptors leads to activation of the apoptotic 
pathway. Binding of ligands to death receptors in the plasma membrane initiates a sequence 
of events culminating in morphological restructuring of the cell by activated caspase 
substrates. Thus the cell is able to response to unfavourable changes in the external
environment.
receptor
Ligand
S
- 1 4 -
Chapter 1 Introduction
The intrinsic signalling pathway occurs in response to an unfavourable intracellular 
environment and is most usually initiated from the mitochondria by the release of cytochrome c 
from the intermembrane space (illustrated in Figure 2). This may happen through the opening 
of a pore in the mitochondrial membranes termed the mitochondrial permeability transition pore 
(MPTP). Release of cytochrome c has frequently been demonstrated in conjunction with the 
opening of this pore (7-9), but it has also been demonstrated that apoptosis can proceed 
without any decline in mitochondrial membrane potential that is associated with induction of 
the pore (10-13), so the significance of cytochrome c release from the MPTP is unclear. An 
alternative explanation is that other proteins exhibiting pore-like activity, such as members of 
the Bcl-2 family, are responsible for regulating the release of cytochrome c. In particular, Bax 
and Bak are known to have a strong pro-apoptotic action, most probably through 
oligomerization to form pores in the outer mitochondrial membrane (14,15), and possibly in 
conjunction with some elements of the MPTP (16,17). It is known that other family members 
such as Bcl-2 and Bcl-xL are cytoprotective (14,15,18), but the exact mechanisms are yet to 
be elucidated. Upon release into the cytosol, cytochrome c binds to apoptosis-activating factor 
(Apaf)-1. In the presence of dATP these form a complex that recruits and activates caspase 9 
(19) that then dissociates from the complex in order to cleave caspase 3 (20).
- 15-
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Bax/Bak MPTP
Cytochrome c
Pro-caspase 9
Activated caspase 9
Proteolytic caspase cascade
Cleavage of caspase substrates
Figure 2: Intrinsic signalling, usually through the mitochondria, activates the apoptotic pathway. 
Release of cytochrome c through Bax/Bak and possibly through the mitochondrial permeability 
transition pore (MPTP) initiates a sequence of events culminating in morphological 
restructuring of the cell by activated caspase substrates.
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Fourteen mammalian forms of caspases, the major executioners of apoptosis have so far been 
identified (reviewed in 21,22). Those whose role in apoptosis is known fall into 2 groups. 
Apoptosis initiators, comprising caspases 2,8,9 and 10, contain either a caspase recruitment 
domain (CARD) and respond to activation of extrinsic pathways or a death effector domain 
(DED) and respond to initiation of the intrinsic signalling pathway. Both types recruit, cleave 
and activate the apoptosis effector caspases, comprising caspases 3,6 and 7. Activated 
effector caspases can in turn cleave initiator caspases, creating a positive feedback loop. 
Besides this, other caspases are activated in a highly ordered proteolytic cascade (23), and 
other caspase substrates are cleaved in order both to implement the process of apoptosis and 
to prevent its inhibition.
Thus caspases activate gelsolin that, in turn, cleaves actin (24), activate DNA fragmentation 
factor that degrades DNA (25) and directly cleave structural proteins such as fodrin (26), 
vimentin and nuclear lamins A and B (27). A number of kinases are also cleaved, although the 
effects of these are less clear excepting a few specific cases such as the activation of MEKK-1 
that can affect the rate of apoptosis through regulation of JNK signalling cascades (28,29).
To overcome inhibition of apoptosis, inhibitors of apoptosis proteins (lAPs) that regulate 
caspase activity are cleaved and inactivated to allow uninhibited caspase function (27), along 
with the DNA repair associated poly-ADP ribose polymerase (PARP) (30) in order to allow 
DNA fragmentation.
Although caspases are generally regarded to be the most significant effectors of the apoptotic 
process, some other proteins have been identified that may have a significant role. Calpains 
for example, have some substrates in common with the caspases and may be involved in the 
intrinsic signalling pathway (reviewed in 31). In addition, a number of regulators and inhibitors 
of apoptosis have been identified including p53 (reviewed in 32) and various kinases such as
- 17-
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phosphatidylinositol 3’-kinase (PI3K), mitogen-activated protein kinases (MAPK) and protein 
kinase A and C (reviewed in 33).
Ultimately, the substrates of caspase and other effectors restructure the dying cell in a well- 
known and clearly defined sequence of events that include chromatin condensation, nuclear 
DNA fragmentation, cell shrinkage, the dismantling of cell organelles and the formation of 
‘apoptotic bodies’. Neighbouring cells or cells of the immune system then engulf these bodies, 
thus avoiding spillage of enzymes and a consequential inflammatory response.
In contrast, necrosis is an uncontrolled event. One of the earliest visible signs of necrosis is the 
swelling and disruption of the mitochondria, as opposed to apoptosis where the mitochondria 
typically remain structurally normal. Necrosis does not proceed by any defined series of events 
and invariably results in the integrity of the plasma membrane being compromised, allowing 
the release of damaging enzymes into the extracellular environment.
The issue of the occurrence of apoptosis and necrosis in cardiac ischaemia-reperfusion injury 
has been the subject of much debate. The suggestion that apoptosis or a variation of the 
pathway may have a role in ischaemia-reperfusion injury has excited much interest in the 
process of cell death in this situation. Since the classically described process of apoptosis 
proceeds by a distinct and controlled pathway, it offers many more opportunities for 
intervention and inhibition than necrosis. This has led to the hope that the tissue injury 
occurring during ischaemia and reperfusion may potentially be prevented or at least 
substantially reduced through the inhibition of the apoptotic process.
The classical morphological symptoms of apoptosis have been described many times in 
cardiac cells (34-37). In addition, many of the biochemical markers of the apoptotic process, 
such as involvement of caspases (37-40), release of cytochrome c from the mitochondria (40-
- 18-
Chapter 1 Introduction
42) and the appearance of DNA fragmentation (34,43,44) have been reported. Apoptosis has 
also been identified as a significant factor in a wide variety of cardiac disease states including 
idiopathic dilated cardiomyopathy (34,45), acute myocardial infarction (46,47), hypertension 
(48-50) and intractable congestive heart failure (51).
In the case of ischaemic injury, apoptosis has been reported in simulated in vitro ischaemia- 
reperfusion and isolated perfused organs (52), in vivo animal studies (44,53,54) and also in 
post-mortem human hearts (34,45,47). Conversely, there are also groups who have shown 
only the involvement of necrosis or an extremely insignificant occurrence of apoptosis in these 
very same situations (37,55-57).
The main controversy surrounding this issue is the methods used to detect apoptosis. One of 
the most frequently employed methods is TUNEL (terminal deoxynucleotidyl transferase- 
mediated dUTP nick end labelling) staining, a technique relying on histochemical detection of 
the double-strand DNA breaks that are an accepted hallmark of apoptosis. However, it has 
been shown that TUNEL staining can also detect single-strand DNA breaks, which may occur 
during apoptosis or necrosis and also viable cells undergoing DNA repair (58). Additionally 
there are an increasing number of reports of cells displaying characteristics of both apoptosis 
and necrosis, such as histologically apoptotic cells with no DNA fragmentation (59) and cells 
that can be rescued from apparent necrosis by caspase inhibition (58). While this may be due 
to errors in detecting and defining apoptosis, it is also becoming increasingly likely that 
apoptosis and necrosis are simply two extreme examples of the process of cell death. The 
actual pathway by which the cell dies may actually be a combination of both recognised 
processes, with factors including the availability of ATP energy determining precisely how cell 
death will be executed. A defining characteristic of studies in these areas is that severe 
ischaemic conditions result in necrotic cell death whereas milder forms of ischaemia tend to 
induce apoptosis. This is supported by more recent studies demonstrating that the main area
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of cardiac infarct is subjected mostly to necrotic cell death whereas myocytes on the edge of 
the infarct area and those somewhat distant from the area of main damage die through the 
slower process of apoptosis (53,60). It is also now considered that apoptosis may be a vital 
element of the cardiac remodelling that can occur subsequent to ischaemic damage (53).
Several studies have now demonstrated that the availability of ATP may be a crucial factor 
determining whether apoptosis can be implemented or whether the cell will succumb to 
necrosis (61-63). As the majority of ATP is generated by the mitochondria located respiratory 
chain, this immediately suggests an important role for the mitochondria in cell death.
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1.3 The mitochondria
1.3.1 Structure and function of the mitochondria
The mitochondria are frequently described as the powerhouse of the cells, as they produce the 
vast majority of the energy required to drive essential intracellular reactions via the production 
of ATP. The outer mitochondrial membrane that encloses the mitochondria is non-selectively 
semi-permeable, allowing all molecules of 5000 Daltons or less to readily pass into the 
intermembrane space. The highly specialised inner mitochondrial membrane is highly 
convoluted and forms a series of inward projections known as cristae. This membrane is 
virtually impermeable but contains transport proteins that selectively regulate the passage of 
specific metabolites and inorganic ions in and out of the matrix space that it encloses. Also 
contained in the inner mitochondrial membrane is ATP synthase and the proteins that carry out 
the reactions of the respiratory chain. The cristae provide a greater surface area for the 
containment of these various proteins, and mitochondria taken from cardiomyocytes contain 
more cristae than mitochondria from other sources due to the greater requirement for ATP in 
the constantly contracting cardiac myocytes.
A small proportion of ATP is produced in the cytosol by glycolysis, but pyruvate generated from 
this process is subsequently actively transported into the mitochondrial matrix where the 
tricarboxylic acid (TCA) cycle occurs. The high-energy electrons that result from this process 
are then passed along the inner mitochondrial membrane-bound components of the respiratory 
chain generating the electrochemical gradient. This in turn drives the process of oxidative 
phosphorylation that produces the majority of ATP.
1.3.2 The importance of ATP
ATP consists of adenosine, ribose and 3 phosphate groups. The terminal phosphate groups 
are highly reactive so that their hydrolysis or transfer to another molecule is an extremely
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thermodynamically favourable reaction. Specialised enzymes can then couple this reaction to 
other, energetically unfavourable cellular reactions. For this reason ATP is the principle carrier 
of chemical energy in the cell. Reactions that are ATP-dependent include protein synthesis, 
active transport across membranes and muscle contraction.
1.3.3 The respiratory chain
The process of the TCA cycle based in the mitochondrial matrix results in the production of 
high-energy electrons contained in FADH2 and NADH. FADH2 is membrane bound and feeds 
electrons directly into one of the protein complexes of the respiratory chain, whereas NADH 
passes electrons to the components of the respiratory chain via random collisions with the 
membrane-bound protein carriers.
There are a large number of membrane-bound electron carriers in the respiratory chain. These 
are associated into 4 complexes - NADH dehydrogenase (complex I), succinate 
dehydrogenase (complex II), ubiquinol-cytochrome c reductase (complex III) and cytochrome 
oxidase (complex IV), with coenzyme Q and cytochrome c acting as electron carriers between 
the complexes. Electrons are passed along the respiratory chain through electron carriers with 
increasingly greater redox potentials (affinity for electrons) until they are eventually passed to 
oxygen and combined with 2H+ to form H2O.
The transfer of electrons between the complexes of the respiratory chain is an energetically 
favourable reaction that is coupled to the unfavourable reactions required to pump protons out 
of the matrix into the intermembrane space. This movement of protons creates an electrical 
and pH gradient due to the higher concentration of H+ outside the inner mitochondrial 
membrane. This electrochemical gradient creates a proton-motive force that is measurable at 
approximately -180mV and is generally referred to as the mitochondrial transmembrane 
potential or mA'F. Protons naturally flow down this gradient back into the matrix. They
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penetrate the inner mitochondrial membrane by passing through ATP synthase, a large protein 
complex that utilises the energy to synthesize ATP from ADP and inorganic phosphate (Pi). 
The whole process of generating energy through the respiratory chain to drive ATP synthesis 
is known as oxidative phosphorylation and is essential for the viability of the cell.
1.3.4 Regulation of calcium
Ca2+ is a ubiquitous and crucially important intracellular signalling agent in all mammalian cells. 
Extracellular levels of Ca2+ are very high compared to the low cytosolic concentration, thus 
creating a large gradient across the cytosolic membrane. The activation of a Ca2+-sensitive 
receptor causes entry of Ca2+ into the cytosol triggering Ca2+ responsive processes in the cell. 
In order for this mechanism to function successfully, Ca2+ must be continuously removed from 
the cytosol to maintain a low concentration. This is achieved largely through the action of Ca2+ 
transporters located in the membranes of the cell and the endoplasmic reticulum. These 
transporters pump Ca2+ across the membrane, utilising the energy of ATP hydrolysis so that 
Ca2+ can be moved against even a large gradient. In addition some cells including 
cardiomyocytes also contain an antiporter that can move Ca2+ out of the cell in exchange for 
Na+. This mechanism however, has a relatively low affinity for Ca2+ and comes into effect only 
under conditions of greatly increased cytosolic Ca2+ concentration. A further mechanism for the 
removal of cytosolic Ca2+ is contained in the membrane of the mitochondria. This low-affinity, 
high capacity uniporter transports ions down its electrochemical gradient into the mitochondrial 
matrix but is dependent upon the mitochondrial transmembrane potential for its activity. It has 
been demonstrated that the uniporter cannot function in the absence of high mA'F, even in the 
presence of a high Ca2+ gradient (64). Ca2+ is returned into the cytoplasm largely via the Na+- 
Ca2+ ion exchanger except in exceptional circumstances as will be further discussed. There is 
now a substantial body of evidence that the mitochondria are almost invariably involved in
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cellular Ca2+ signalling, notably in the control of cellular metabolism through upregulation of the 
TCA cycle. Although the majority of this work has been in non-cardiac cell types (65-67), there 
are also some publications demonstrating the ability of mitochondrial Ca2+ to influence cardiac 
cell metabolism (68-70) and various models of Ca2+-dependent cardiomyocyte metabolism 
have now been proposed (71-73).
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1.4 The Mitochondria in Ischaemia
1.4.1 Ischaemic conditions in the cell
As detailed above, the presence of oxygen in the cell is essential for the correct functioning of 
the respiratory chain. During ischaemia the lack of oxygen forces the cells to rely only on 
glycolysis for the production of ATP. This naturally results in the build-up of lactic acid that in 
turn inhibits glycolysis (74) exacerbating the depletion of adenosine nucleotides and the 
corresponding increase in inorganic phosphates and creating an acidic pH.
Intracellular pH is regulated by the active transport of ions across the plasma membrane, 
largely by ATP-dependent transporters and ion exchangers. H+ is driven out of the cell in 
exchange for Na+. In an ischaemic environment, this accumulation of Na+ combined with the 
effects of oxidative stress (75), render the Na+-Ca2+ ion exchanger unable to remove Ca2+ from 
the cytosol (76,77). In addition, the depleted levels of ATP impair the activity of the ATP- 
dependent Ca2+ transporter (78,79) resulting in the accumulation of cytosolic Ca2+ associated 
with ischaemia (80,81).
1.4.2 Inhibition of the mitochondrial respiratory chain and generation of superoxide
The effect of ischaemia on the respiratory chain has been studied in mitochondria isolated 
from a variety of animal models of ischaemic injury, including a number of cardiac studies. It 
has been found that ischaemia causes significant inhibition of complexes I (82-87), II (85, 
87)and III (85), and also mitochondrial ATPase (complex V) (83). Low pH is one of the cited 
causes of respiratory chain enzyme inhibition and has been demonstrated for complex I (84). 
Complex IV however appears to be unaffected by ischaemia (85).
Inhibition of respiratory chain complexes inevitably leads to a fall in ATP production and 
impairment of ATP-dependent ion pumps as well as compromising other important ATP- 
dependent reactions.
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Ischaemic inhibition results in the respiratory chain complexes becoming reduced (88, 89) as 
they harbour electrons instead of passing them along the chain to O2 as normal. This results in 
the production of free radicals as the complexes of the respiratory chain randomly pass the 
excess electrons to residual oxygen creating superoxide radicals (90). A number of studies of 
simulated ischaemia in both isolated cells and whole tissue have shown that the major sites of 
superoxide production appear to be complexes I and III (91-94). This concurs with the finding 
that these complexes suffer the most severe inhibition during ischaemia (95-99).
An extremely important factor in the generation of superoxide by the respiratory chain is the 
concentration of residual oxygen in the cardiac tissue. It has in fact been shown that removal 
of oxygen prevents the generation of free radicals and therefore limits damage (100).
Another frequently cited source of free radicals in cardiomyocytes is xanthine oxidase. 
However, there is apparently extremely little detectable xanthine oxidase activity in human 
cardiac tissue so this system may not be an important generator of free radicals from a clinical 
point of view (101).
It has long since been established that various reactions in the cell produce free radicals under 
normal physiological conditions, including the respiratory chain. Therefore cells contain 
important defence mechanisms against free radicals. Superoxide radicals are generally 
degraded to produce H2O2 and O2, a reaction that is catalysed by superoxide dismutase (SOD) 
or by spontaneous dismutation. In the mitochondria the manganese-associated form, MnSOD, 
performs this function. During ischaemia however, free radicals are generated at a higher than 
normal level and moreover, a number of studies have shown widespread inhibition of 
mitochondrial enzymes during ischaemia, including MnSOD (102-105). This results in the 
production of free radicals at a faster rate than can be effectively removed, leading to further 
suppression of oxidative phosphorylation (106).
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1.5 The Mitochondria in Reperfusion
1.5.1 Generation of hydrogen peroxide and hvdroxvl radicals
As discussed in the previous section, under ischaemic conditions the complexes of the
respiratory chain are inhibited and become reduced resulting in the donation of electrons to
residual oxygen to produce superoxide.
It was shown, as early as the 1970s, that superoxide is merely the precursor of more potent 
free radical products. Although deliberately generated superoxide has been shown to have 
extremely toxic effects on numerous occasions, hindsight has attributed this to the action of 
hydroxyl radicals (107). Many studies have since shown that scavengers of the various 
precursors of hydroxyl radicals can significantly attenuate ischaemia-reperfusion injury in a 
wide variety of situations. Although most studies have applied free radical scavengers 
continuously throughout the period of ischaemia as well as reperfusion (108-110), a study by 
Ambrosio and colleagues applied SOD only during reperfusion. This study in an open-chest 
dog model, found that application of SOD resulted in a significant reduction in infarct size 
(111). This highlights the significance of the burst of free radical generation observable upon 
reperfusion that is presumably due to the donation of electrons to the restored oxygen.
There are now reports also demonstrating significant generation of H2O2 and hydroxyl radicals 
following ischaemia-reperfusion injury that may be attributable to the degradation of 
superoxide radicals produced during ischaemia (90,100). As the superoxide is present in 
greater amounts than normal, an excess of H2O2 is consequently produced. Under 
physiological conditions, H2O2 is degraded to safe, non-reactive products by peroxidases and 
catalases. However during ischaemia-reperfusion injury, free radicals are produced in a 
quantity that eclipses the activity of the endogenous antioxidant defences (92), an effect that is 
exacerbated by the aforementioned ischaemic suppression of mitochondrial enzymatic activity.
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This combination of circumstances allows the natural breakdown of H2O2 to produce hydroxyl 
radicals. This reaction is especially likely to occur in the mitochondria due to the presence of 
iron-based compounds in the respiratory chain (112) that may encourage the reduction of H2O2 
via the Fenton equation:
Fe2+ + H202 --------- ► Fe3++ OH~ + OH* (hydroxyl radical)
Hydroxyl radicals are extremely reactive and can cause widespread damage by attacking 
membranes, DNA and other essential cell components. Unlike superoxide and H2O2 no 
specific endogenous enzymes are produced to scavenge them since under physiological 
circumstances the generation of hydroxyl radicals is avoided by the catalytic conversion of 
H2O2 to non-reactive products.
1.5.2 Uptake of calcium
During ischaemia excess Ca2+ accumulates in the cytoplasm as detailed above. Upon 
reperfusion the depleted levels of ATP prevent Ca2+ being removed by ATP dependent ion 
transportation (113). Instead, the pathologically high levels of cytosolic Ca2+ cause activation of 
the Ca2+ uniporters, which take up Ca2+ into the mitochondrial matrix (80,81,114). Due to the 
multiple Ca2+ binding sites contained in the matrix, mitochondria are able to effectively buffer 
Ca2+ and accumulate large quantities before a rise in free matrix Ca2+ can be observed (80,
81). Eventually however, the rise in matrix Ca2+ is sufficient to cause efflux of Ca2+ from the 
mitochondria through the process of mitochondrial permeability transition.
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1.5.3 Onset of mitochondrial permeability transition
During reperfusion, the sudden increase in oxygen combined with reduced respiratory chain 
complexes produces free radicals as described above. This ischaemic inhibition of the 
respiratory chain also results in depleted levels of ATP and a consequent accumulation of 
inorganic phosphates. All of these circumstances are known to contribute to the onset of 
mitochondrial permeability transition, induced by the high matrix Ca2+ concentration detailed 
above.
During mitochondrial permeability transition (MPT), the inner mitochondrial membrane that is 
normally selectively permeable only by active transport, becomes non-specifically permeable 
to molecules of < 1500 Daltons. As early as 1979, Hunter and Haworth first proposed the 
existence of a channel to account for the phenomenon of MPT (115,116). This theory was 
subsequently lent much weight by the potent inhibition of MPT by cyclosporin A (CsA) 
described by Crompton and co-workers (117).
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1.6 The mitochondrial permeability transition pore
This pore has since been termed the mitochondrial permeability transition pore (MPTP) and 
has come under intense study due to its reported influence on both necrotic and apoptotic cell 
death (118-122). It is held that during necrosis, the levels of ATP are too low to sustain cell 
functionality and the MPTP opens irreversibly releasing Ca2+ into the cytosol. The mitochondria 
become swollen and disrupted and functionally collapse leading to the death of the cell (123, 
124). During this process the plasma membrane becomes compromised and damaging 
intracellular enzymes are released into the surrounding tissue potentially triggering an 
inflammatory response. Apoptosis however is an energy-requiring process, which can only 
operate in conditions of high ATP (61,62). Reduction of the transmembrane potential has 
been demonstrated in many systems and this is considered by many to be due to the opening 
of the MPTP (125,126). However, it is thought that this may be a transient, reversible opening 
since ATP synthesis is necessary for apoptosis to be fully implemented. Opening of the pore 
may allow the release of pro-apoptotic factors such as pro-caspase 3, apoptosis-inducing 
factor and cytochrome c from the intermembrane space. Alternatively this may occur via an 
alternative method, for example the proposed release of cytochrome c via Bax (15).
As mentioned previously, both apoptotic and necrotic cell death have been cited as major 
factors in ischaemia and reperfusion induced damage suggesting a role for the MPTP. 
Additionally, many studies have now produced clear evidence for the importance of the MPTP 
in reperfusion in its own right. Passage of molecules through the mitochondrial membranes 
consistent with the induction of the MPTP has frequently been observed upon reperfusion 
(127-130), demonstrating that MPTP is almost certainly a significant pathological event.
Studies with CsA, which inhibits the MPTP, have served to confirm this hypothesis. CsA offers 
potent protection against simulated ischaemia in both isolated mitochondria (131,132) and
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cultured cells (132-134) and perhaps most tellingly, has also been shown to protect a variety of 
whole tissues (133,135-138) from reperfusion injury, indicating that the process is not merely 
an in vitro artefact. In addition, various reports have shown that protection against reperfusion 
related tissue damage is only provided by analogues of CsA that block the MPTP in isolated 
mitochondria (139,140). This gives strong evidence that it is the direct influence of CsA on the 
MPTP that is the crucial factor as opposed to other effects such as the ability of complexes of 
CsA and cyclophilin (CyP) to bind calcineurin.
The effect of MPTP induction has been studied experimentally in a variety of models of cell 
death. Many of the publications on this subject have taken the release of cytochrome c into the 
cytoplasm as evidence for the involvement of permeability transition in the cell death process 
(7,141). Although release of cytochrome c has previously been accepted as proof of the 
opening of the MPTP, recent studies have shown that release may occur independently of a 
reduction in mitochondria transmembrane potential (10) and therefore be achieved without any 
disruption to mitochondrial function (11). However, many groups studying the effect of the 
MPTP have done so using more direct assays of mitochondrial viability. Measurement of the 
transmembrane potential has shown a reduction during apoptosis induced by cytotoxic T 
lymphocytes (142), and treatment of primary thymocytes with MPT inducers such as carbonyl 
cyanide m-chlorophenylhydrazone (CCCP) and protoporphyrin IX produced some of the 
classical signs of apoptosis along with reduction of transmembrane potential (119). 
Furthermore, some groups have developed the methodology to directly measure the opening 
of the MPTP as opposed to merely measuring mAvF. These assays have largely been based 
on the inability of certain substances to enter the mitochondria unless the pore has opened. 
Crompton and colleagues use of radiolabelled sucrose to track the permeability of the inner 
mitochondrial membrane produced some of the earliest convincing evidence for a non-specific
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mitochondrial pore (127,143,144). Halestrap and co-workers used entry of [3H]-DOG 
(deoxyglucose) into the mitochondria of isolated, perfused hearts to show that the MPTP 
opens only during the reperfusion phase of ischaemia-reperfusion injury (130). Additionally, 
Lemasters and colleagues have developed the use of the fluorochrome calcein as an 
assessment of pore opening during tumour necrosis factor-a and simulated ischaemia- 
reperfusion injury (145), although this protocol has proved to be somewhat controversial as will 
be further discussed (see Chapter 8.1.2). Using these direct methods, it has been shown that 
inhibitors of the MPTP can inhibit apoptosis in vitro (118,145-149) and it has also been shown 
that CsA can protect isolated perfused hearts against ischaemia-reperfusion injury (124). 
Conversely, Minamikawa and colleagues showed that a human osteosarcoma cell line could 
undergo MPT reversibly without the occurrence of cell death (150).
1.6.1 Consequences of mitochondrial permeability transition pore induction 
Therefore the importance of the MPTP in any form of cell death remains a much-debated 
point. However, the fact that mitochondria are the generators of the vast majority of cellular 
energy makes it extremely likely that preservation of the mitochondrial transmembrane 
potential is essential for the survival of the cell. The induction of a pore in the inner 
mitochondrial membrane has a potentially disastrous effect on oxidative phosphorylation. As 
the electrochemical gradient is maintained by the strictly controlled passage of ions across the 
membrane any major increase in permeability will result in a random influx of ions and 
consequent collapse of the gradient. This destroys the driving force behind ATP synthase so 
that no ATP can be generated via oxidative phosphorylation with predictable consequences for 
ATP-dependent reactions in the cell. Some of these reactions such as protein folding are 
particularly vital in a post-ischaemic environment where the cell is attempting to recover from 
injury. Lack of ATP may turn reversible damage into irreversible damage or it may result in a
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potentially apoptotic cell undergoing necrosis that could facilitate a damaging inflammatory 
response.
It has been suggested that the mA'F may fluctuate in a normal physiological state and that this 
may be accounted for by the MPTP opening transiently (127,151). It is clear however that any 
prolonged opening of the pore would destroy the mA'F and therefore be disastrous for energy 
production in the cell.
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1.7 Molecular structure of the mitochondrial permeability transition pore 
The exact structure of the MPTP is not yet completely clear, as a number of groups have 
published studies containing potentially conflicting material. The one component of the pore 
that remains undisputed is the adenosine nucleotide transactor (ANT), and cyclophilin D 
(CyPD) is widely accepted as a potentially essential element. Beyond that there are a large 
number of molecules including the voltage dependent anionic channel (VDAC), hexokinase, 
Bcl-2 and Bax that have been found in association with other elements of the MPTP under 
varying circumstances.
1.7.1 The adenosine nucleotide translocase
ANT is an abundant mitochondrial protein located in the inner membrane. Under physiological 
circumstances it mediates the exchange of ADP-ATP across the membrane, an essential 
process that supplies ATP to the cytosol. Hunter and Haworth first suggested involvement of 
the ANT in the MPTP in 1979 (115,116) and a subsequent study by LeQuoc and LeQuoc 
(152) demonstrated the ability of reagents that stabilise the ANT in one of its 2 conformations, 
to markedly affect the sensitivity of the MPTP to [Ca2+]. More recently, patch clamping of 
isolated ANT contained in liposomes demonstrated the ability of ANT to form a high 
conductance channel in the presence of Ca2+ (153) and another study of vesicle bound, 
reconstituted ANT showed Ca2+-dependent release of small molecules (154).
1.7.2 The voltage dependent anion channel
The VDAC (also known as porin) is the most abundant protein in the outer mitochondrial 
membrane and as with the ANT, is involved in cross membrane transport under normal 
circumstances. It has been demonstrated that VDAC binds strongly to the inner mitochondrial 
membrane, creating contact points through association with ANT. Experiments with patch
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clamped mitochondria membranes showed that a high conductance, CsA-sensitive channel 
displayed some characteristics associated with VDAC (155) and led to the possible scenario 
that the MPTP may naturally occur at these points of contact between the inner and outer 
mitochondrial membranes. This theory has been lent weight by recent evidence that the ANT-1 
isoform, which is located exclusively in the peripheral inner mitochondrial membrane, has a far 
higher affinity for CyPD than the ANT-2 isoform, which is located both peripherally and in the 
cristae (156).
Some groups such as that of Halestrap dispute the importance of VDAC involvement in the 
MPTP. They have published studies demonstrating that the only components necessary to 
replicate the established behaviour of the MPTP are ANT and CyPD, suggesting that VDAC is 
likely to play only a regulatory role (157). However, the fact that so many studies have now 
successfully purified complexes of VDAC-ANT and also VDAC-ANT-CyPD has lent weight to 
the proposal that it may be an integral and important component of the MPTP in vivo (156,
158,159). This of course does not rule out the option that ANT-CyPD complexes may form the 
MPTP alone especially as the purification protocols vary between the studies and in some 
cases the methodology is under dispute. However, although mitochondria contain 
approximately 10 times more ANT than VDAC, much of the excess ANT may be accounted for 
by the cristae located isoform so some if not all of the CyPD-binding isoform of ANT may also 
be complexed with VDAC.
One extremely interesting point to result from the study of VDAC-ANT complexes is the finding 
by Crompton and colleagues that VDAC-ANT-CyPD complexes will readily assemble in the 
absence of factors required for MPTP induction. The same group also showed application of 
ADP to isolated mitochondria increased the amount of free CyPD detectable in the matrix by 
radiolabelled, photoactive CsA (160,161). These findings strongly suggested that CyPD can 
be found associated with ANT in physiologically normal isolated mitochondria and led the
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authors to propose that the MPTP complex may form and function under physiological 
conditions.
A number of other molecules have been found to be associated with VDAC-ANT complexes 
some of which have been shown to play a regulatory role. Complexes of VDAC-ANT 
reconstituted in vesicles were seen to display Ca2+ sensitive MPTP-like activity as judged by 
the release of malate from the vesicles. When octameric mitochondrial creatine kinase was 
associated with the complex through binding to ANT, MPTP-induction was completely 
inhibited. When cytosolic hexokinase was also associated with the complexes through binding 
to VDAC, it was found that MPTP-induction was inhibited or encouraged by, respectively, 
substrates and inhibitors of hexokinase (158).
1.7.3 Cvclophilin D
The ability of CsA to potently inhibit induction the MPTP has inevitably drawn the focus to the 
intracellular receptors of CsA, the cyclophilins.
The cyclophilin family as found in mammalian tissues consists of cyclophilin A (CyPA), a 
cytosol-derived 18kDa protein, cyclophilin B and C (21 kDa) found in the endoplasmic 
reticulum, and CyPD an 18kDa protein localised to the mitochondria (162-165). The 
cyclophilins all contain two active sites -  a site of endonuclease activity (166) and a site of 
peptidyl prolyl cis-trans- isomerase (PPI-ase) activity (162).
Peptide bonds within proteins can exist in both a cis and a trans form. During protein folding 
and refolding, the rate of reaction is frequently determined by the time required for the relevant 
peptide bond to shift from the c/'s to the trans state. Proteins known as peptidyl prolyl cis-trans- 
isomerases catalyse this shift thus speeding up the rate-limiting reaction. Besides the
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cyclophilins a further two structurally unrelated families of proteins displaying PPI-ase activity 
have been identified, the FK506 binding proteins (FKBPs) and the parvulins (162,167-169). 
Cyclophilins have a multitude of physiological functions within the cell, being involved in such 
activities as protein folding (170) and pre-mRNA splicing (171) and function in the regulation of 
protein complexes such as the oestrogen receptor (172) and the nuclear pore complex (173). 
The activities of cyclophilins are now also coming into focus in a pathological context. Besides 
the probable role of CyPD in MPT, cyclophilins are induced as part of the stress response 
(174), possess endonuclease activity of potential importance in apoptosis (175) and CyPA has 
proved to be essential for the successful replication of the type 1 HIV virus (176-179).
In summary, the cyclophilin family are involved in a wide variety of intracellular activities. 
Furthermore, new cyclophilin-like proteins with an array of properties are regularly being 
discovered (180-182) suggesting that further key functions may yet be attributed to this 
increasingly important family of proteins.
Perhaps the best-characterised function of the cyclophilins to date is their involvement in 
cyclosporin A (CsA) mediated immunosuppression. CsA binds specifically to cyclophilins and 
blocks the activity of calcineurin leading to inhibition of cytokine expression and suppression of 
the immune response. CsA and its analogues are fungal-derived metabolites that exhibit 
strong immunosuppressive activity. More recently, derivates such as A/-methylVal-4- 
cyclosporin have been produced that, whilst binding to cyclophilins do not suppress the 
immune response (140). CsA has long since been identified as a potent inhibitor of the MPTP, 
and the finding that the mitochondrial cyclophilin, CyPD, is the only mitochondrial receptor for 
CsA (140) has resulted in extensive study of this protein.
The group of Halestrap demonstrated that CsA and several analogues inhibited the 
mitochondrial cyclophilin enzymatic activity at a potency that correlated with their ability to
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block MPTP induction (139), work that has more recently been corroborated by a publication 
from Nicolli and co-workers (140). These findings have resulted in the proposal that the 
mitochondrial CyP could be an integral and important part of the MPTP (183) and the 
subsequent identification of what has since been termed cyclophilin D (184).
As CyPD is a soluble protein contained in the mitochondrial matrix within the bounds of the 
virtually impermeable inner mitochondrial membrane, its association with the MPTP must 
logically be via interaction with an inner mitochondrial membrane-bound protein. This concept 
has been supported by studies showing that factors such as oxidative stress and increased 
matrix volume promoted CyPD binding to the inner mitochondrial membrane (185,186). The 
fact that ANT is located in the inner mitochondrial membrane and had already been marked as 
a probable component of the MPTP made it an immediate and obvious candidate for CyPD. 
Experiments with CyPD affinity columns have shown both that ANT alone of all inner 
mitochondrial membrane proteins binds to CyPD (140,157) and also that complexes of VDAC- 
ANT demonstrate extremely potent CyPD binding (159). Additionally, when VDAC-ANT 
complexes were isolated with hexokinase that binds to VDAC, CyPD was also found in 
association with the complex. However, in complexes of VDAC-ANT and creatine kinase that 
binds directly to ANT no CyPD was detected, implying that creatine kinase prevented CyPD 
binding to ANT (158). Although ANT and VDAC-ANT are both able to form Ca2+-sensitive high 
conductance channels, the consistent finding that CsA potently inhibits MPTP induction in 
isolated mitochondria, intact cells and isolated perfused hearts make it extremely probable that 
CyPD is a genuine and important component of the MPTP.
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1.7.4 Other potential regulatory molecules
In addition to those detailed above, a number of other molecules have been identified that may 
have a regulatory effect on the MPTP. These include the kinases alluded to previously and 
some members of the Bcl-2 family such as Bax, Bak, Bcl-xL and Bcl-2 (16).
In summary, the studies detailed here demonstrate that function and regulation of the MPTP is 
a complex, controversial and expanding subject. Although some conflicting results have been 
obtained and regulatory molecules appear to differentiate widely according to the situation, in 
is without doubt that a wide variety of molecules must be involved in vivo, and more may yet 
be discovered.
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Figure 3: The molecular mechanism and induction of the mitochondrial permeability transition 
pore (MPTP) is a controversial area. This representation summarises the major studies in the 
field to give a possible scenario (IMM/OMM: inner/outer mitochondrial membrane; ANT: 
andenosine nucleotide translocase; VDAC: voltage dependent anion channel; CyPD:
Cyclophilin D).
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1.8 The molecular mechanism of the mitochondrial permeability transition pore 
Induction of the MPTP requires a specific and now well-established set of conditions. 
Numerous studies have found that the primary trigger for MPTP induction is a high 
concentration of Ca2+ in the mitochondrial matrix. Other factors that are known to affect the 
sensitivity of the MPTP to Ca2+ are oxidative stress, pH, adenosine nucleotide depletion, 
increased inorganic phosphate and reduced mA'F as illustrated in Figure 3.
1.8.1 Matrix Ca2+concentration
The concentration of Ca2+ in the mitochondrial matrix has long been considered the most 
important factor determining induction of the MPTP. Numerous reports as detailed above have 
shown that a high concentration of matrix Ca2+ can induce the MPTP in isolated mitochondria. 
Some studies have also shown that a high enough Ca2+ concentration can cause MPT even in 
the presence of the classical MPTP inhibitor, CsA (187-189). The close relationship between 
matrix Ca2+ concentration and MPTP induction was effectively highlighted by Al-Nasser and 
Crompton who published work showing matrix Ca2+ dependent transient opening and closing 
of the MPTP in isolated liver mitochondria. Induction of the MPTP was demonstrated to be 
proportional to the matrix Ca2+ concentration and independent of mA'F (127). Subsequently, it 
has been proposed that the binding of Ca2+ to the ANT may initiate a conformational alteration, 
causing it to form a channel (183). There is supporting evidence that Ca2+ binds to a very 
specific site of action on the matrix ANT surface, as Ca2+ induced MPT is effectively inhibited 
by other divalent cations (190).
1.8.2 Adenosine nucleotides and inorganic phosphates
The potent inhibitory effect of adenosine nucleotides on the MPTP has frequently been 
demonstrated. As the major function of the ANT is to transport adenosine nucleotides across
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the inner mitochondrial membrane, the high affinity binding of adenosine nucleotides to the 
ANT is a well-established fact.
Studies using both reconstituted MPTP complexes and isolated mitochondria have suggested 
that ADP is a far more potent inhibitor of MPT than ATP (158,189). A study of purified 
reconstituted ANT showed that physiological concentrations of ADP inhibited Ca2+ induced 
MPTP-like activity (154). This demonstrates that the inhibitory effect on ADP on the MPTP is 
almost certainly mediated through the ANT binding site. The authors in fact make the point that 
the conversion of ANT to a non-specific channel can only take place at low adenosine 
nucleotide levels. During ischaemia-reperfusion, such depletion of adenosine nucleotides is in 
evidence (191-194) improving the likelihood of MPTP induction. In addition, ADP binding to 
ANT is antagonised by mitochondrial membrane depolarisation and by oxidative stress (189), 
both of which are common criteria of reperfusion injury.
An obvious consequence of adenosine nucleotide depletion is a corresponding build up of 
inorganic phosphates. It has been demonstrated that the accumulated intracellular phosphate 
may have the effect of lowering the matrix ADP content, thus removing ADP inhibition of the 
MPTP (195,196). This proposition may account for repeated reports of inorganic phosphate 
induced activation of the MPTP (143,144,197). However it is interesting to note that an 
additional study by the same group has shown an inhibitory role for low concentrations of 
inorganic phosphate, due to its reported ability to complex matrix Ca2+ (198). This suggests 
that physiological concentrations of phosphates could have an inhibitory effect on the MPTP 
that is removed by the onset of ischaemia.
1.8.3 Acidic pH
The onset of ischaemia results in an acidic pH that has been shown to inhibit the pore, 
although the precise mechanism of this inhibitory effect is not yet apparent (127,190,197).
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Bernardi and co-workers have published data showing that H+ may modulate the binding of 
CyPD to ANT by affecting a specific ANT histidine residue (190,199). However, Halestrap and 
colleagues have found no evidence for the effect of acidic pH on CyPD binding and instead 
speculate that H+ may compete with Ca2+ for the same binding site on the ANT therefore 
reducing the sensitivity of the MPTP to Ca2+ (157,186).
Whatever the mechanism, it is generally accepted that upon reperfusion the pH increases 
again moving the inhibition and allowing opening of the pore (190,200). However a recent 
report showed that in energised mitochondria, an acidic pH caused MPTP induction due to 
increased uptake of inorganic phosphate. The authors therefore suggest that acidosis during 
ischaemia and reperfusion may increase MPTP induction and exacerbate tissue damage 
(197).
1.8.4 Oxidative Stress
There is increasing evidence to show that agents of oxidative stress are also potent inducers 
of the MPTP. A study by Takeyama and colleagues showed that damage sustained by 
mitochondria on exposure to free radicals was completely inhibited by CsA, suggesting that the 
presence of free radicals triggered induction of the MPTP resulting in mitochondrial damage 
(201). Other studies in isolated mitochondria have also shown that agents of oxidative stress 
can trigger Ca2+-dependent inner mitochondrial membrane permeability transition (143,202) 
that can be inhibited by CsA and bongkrekic acid (143,148). Studies of oxidants have shown 
that they impede ADP inhibition of MPTP induction (189,203) and a comparison of oxidative 
agents with thiol reagents has suggested that oxidants may modify cysteine residues on the 
ANT. This could be expected to antagonise the binding of ADP and possibly also CyPD, 
thereby sensitising the MPTP to the action of Ca2+ binding (189).
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1.8.5 Mitochondrial transmembrane potential
Bemardi and colleagues have produced substantial evidence to show that the likelihood of 
MPTP induction is increased as the mitochondrial transmembrane potential (mA'F) decreases 
(125). The group then followed up these findings by demonstrating that oxidation of critical thiol 
groups contained in the MPTP increases the probability of its induction despite a high mA'F 
(204,205). Halestrap and colleagues have since extended this work, producing evidence that 
these thiol groups are situated on the ANT itself, in the vicinity of the matrix adenosine 
nucleotide binding site. Based on the electrically driven nature of ATP and ADP exchange by 
the ANT, the group has hypothesised that a high mA'F increases the affinity of the matrix 
adenosine nucleotide binding site for ADP, thus effecting a strong inhibition on the MPTP 
(189).
-44-
Chapter 1 Introduction
1.9 The role of cyclophilin D
As previously detailed, recruitment of CyPD to the inner mitochondrial membrane has been 
demonstrated under conditions known to provoke opening of the MPTP. In addition to this, 
numerous studies have revealed potent inhibition of the MPTP by the CyP-binding CsA and a 
corresponding protection from reperfusion-linked damage. Thus, it is now generally accepted 
that CyPD is probably an important component of the MPTP that encourages its induction 
through binding to ANT.
Bemardi’s group shows that CyPD is detectable both in the mitochondrial matrix and 
associated with the inner mitochondrial membrane suggesting that under normal conditions 
only a fraction of CyPD is associated with ANT (140). Crompton has also presented evidence 
that at least some CyPD is physiologically associated with the inner mitochondrial membrane 
(160). Halestrap showed that various agonists that encourage MPT also increased recruitment 
and binding of CyPD to the inner mitochondrial membrane (185,186). Taken together, these 
findings are in agreement with a model of pathological conditions promoting CyPD binding to 
ANT in order to influence the formation of the MPTP, an entity that may also function 
physiologically.
However, the issue of exactly how and where CyPD binds to ANT and influences the 
functioning of the MPTP is a point as yet unsettled. A number of conflicting reports from some 
of the key workers in the field have given rise to variant theories.
Halestrap has produced evidence that CyPD may bind to ANT on the matrix surface at a 
specific proline residue - Pro61 (189). This proposal is based on the finding that cross-linkage 
of an adjacent cysteine residue enhances CyPD binding (189) and on the assumption that 
CyPD binds via its active site supported by the ability of CsA to prevent CyPD binding to ANT
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(157). It is additionally sustained by evidence that three yeast-derived ANT isoforms that lack 
this proline residue are also lacking in detectable CsA-sensitive MPTP-like activity (189). 
Conversely, the finding of Crompton’s group that CsA treatment was unable to prevent CyPD 
from binding to VDAC-ANT complexes, despite inhibiting the MPTP-like activity of the complex 
led them to propose that CyPD binds via a different point remote from its active site allowing 
CsA binding (159). Instead the group proposes a complex of VDAC-ANT-CyPD that flickers 
between an open and closed state according to matrix concentrations of Ca2+.
This however, is in disagreement with findings from the previously alluded to CyPD affinity 
column study of Woodfield and colleagues. In addition, this investigation reports the effect of 
CAT and BA, both of which stabilise ANT in one of its two alternative conformations (157). The 
effect of both of these agents was to produce a significant decrease in the amount of ANT that 
bound to CyPD. Thus the authors suggested that the binding of CyPD could potentially induce 
a conformational change in ANT that increases the binding affinity.
However, this last point is in conflict with an increasing amount of evidence that suitably high 
levels of matrix Ca2+ can induce the MPTP irrespective of the presence of CyPD or the 
inhibitory action of CsA. As previously mentioned, there is now strong evidence that purified, 
reconstituted ANT can form a Ca2+-sensitive channel (153,154). In addition, several reports in 
isolated heart and liver mitochondria have demonstrated that the inhibitory effect of CsA on the 
MPTP can be overcome by high matrix Ca2+ concentrations (187-189).
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1.9.1 The influence of CsA
The last point also raises the equally uncertain issue of how the inhibitory effect of CsA is 
mediated.
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Figure 4: The molecular structure of cyclosporin A (C62H111N11O12)
As CyPD is an often-cited component, or at least regulator, of the MPTP, this provides an 
obvious reason for the ability of CsA to inhibit induction of the pore. As molecules exhibiting 
PPI-ase activity are able to induce structural alterations in their substrates, a frequent 
postulation has been that the PPI-ase activity of CyPD may be instrumental in its influence 
over ANT and the induction of the MPTP. This leads to the reasonable assumption that CsA 
mediates its effect on the MPTP by inhibiting CyPD PPI-ase activity. Publication of the 
crystalline structure of the CsA-CyP complex has since confirmed that CsA binds to and blocks 
the active PPI-ase site of CyPs. This occurs with some structural change in CsA but very little 
alteration of CyPD (206). Despite this however, studies that have been published to date have 
failed to completely clarify the mechanism of CsA inhibition.
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A report by Bernardi’s group showing that CsA caused the release of CyPD from preparations 
of mitochondrial membranes led them to propose that CsA binding causes conformational 
changes in CyPD causing its dissociation (140). However, Crompton and colleagues then 
contradicted this finding in a study that demonstrated the inability of CsA to prevent the binding 
of VDAC-ANT complexes to a CyPD affinity column (159). Furthermore, both studies are in 
disagreement with Woodfield and colleagues who found that the pre-incubation of a CyPD 
affinity column with CsA successfully prevented ANT binding and moreover that VDAC, 
although present did not bind (157). In the case of the first report, no MPTP-like activity could 
be detected in the submitochondrial particles under study, suggesting some functional 
abnormality in the mitochondrial proteins that may have allowed CyPD displacement by CsA. 
The discrepancies between the last two reports may be due to differences in methodology as 
the authors have in fact suggested (207,208). However, as Crompton and colleagues showed 
the VDAC-ANT-CyPD complexes to be functionally active, it is also reasonable to suggest that 
in this situation, the binding of VDAC could produce a structural alteration in ANT that allows it 
to bind CyPD despite the presence of CsA. Furthermore, CsA binding successfully inhibited 
the MPTP-like activity, as is the case in isolated mitochondria and intact cells.
This raises the possibility that CsA could potentially act in one of two ways. Binding to CyPD 
may completely prevent its association with ANT making it less sensitive to Ca2+ as endorsed 
by Halestrap. Alternatively, CsA binding to CyPD that is already in association with ANT may 
act purely as a physical barrier, either obscuring the Ca2+ and Pi binding sites and therefore 
increasing the threshold level of matrix Ca2+ required for MPTP induction or blocking the 
passage of larger substances but allowing the movement of ions as suggested by Crompton 
(159). This is supported to an extent by a previous study of Broekemeier and colleagues that
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showed efficiency of CsA inhibition irrespective of whether application was prior to or after the 
MPTP inducing agent (209).
Ultimately, with the publication of so many conflicting pieces of evidence, the mechanism of 
MPTP induction and the action of CsA may not be finally resolved without definitive elucidation 
of the three-dimensional structure of at least part of the complex. In addition, many and varied 
claims have been made for the action of CsA within the cell meaning that complications may 
well arise when knowledge gained in vitro in tested in vivo.
The best-characterised action of CsA to date besides inhibition of the MPTP through CyPD 
binding is its immunosuppressive effects via calcineurin inhibition. CsA is believed to bind to 
cyclophilin A (CyPA) with these complexes then associating with calcineurin to inhibit its 
phosphatase activity. This in turn prevents the dephosphorylation and consequential nuclear 
import of NFAT (nuclear factor of activated T-cell) transcription factors thus blocking the 
pathway leading to the expression of immune response cytokines in the T-cell. This same 
signalling pathway is present in cardiac cells and, when activated, leads to the transcription of 
hypertrophic genes. This has therefore suggested a preventative role for CsA in hypertrophic 
heart disease. However, although a substantial number of studies have been carried out in 
both cultured cardiomyocytes and rodent models of cardiac hypertrophy, the experimental data 
in support of this hypothesis is conflicting. Some studies have demonstrated almost complete 
attenuation of cardiac hypertrophy by CsA whereas other data has been completely negative. 
In fact there is some evidence to suggest that CsA could even exacerbate hypertrophy and it 
certainly has other unwanted side effects such as secondary hypertension (reviewed in 210,
211). A number of possible explanations for the conflicting data have been put forward 
including model-specific effects, genetic sensitivity to CsA and side effects resulting from 
systemic administration of CsA (210), but no consensus has yet been reached.
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Other calcineurin-independent effects have also been attributed to CsA including inhibition of 
some mitogen-activated protein kinases (MAPKs), long-term effects on the sarcoplasmatic 
reticulum Ca2+-release channel and on L-type Ca2+ channels and immunosuppressive activity 
through TGFpi (reviewed in 210). CsA has also been shown to induce apoptosis in various 
tissues (212-215). It is widely accepted that CsA binds specifically to members of the 
cyclophilin family and, as yet, no other intracellular targets have been proposed. All of the 
effects mentioned above are therefore assumed to be a consequence of CsA binding to 
cyclophilins within the cell.
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1.10 Aims and hypothesis
Although the molecular structure of the mitochondrial permeability transition pore (MPTP) and 
the mechanism of its induction are by no means fully elucidated, the majority of the evidence 
highlights an important functional role for cyclophilin D. Therefore the studies reported in this 
investigation attempted to draw together several strands of research with the aim of: (i) 
examination of the induction of the MPTP in response of a variety of pathological stimuli in 
neonatal primary cardiomyocytes, which may offer a more authentic and valuable insight than 
an established cell line; (ii) investigation of the effect of MPTP induction on an array of 
important parameters of cell viability; (iii) exploration of the role of cyclophilin D in MPTP 
induction; (iv) study of relevant parameters in an in vivo model of ischaemia-reperfusion injury.
The hypothesis upon which this investigation is founded is:
Induction of the mitochondrial permeability transition pore plays an important role in 
cardiac ischaemia-reperfusion injury. Inhibition of molecular components of the pore 
such as cyclophilin D therefore offers protection to cardiac tissue against ischaemia- 
reperfusion injury.
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2: Materials and Methods
2.1 Materials
All chemicals were obtained from Sigma (UK) unless otherwise stated. Cell culture reagents 
and plates were purchased from Life Technologies (Gibco). HPLC-grade water was purchased 
from Fisher. Cyclosporin A, propidium iodide, bongkrekic acid and FK506 were obtained from 
Calbiochem.
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2.2 Culture and treatment of neonatal primary cardiomvocvtes
2.2.1 Preparation of primary cardiomvocvtes
Primary rat neonatal cardiomyocytes were isolated by collagenase/ pancreatin digestion using 
1-3 day old (Sprague-Dawley) neonate hearts according to the method of Chien and 
colleagues (216).
Neonates were killed by rapid decapitation, rinsed in 70% ethanol and placed in petri dishes. A 
midline incision was made through the sternum and the heart was excised using forceps. The 
hearts were then trisected and placed in sterile ADS buffer (116.4mM NaCI, 15.8mM HEPES, 
0.9mM NaHhPCU, 5.5mM Glucose, 5.4mM KCI and 0.8mM MgS04at pH 7.35) on ice and 
transferred to a sterile cell culture environment.
The hearts were then digested for 7 min at 37°C in an enzyme solution consisting of 30mg 
Type II collagenase (Worthington Biochemical Corporation) and 0.6mg/ml pancreatin 
(GibcoBRL) in 7ml of ADS buffer. As the heavier cardiac material settled in the bottom of the 
tube the supernatent, at this point containing mostly blood cells and debris, was easily 
removed using a pipette, discarded, and the digestion was repeated once.
To obtain cardiomyocytes, the hearts were then subjected to further digestion in 7ml of the 
same enzyme solution for 15 min at 37°C. The solution removed from the hearts after this 
digestion was retained, added to 2ml foetal calf serum (FCS) and centrifuged at 1000rpm for 6 
min. The supernatant was discarded and the cells were retained in 4ml FCS at 37°C. The 
hearts were digested for 15 min a further 5 times and the cardiac cells obtained were pooled 
and centrifuged at 1000rpm for 6 min.
The pellet of cardiac cells was then resuspended in plating media consisting of 68%
Dulbecco’s Modified Eagles Medium (DMEM), 17% Medium 199 (M199), 100U/ml 
penicillin/streptomycin (Life Technologies), 10% horse serum and 5% FCS at a concentration 
of approximately 10ml media per 6 neonate heats used. This suspension was pipetted into
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standard 10ml tissue culture dishes and incubated at 37°C for 45 min. During this period 
contaminating fibroblasts attach to the petri dished while myocardial cells remain suspended in 
the media. These unattached cells were then removed and plated at a concentration of 1x106 
/ml plating media into culture dishes pre-coated with 1% gelatin in Dulbecco’s phosphate 
buffered saline (PBS). After 24 hours, the media was changed for a low-serum maintenance 
media consisting of 80% DMEM, 10% M199 and 1% FCS.
Experiments were conducted approximately 48hr after initial plating using spontaneously 
beating cardiomyocytes.
2.2.2 Induction of apoptosis in primary cardiomvocvtes
Primary cardiomyocytes were treated with the widely recognised apoptosis inducer 
staurosporine (SSP) for up to 24hr. SSP was reconstituted in 50% methanol, diluted to its’ final 
concentration (5jiM) in maintenance media and applied to the cardiomyocytes.
2.2.3 Induction of necrosis in primary cardiomvocvtes
Necrotic cell death was induced by addition of t-butylhydroperoxide (t-BOOH) for 1 hr. t-BOOH 
was purchased as a 70% stock solution, diluted to its’ final concentration (100}iM) in 
maintenance media and applied to the cardiomyocytes.
2.2.4 In vitro simulation of ischaemia-reperfusion injury
To subject the cardiomyocytes to conditions of simulated ischaemia and reperfusion, the 
culture media was removed and replaced with a solution based on a protocol of Esumi and 
colleagues (217) incorporating modifications by Dr.R.Heads (personal communication). This 
consisted of 137mM NaCI, 15.58mM KCI, 1.2mM MgCI2.6H20,2.5mM CaCI2.2H20,20mM 2- 
deoxyglucose, 20mM Na lactate and 1mM sodium dithionite This solution in combination with a
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hypoxic environment was designed to simulate the conditions of in vivo ischaemia by 
replicating the approximate concentrations of potassium, hydrogen and lactate ions and by the 
presence of 2-deoxyglucose to inhibit glycolysis and sodium dithionite to scavenge oxygen and 
inhibit mitochondrial respiration. The cells in this solution were then placed in a hypoxic 
chamber at 37°C for up to 3 hours. The chamber was perfused with 95%N2 and 5% CO2 at a 
flow rate of 5 litres/hr for 1 hr and thereafter at a rate of 1.5litres/hr resulting in a p02 of 
2mmHg.
Upon removal from the chamber the cardiomyocytes were either analysed immediately, or 
reperfused in culture media for up to 24 hours prior to analysis.
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2.3 Analysis of cell viability
2.3.1 Electron microscopy
All electron microscopy was performed by Mrs. Padmini Sarathchandra.
Primary cardiomyocytes cultured on petri dishes as described above were washed briefly with 
0.1 M phosphate buffer and fixed in 3% (v/v) glutaraldehyde (Agar Scientific Ltd, UK) in 0.1 M 
phosphate buffer for 2 hours. After two buffer washes, the secondary fixation was performed 
with 1% (w/v) osmium tetroxide (Agar Scientific Ltd, UK) in 0.1 M phosphate for one hour at 
room temperature. Following the secondary fixation, cardiomyocytes were washed twice with 
distilled water and block stained with 4% (w/v) aqueous uranyl acetate (Agar Scientific Ltd, UK) 
for one hour in the dark, washed in distilled water and scraped into Eppendorf tubes. The 
specimens were dehydrated through increasing acetone series and infiltrated with 1:1 acetone: 
araldite CY212 resin (Agar Scientific Ltd, UK) overnight. After two changes of fresh resin, for a 
minimum of 3hr each, samples were embedded in araldite CY212 resin and blocks were 
polymerised at 60°C for 18hr.
Ultra-thin (100nm) sections were cut using a Diatome diamond knife, on a Reichert-Jung 
Ultracut E ultramicrotome, floated onto distilled water, collected on formvar-coated copper 
grids and stained with 2% uranyl acetate for 30 min and in lead citrate for 5 min. The stained 
sections were then viewed on a Jeol 1200EX electron microscope.
2.3.2 Detection of cellular DNA content in primary cardiomvocvtes
Cells undergoing apoptosis typically exhibit DNA fragmentation. If these fragments are allowed 
to diffuse from permeablised cells, then these cells will display a reduced DNA content 
compared to a control sample (218). Therefore, cardiomyocytes subjected to an inducer of 
apoptosis were permeablised and analysed for loss of DNA.
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Primary cardiomyocytes were harvested using a 0.25% trypsin/EDTA solution and centrifuged 
at 1500rpm for 5 min. The cells were then fixed in 4% paraformaldehyde/PBS for 30 min, 
followed by permeabilisation and simultaneous staining of DNA in the hypotonic fluorochrome 
solution (0.1% sodium citrate, 0.1% X-Triton and 40p,g/ml propidium iodide) described by Fried 
and colleagues (219) for 15 min at room temperature in the dark. The cells were then 
resuspended in PBS and incubated for a further 15 min in the dark at 37°C to allow the 
diffusion of small DNA fragments (218) prior to measurement of propidium iodide fluorescence 
on a flow cytometer (Becton Dickinson FACSCalibar, excitation 488nm, emission 495nm) and 
analysis of data using CellQuest software.
2.3.3 Detection of LDH release
Quantification of enzyme release from cells with compromised plasma membranes was utilised 
as a marker of necrosis. A kit for the detection of lactate dehydrogenase (LDH) was obtained 
from Sigma Diagnostics and media collected from the cardiomyocytes was analysed according 
to the manufacturer’s instructions. The diagnostic kit is based on the ability of LDH to catalyse 
the reduction of pyruvate according to the following equation,
Pyruvate + NADH + H+ LDH ^ L-Lactate + NAD+
<4----------
The production of NAD+ results in a decrease in absorbance at 340nm, which is directly 
proportional to LDH activity. The assay reagent is made by combining 0.4ml of 16.2mmol/L 
pyruvate with 10ml of 0.194mmol/L NADH in 54mmol/L phosphate buffer at pH 7.5. Addition of 
8pil of the sample to 200jjlI of the reagent starts the reaction. After incubating for 30 seconds, 
the sample was read at 340nm on a microplate reader (Molecular Devices VERSAmax) and 
was then read every 60 seconds for 3 min. The average change in absorbance (AA) per
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minute was calculated and LDH activity was determined for each sample according to the 
following equation:
LDH activity (U/L) = AA per min x Total vol. x 1000 
6.22 x Light Path x Sample vol.
2.3.4 Analysis of metabolic activity
Metabolic activity of the cardiomyocytes was assessed by the reduction of 3-(4,5- 
dimethylthiazol-2-yl)-2-diphenyl tretrazolium bromide (MTT) reagent by metabolically active 
cells. The MTT reagent is taken up into the cells where it is reduced, producing purple crystals 
of MTT formazan (220).
MTT reagent was applied at a final concentration of 500|ig/ml PBS. After 30min an equal 
volume of a solution of isopropanol containing 0.1 N HCI and 1% X-Triton was added to stop 
the reaction and dissolve the crystals. The resulting colour intensity was analysed at 570nm on 
a microplate reader (Molecular Devices VERSAmax).
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2.4 Analysis of mitochondrial transmembrane potential in primary cardiomvocvtes
2.4.1 Quantification of mitochondrial transmembrane potential
The decrease in mitochondrial membrane potential was evaluated according to the method 
established in cells by Zamzami (221). Modifications proposed by Rottenberg were 
incorporated whereby 3,3’dehexylocarbocyanine iodide (DiOC6(3)) was used at a 
concentration of <1nM to eliminate membrane quenching resulting in greatly enhanced 
sensitivity (222). The fluorochrome (DiOC6(3)), due to its cationic lipophilic structure, 
penetrates freely through membranes into the mitochondrial matrix driven by the mA\|/ as a 
function of the Nemst equation (120). The cardiomyocytes were treated according to the 
experimental protocol, harvested using trypsin/EDTA, centrifuged at 1500rpm and incubated 
for 20 min at 37°C in media containing 0.8nM of (DiOC6<3)). The fluorescence levels were 
measured on a Becton Dickinson FACSCalibar flow cytometer (excitation 488nm, emission 
495nm) and induction of the MPTP was quantified by the decrease in fluorochrome binding.
2.4.2 Visualisation of cardiomvocvtes by confocal microscopy
Primary cardiomyocytes were cultured on 1% gelatin-coated round, glass coverslips. The cells 
were washed with and immersed in PBS prior to visualisation on a Carl Zeiss LSM510 inverted 
confocal microscope system using the manufacturer’s own software. 20nM or 0.8nM of 
(DiOCe(3)) and 1|xM carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP) were added 
to the cells during visualisation.
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2.5 Detection and analysis of Cyclophilin D
2.5.1 Isolation of mitochondria from primary cardiomvocvtes
Mitochondria were isolated from primary cardiomyocytes using digitonin according to the
method of Trounce and colleagues (223). Primary cardiomyocytes were harvested, centrifuged
and washed in separation buffer of pH 7.2 containing 210mM mannitol, 70mM sucrose, 10mM
MOPS and 1mM EGTA. The samples were centrifuged at 3000 x g for 5 min, treated with 10%
digitonin to permeablise the cells and then homogenized 10 times retaining the cells on ice at
all times. After a further centrifugation at 3000 x g, the resulting supernatant was centrifuged
twice at 12000 x g for 10min to pellet the mitochondria. All centrifugation was performed at 4°C
in a refrigerated centrifuged. The resulting mitochondria exhibited normal ultrastructure as
shown in Figure 5.
Figure 5: Mitochondria isolated from neonatal primary cardiomyocytes displayed normal 
ultrastructure with parallel, densely packed cristae and intact membranes (Magnification x 
30,000).
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2.5.2 Measurement of PPI-ase activity
PPI-ase activity of the mitochondrial fraction was measured by the spectrophotometric method 
described by Fischer and colleagues (224) incorporating modifications proposed by Kofron and 
co-workers (225). This method employs the ability of a-chymotrypsin to hydrolyse peptide 
containing the sequence X-Pro-Phe-pNA for which it has an extremely high affinity. This 
produces p-nitroaniline, which is detectable through its absorbance at 390nm. The rate-limiting 
step in this reaction is that hydrolysis only occurs when the X-Pro bond is in the trans form. 
Molecules displaying PPI-ase activity such as the cyclophilins have the ability to shift the X-Pro 
bond from the cis to the trans form, producing a detectable increase in the rate of the reaction. 
Prior to measuring PPI-ase activity, the isolated mitochondria were resuspended in isolation 
buffer containing protease inhibitors and quantified using the Lowry protein concentration 
assay (Bio-Rad) according to the manufacturer’s instructions. An equal concentration of 
mitochondria was always added to each assay.
35mM HEPES buffer pH 7.8,0.8mg/ml a-chymotrypsin and isolated mitochondria were 
combined in a plastic cuvette to a final volume of 990|xl and cooled to 4°C. The assay was 
then initiated by the addition of 10pJ of 8mM of the peptide N-succinyl-Ala-Ala-Pro-Phe p- 
nitroanilide (Suo-AAPF-pNA) dissolved in 470mM LiCI/trifluoroethanoI (TFE) Recording of the 
absorbance at 390nm commenced immediately using a Unicam Helios spectrophotometer. 
Dissolving Suc-AAPF-pNA in LiCI/TFE significantly increases the proportion of the cis X-Pro 
isomers in the solution, thereby ensuring that the trans isomers are not all hydrolysed in a 
“burst phase" during mixing (225).
Absorbance over a 2-minute period was recorded and the rate of reaction (k) was quantified by 
comparison to a previously constructed standard curve using a data-frtting computer software 
package (GraFit, Erithacus Software).
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The percentage increase in rate, caused by the addition of CyP or mitochondrial fraction, over 
that of the basic reaction was quantised according to the following equation:
% increase = kobs -  kO x 100
kO
kobs is the rate of reaction with PPI-ase (CyP or mitochondria). 
kO is the rate of reaction with no PPI-ase added.
2.5.3 Synthesis of a specific anti-Cvdophilin D antibody
An antibody specific to Cyclophilin D (CyPD) was synthesised according to the method of 
Bergsma and colleagues (162). This was however slightly modified to produce a rat-specific 
antibody (as opposed to human) and therefore the following peptide sequence corresponding 
to the carboxyl terminus of rat CyPD was synthesised:
D V V K K I E S F G S K S G K
This peptide was synthesised at the Babraham Institute, Cambridge, coupled to the carrier 
protein keyhole limpet haemocyanin and then utilised to raise specific antibodies in rabbits 
according to a standard protocol also at the Babraham Institute.
In order to purify the CyPD-specific antibody from the rabbit serum, an immunoaffinity column 
was prepared using AffV-Gel 10 (Bio-Rad) according to the manufacturer’s instructions. 2ml of 
Affi-Ge! 10 was washed twice with 10ml of cold isopropanol, the excess was removed and 
50mg of CyPD-specific peptide dissolved in 1ml dimethyl sulfoxide (DMSO) was added to the 
gel. The mixture was agitated for 6hr at room temperature after which the gel was washed
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again and then any unreacted groups were blocked by washing with an excess of 
ethanolamine.
The gel with bound peptide was placed in a glass Econo-Column (Bio-Rad), washed several 
times by elution with 0.1 M sodium phosphate pH 8.0 and then washed one final time whilst 1ml 
fractions were collected. After 10 fractions were collected, the buffer was changed to 100mM 
Glycine/HCI buffer at pH 2.2. The change of buffer causes slight structural alterations in the 
antibodies so they are unable to remain bound and are eluted from the column with the 
Glycine buffer. After collection of a further 10 fractions, the absorbance of all fractions at 
280nm was analysed to determine the location of the antibodies. These fractions were then 
pooled, returned to a neutral pH by addition of a small amount of 0.1 M sodium phosphate pH 
8.0 and dialysed in PBS at 4°C overnight.
Concentration of the purified antibody was calculated by measurement of protein concentration 
and comparison to a standard curve of IgG absorbance at 620nm.
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2.6 Analysis of ATP production in primary cardiomvocvtes
Primary cardiomyocytes grown in 12-well plates and treated as previously described were 
harvested by trypsin/EDTA, washed twice in PBS and resuspended in 500jil PBS. To ensure 
consistency of data, the protein content of each sample was determined as previously 
described and PBS was added so that all samples attained the same protein concentration.
A kit purchased from Sigma Diagnostics was used to determine the amount of adenosine 5’- 
triphosphate (ATP) released from the primary cardiomyocytes. The system is based on the 
ability of ATP to interact with luciferin and firefly luciferase to produce light, according to the 
following equations:
ATP + Luciferin Firefly Luciferase pAdenvl-luciferin + PPi
< ----------------
Mg++
Adenyl-luciferin + O2 ---------------- ► Oxyluciferin + AMP + CO2 + Light
When the amount of ATP is the limiting factor, the light emitted is proportional to the ATP 
present in the sample.
100pJ of ATP Assay Mix (luciferase, luciferin, MgS04, DTT, EDTA, BSA and tricine buffer 
salts) was added to each well of a non-transparent microplate and allowed to stand for 3 min. 
Meanwhile, 100jjJ ATP releasing agent was added to each well of another microplate along 
with 50jjJ dhhO and 50pJ of primary cardiomyocytes suspended in PBS. 100pJ of this mixture 
was then added to the ATP Assay Mix using a multi-channel pipette and after precisely 10 
seconds, the amount of light emitted was measured.
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In order to calculate the ATP released in each instance, an internal standard was required for 
each sample. This was achieved measuring a second 50pJ aliquot of each sample, replacing 
the 50pJ dhhO with 50jliI ATP of a known concentration. The ATP content of each sample 
could then be calculated according to the following equation where SAM is sample, IS is 
internal standard and ATP is measured in moles:
ATP (sam) = ATP (is) x Light (sam)
Light (sam + is) -  Light (sam)
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2.7 Measurement of free radical activity
Free radical activity in primary cardiomyocytes was detected using 2’,7’- 
dichlorodihydrofluorescein diacetate (H2DCFDA) obtained from Molecular Probes. This is a 
widely used probe which upon diffusion into the cell, is hydrolysed by intracellular esterases to 
produce 2’,7’- dichlorodihydrofluorescein which is then oxidised by intracellular free radicals 
resulting in fluorescence which is detectable on a flow cytometer.
Primary cardiomyocytes were cultured and treated as described previously. H2DCFDA was 
dissolved in DMSO, diluted in Maintenance Media to a final concentration of 500nM and added 
to the cells simultaneously with the inducer of cell death (e.g. SSP). The cardiomyocytes were 
incubated in the dark prior to harvesting using 0.25% trypsin/EDTA, 2 washes in PBS and 
analysis on a flow cytometer (Becton Dickinson FACSCalibar: excitation 488nm, emission 
495nm) during which the samples were shielded from direct light.
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2.8 Immunochemical Assays
2.8.1 Western blotting
Primary cardiomyocytes were scraped directly into Laemmli Sample Buffer containing 5% 0- 
mecaptoethanol. Mitochondrial pellets isolated from adult rat cardiac tissue were resuspended 
in the same and all samples were boiled for 10 min to denature the proteins.
25jil of each sample was run at 200V on a 12% Tris-HCL Ready Gel (Bio-Rad) and transferred 
to Hybond ECL Nitrocellulose membrane (Amersham Life Science) using the Bio-Rad Mini- 
PROTEAN II system according to the manufacturers instructions.
The membrane was blocked for 1hr in PBS containing 5% Marvel and 0.02% Tween 20 and 
washed briefly in PBS. It was then sealed in a plastic bag containing 2ml anti-CyPD antibody 
and shaken vigorously for 1hr. Following 3 x 10 min washes with PBS containing 0.02% Tween 
(PBST), the membrane was then immersed in 5ml of the secondary antibody (swine anti-rabbit 
HRP-linked) at a 1:1000 dilution and shaken for 1 hr. After a further 3 x 10 min washes in 
PBST, the membrane was immersed for 2 min in equal amounts of ECL detection reagents 1 
and 2 (Amersham Life Science), enclosed in Saran wrap and exposed to X-ray film in the dark.
2.8.2 ELISA assay
CyPD peptide (see 2.5.3) was dissolved in PBS to a concentration of 0.5mg/ml and 10|il was 
added to the wells of a 96-well Immuno-plate (Life Technologies). The plate was then 
incubated at 4°C overnight. The wells were washed 3 times with PBST and then blocked with 
200pJ of 2% Marvel/PBS at 4°C for 2 hr. Dilutions of each sample were made at 1 in 50,200, 
800,3200 and 12800 and 50jil of each dilution were incubated in triplicate for 1 hr at room 
temperature. The plate was then washed 3 times in PBST and 50pJ of a 1 in 500 dilution of 
swine anti-rabbit horseradish peroxidase antibody (Dako) was applied to all wells for 1 hr.
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The plate was then washed again as previously and lOOjxl of 0.1 M sodium phosphate pH 6.0 
containing 2mg/ml o-Phenylenediamine Dihydrochloride with 1jil/ml H2O2 was added to all 
wells. After approximately 6 min to allow colour development, the absorbance was read at 
450nm using a microplate reader (Molecular Devices VERSAmax).
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2.9 Measurement of protein concentration
Protein concentration was measured using the Bio-Rad DC Protein Assay, which is itself 
based upon the original Lowry method. When protein in the sample is reacted with an alkaline 
copper tartrate solution, the protein is then able to reduce Folin reagent resulting in 
development of a blue colour with maximum absorbance at 750nm. The assay was conducted 
in 96-well microplates according to the manufacturer’s instructions as follows.
A working reagent was prepared by adding 20|il of Reagent S (a detergent) to every 1ml of 
alkaline copper tartrate solution used. 2 5 j l l I  of this working was added to 5pJ of each of the 
samples in a microplate and 200pJ of Folin reagent was added to all. After mixing, the colour 
was allowed to develop for 15 min prior to measuring absorbance at 750nm using a microplate 
reader (Molecular Devices VERSAmax).
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2.10 Model of cardiac ischaemia-reperfusion injury in adult Spraque-Dawlev rats
2.10.1 Surgical procedure
All animal surgery was performed by Mr. Colin Shurey in strict accordance with Home Office 
regulations under licence number 70/4780.
An adult female Sprague-Dawley rat of 10-12 weeks old was anaesthetised with Hypnorm and 
Diazepam and ventilated at 4ml/breath, 30 breaths/minute.
A short incision was made downwards from the xiphistemum, the abdominal muscle was 
incised and the rat was dissected bilaterally to the base of the ribcage. From these lateral 
points the skin was then incised up to the axillae and the diaphragm was divided. The ribs 
were then divided so that the ribcage could be retracted back over the head, thus exposing the 
heart.
A 7/0 silk suture was passed around a major branch of the left coronary artery -  the Left 
Anterior Descending (LAD) with at least a 1mm gap either side of the vessel and tightened in 
order to occlude the vessel. To reperfuse, the suture was loosened to allow the normal flow of 
blood to resume.
To confirm successful LAD occlusion, the suture was tightened again and 2ml Evans Blue dye 
was injected into the bloodstream via a femoral vein. All areas with normal flow of blood were 
infiltrated by the blue dye whilst a significant section of the left ventricle was excluded. This 
area of tissue was excised and taken for analysis.
Control rats were subjected to the same procedure excepting tightening of the suture and 
injection of Evans Blue dye. A section of the left ventricular wall was then excised for analysis.
2.10.2 Preparation of cardiac tissue samples for electron microscopy
Samples of cardiac tissue were excised from the left ventricular wall and fixed in 0.1 M 
phosphate buffer containing 3% (v/v) glutaraldehyde (Agar Scientific Ltd, UK) in 0.1 M
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phosphate buffer for 2 hours. After two buffer washes, a secondary fixation was performed with 
1% (w/v) osmium tetroxide (Agar Scientific Ltd, UK) in 0.1 M phosphate for one hour at room 
temperature. The samples were then dehydrated through an increasing acetone series and 
infiltrated with 1:1 acetone: araldite CY212 resin (Agar Scientific Ltd, UK) overnight. After two 
changes of fresh resin, for a minimum of 3hr each, samples were embedded in araldite CY212 
resin and the resulting blocks were polymerised at 60°C for 18hr.
Ultra-thin (100nm) sections were cut using a Diatome diamond knife, on a Reichert-Jung 
Ultracut E ultramicrotome, floated onto distilled water, collected on formvar-coated copper 
grids and stained with 2% uranyl acetate for 10 min followed by Reynolds lead citrate for 10 
min. The stained sections were then viewed on a Jeol 1200EX electron microscope.
2.10.3 Assessment of plasma LDH activity
0.5ml blood samples were taken from Sprague-Dawley rats via a femoral vein. The samples 
were then centrifuged at 1500rpm to remove blood cells and the plasma was stored at -70°C 
prior to measurement of LDH activity by the method described in section 2.3.3.
2.10.4 Isolation of mitochondria from the left ventricle
The left ventricle was excised from the adult rat heart and placed in chilled isolation buffer 
containing 1mM EGTA. The isolation buffer consisted of 225mM Mannitol, 75mM Sucrose, 
10mM MOPS, 10mM Tris Base in HPLC grade water, pH 7.2 - 7.25 at 4°C. The cardiac tissue 
was then minced with scissors and briefly homogenised whilst being maintained on ice at all 
times. The homogenate was then centrifuged at 600g for 5 min followed by a further 
centrifugation of the supernatant at 1000g for 5 min. The resulting supernatant was then 
centrifuged at 8800g for 10 min and the mitochondrial pellet was resuspended in isolation
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buffer with no EGTA. The mitochondria were then washed twice at 8800g for 10 min and 
resuspended in a small amount of buffer suitable for the intended analysis.
The resulting purified mitochondria exhibited normal ultrastructure as shown below in Figure 6.
Figure 6: Mitochondria isolated from adult Sprague-Dawley cardiac tissue displayed normal 
ultrastructure with parallel, densely packed cristae and intact membranes (Total magnification
x 30,000).
2.10.5 Assessment of mAY bv the retention of tetraphenylphosphonium 
An electrode system for the accurate detection and quantification of tetraphenylphosphonium 
(TPP+) was kindly provided and set up by Professor A. Panov of the Department of Neurology, 
Emory University School of Medicine. The TPP+-sensitive electrode made by Prof. Panov, is 
itself filled with 10mM TPP+. The reference electrodes were commercially available Ag/AgCI 
electrodes and connecting tubes were filled with 3M KCI. The electrodes were connected to a 
transformer and the data was amplified and recorded and stored on computer. All hardware
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and software was purchased from C&L Co, Pennsylvania except the amplifier/filter 202A from 
Warner Instrument Corp. USA.
TPP+ is taken up into mitochondria proportionally to the mA'F - the higher mA'F, the more 
TPP is absorbed. In this system of electrodes, the presence of TPP+ in the solution 
surrounding the electrode creates an increase in voltage that can be converted to give the 
mean mA'F. When Ca2+ is added to the medium it is taken up into the mitochondrial causing 
an increase in matrix Ca2+concentration and a consequential reduction in mA'F. The higher 
the initial value of mA'F is the more Ca2+ can be added prior to depolarisation.
The tips of the TPP+ and reference electrodes were lowered into 2ml of Vercesi medium 
(200mM sucrose, 25mM KCI, 3mM Gly-Gly, 2mM K2HPO4 and 1mM MgCl2*6H20) containing a 
magnetic stirrer, which was gently activated for the duration of the experiment. 10mM 
succinate was added and recording of data immediately commenced. 10pJ of 0.1 mM TPP+ 
was added 3 times at 30 second intervals in order to provide calibration for the experiment and 
a suspension of mitochondria from the left ventricles of 2 Sprague-Dawley rats was added to a 
final concentration of 1 mg/ml. This caused a sharp decrease in measurable TPP+ due to its 
uptake by the mitochondria. After 1 min 5 |il of 10mM Ca2+ was added at 1-minute intervals, 
this resulted in a steady increase in measurable TPP+ and Ca2+ addition continued until TPP+ 
levels became constant showing that full depolarisation had occurred. 
mA'F was calculated according to the following equation:
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mA'P (-mV) = (RT/nF) x [TPP+] inside mitochondria I [TPP+] outside mitochondria 
Where:
R = gas constant T = room temperature
n = charge number F = Faraday constant
The actual equations used were those presented by Kamo and colleagues (226) with 
additional calculations to allow for TPP+ binding to the mitochondrial membranes according to 
Jensen and co-workers (227). The binding constants for cardiac derived mitochondria were 
taken from a publication of LaNoue and colleagues (228).
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2.11 Statistical Analysis
All data were analysed using a statistical package associated with Graphpad Prism software. 
One-way analysis variance was used with the Bonferroni post-test to compare multiple groups, 
All primary cardiomyocyte experiments were performed in replicates of 4 and repeated using 
cardiomyocytes from 3 separate cultures.
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3: Apoptosis, Necrosis and Simulated Ischaemia: The Effect of MPTP
Inhibition
3.1 Introduction
As ischaemia-reperfusion injury is such a common cause of injury in many solid tissues, the 
type of cell death occurring in this situation is clearly an important factor in implementing any 
preventative measures. Until comparatively recently all cell death due to ischaemia in solid 
tissues was believed to take the form of coagulative ischaemia, a common form of ischaemia 
in which the area of tissue affected retains its basic structure for some time following the death 
of the cells. Recently however, the role of apoptosis in cardiac tissue has generated much 
interest due to experimental evidence of it’s possible involvement in both ischaemia- 
reperfusion injury and muscle fibre slippage following an infarction (45,55,229-232).
As previously mentioned, there are many conflicting reports concerning the nature of cell death 
in cardiac injury and the involvement of apoptosis is a contentious issue. This is further 
exacerbated by the emerging opinion that apoptosis in pathological situations may be an 
extreme example of cell death as opposed to a distinct process. As well as complicating the 
already contentious issue of quantification of cell death, this also questions the wisdom of 
applying specific inhibitors of apoptosis to pathological situations.
Induction of the mitochondrial permeability transition pore (MPTP) is demonstrably involved in 
both apoptosis and necrosis and has been envisaged as a therapeutic target irrespective of 
the mechanism of cellular injury. In this chapter therefore, the effect of the MPTP inhibitor 
Cyclosporin A (CsA) was investigated in 3 models of cardiomyocyte death.
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3.2 Objective
The aim of this project was to establish models of apoptotic, necrotic and ischaemic cell death 
in neonatal rat primary cardiomyocytes and to evaluate the effect of MPTP inhibition in each 
situation.
The purpose of the study was to determine whether inhibition of the MPTP could rescue 
cardiomyocytes from death regardless of the pathological process.
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3.3 Materials and Methods
Neonatal primary cardiomyocytes were isolated and cultured as described in chapter 2.2.1. 
Cell death was induced using staurosporine (SSP), t-butylhydroperoxide (t-BOOH) and a 
solution designed to replicate the extracellular conditions of ischaemia-reperfusion injury as 
detailed in chapter 2.2.2-4.
A range of methods as described in chapter 2.3 was then employed to quantify the resulting 
cell death.
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3.4 Results
3.4.1 Neonatal primary cardiomyocyte cultures
Neonatal rat primary cardiomyocytes were grown in 24 or 12-well plates as appropriate to the 
experimental procedure. The cultured cells formed a spontaneously beating monolayer, while 
some dead cells that did not adhere, remained attached to the live cells despite repeated 
washes (Figure 7). The adhered cells appeared healthy when analysed by electron microscopy 
(EM) as shown in Figure 8a & b. Occasional fibroblasts could be seen in the cultures as 
pictured in Figure 8c. As fibroblasts in primary culture are able to grow and multiply, they 
became more numerous as the culture aged. Therefore experiments were always performed 
48hr after plating.
Figure 7: Cultured neonatal primary cardiomyocytes 48hr after initial plating.
These photographs of primary cardiomyocytes visualised by phase-contrast show a monolayer 
of dark adhered cells that were beating at the time of photography. The small bright cells are 
those that have died after failing to adhere but remain attached to the cultures (Total 
magnification x 400 [left image] and x 1200 [right image]).
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/  ' V ,
Figure 8(a) This EM photo shows healthy cells with intact membranes, dispersed chromatin 
and numerous healthy mitochondria (Total magnification x 5,700). (b) shows an area of muscle 
fibres with an arrow indicating an intercalated disc (Total magnification x 5,700).
(c) This electron micrograph shows a fibroblast. Although pre-plating removed the vast majority 
of fibroblasts, a few were occasionally seen in the myocyte cultures (Total magnification x
5,700).
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3.4.2 A Model of Apoptosis in Primary Cardiomyocytes
Staurosporine (SSP) is a well-known inducer of apoptosis, which functions through the 
inhibition of protein kinases. SSP applied at a concentration range of 0.5-20|uM over 20hr 
produced a significant drop in cell metabolism and a corresponding release of lactate 
dehydrogenase (LDH) through compromised plasma membranes (Figure 9a & b). EM analysis 
showed that the vast majority of the cells were dying by apoptosis as pictured in Figure 10. 
However, from 10jiM an increasing amount of necrosis was seen and at concentrations of 20jn 
M and above necrosis was the predominant form of cell death (Figure 11). Therefore, 5|liM 
was chosen as a working concentration.
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Figure 9a: Primary cardiomyocytes treated with 0.5-20|iM staurosporine (SSP) for 20hr 
showed a significant and concentration-dependent decrease in metabolic-dependent 
conversion of MTT reagent [*, p<0.05 v. control; **, p<0.01 v. control; ***, p<0.001 v. control].
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Figure 9b: Primary cardiomyocytes treated with 0.5-20piM staurosporine (SSP) for 20hr 
showed a significant and concentration-dependent release of LDH [*, p<0.05 v. control; **, 
p<0.01 v. control; ***, p<0.001 v. control].
Fgure 10: Electron micrograph showing primary cardiomyocytes following 20hr treatment with 
fuM staurosporine (Total magnification x 5,700). These cardiomyocytes display typical signs
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of apoptosis in comparison to the untreated cardiomyocytes in Figure 4a & b. The chromatin is 
condensed and the cell has retracted and rounded, but the cell membranes and organelles are 
intact.
Figure 11: This electron micrograph shows primary cardiomyocytes typical of those that were 
teated for 24hr with 20jiM staurosporine (Total magnification x 5,700). The cardiomyocytes 
are displaying symptoms characteristic of necrosis with broken cell membranes and disruption 
so extreme that the nuclei are not obvious. The vacuoles are enlarged and the lysosomes and 
Mitochondria are disrupted.
n this study, several methods were utilised for the quantification of apoptotic cardiomyocytes, 
as currently there is no definitive single available method suitable for the measurement of 
apoptosis. Measurement of cellular metabolism is inappropriate as high metabolic activity is 
equired for implementation of apoptosis and results will therefore be deceptive. The release of 
jnzymes from cells with compromised plasma membranes is a widely used method, but since 
apoptotic cells retain plasma membrane integrity the assay can only measure post-apoptotic 
lecrotic changes. Analysis of Pl-stained cells by flow cytometry as described in Chapter 2
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distinguishes apoptotic cells through a combination of decreased staining due to DNA 
fragmentation and decrease in cell size. This is therefore a direct assay of cell death but could 
potentially also detect necrotic cells with fragmented DNA as well as apoptotic ones and would 
consequently be unreliable for distinguishing between apoptosis and necrosis. This problem 
also applies to other popular methods such as Hoescht and TUNEL staining. Additionally there 
is the problem of whether the cell death occurring is ‘true’ apoptosis, necrosis or a combination 
of both processes.
To address this problem, 3 assays were used in conjunction to measure the viability of primary 
cardiomyocytes during 24hr of 5\M  SSP application. Cellular metabolism as assayed by 
conversion of MTT to MTT formazan displayed a decreasing trend over 18 hours but only 
became significantly reduced by 24 hours (Figure 12a). These results were confirmed by 
measurement of the release of LDH from cells with compromised plasma membranes (Figure
#
12b). However analysis of SSP-treated cardiomyocytes by flow cytometry using a combination 
of cell size and DNA staining showed a significant decrease in cell viability after only 4hr. Prior 
to DNA staining with propidium iodide (PI), the cells were permeablised to allow diffusion of 
small DNA fragments so that cells with fragmented DNA would be detectable by their reduced 
DNA content shown as a decreased fluorescence. Fluorescence of PI was plotted against cell 
size as measured by forward scatter and the results presented as a dot plot (Figure 13a). This 
clearly showed 2 groups of cells, 1 group of poorly stained, reduced size dead or dying cells 
and 1 group of brightly stained, normal size group of viable cells. All control groups contained 
some dead cells, the number of which varied between primary culture preparations. Treatment 
with SSP caused an increase in the number of dead cells and corresponding decrease in the 
viable population. The decrease of viable cardiomyocytes was expressed as a percentage of 
the control and is shown in Figure 13b.
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Figure 12a: primary cardiomyocytes were treated with 5|iM staurosporine (SSP) for up to 24hr. 
Metabolic activity was then assayed by the reduction of MTT reagent over 30min, revealing a 
decline in activity over the duration of the treatment that became significant between 18 and 
24hr [***, p<0.001 v. control].
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Figure 12b: prior to application of MTT reagent (fig 12a) an aliquot of culture media was 
reserved for analysis of LDH activity as shown in the graph above. This revealed an increased
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release of LDH into the extracellular medium that attained significance between 18 and 24hr 
[***, p<0.001 v control].
Figure 13a: Cell size (FSC-H) and propidium iodide fluorescence (FL2-H) were the measured 
by flow cytometry and plotted in a scatter plot, an example of which is shown above. This form 
of analysis revealed a distinct group of cell small poorly stained cells allowing straightforward 
quantification of the number of large cells with noteworthy staining of DNA (and therefore 
viable) in the upper-right quadrant.
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Figure 13b: the number of viable cells in the upper-right quadrant of the dot plot (shown in 
figure 13a) was expressed as a percentage of the control. This showed a significant decrease 
in the number of viable cells over 24hr of 5^iM staurosporine (SSP) treatment [*, p < 0.05; ***, 
p < 0.001 v. control].
In addition to these quantitative assays, it was noted that treatment with SSP caused cleavage 
of the 32kD caspase 3 precursor as illustrated in figure 14. Lysates of untreated control 
cardiomyocytes were probed with an antibody to the caspase 3 precursor by Western blotting. 
This revealed a clear band of protein at 32kD. However, when lysates of cardiomyocytes that 
had been treated with SSP for 24hr were probed with the same antibody, no protein bands 
were observed, indicating cleavage of the inactive precursor of caspase 3 into the active form. 
Activity of the caspase family of proteins has many times been detected during apoptotic cell 
death and activation of the caspases, especially caspase 3, has often been used as evidence 
of cell death proceeding by apoptotic pathways.
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Figure 14: A representative Western blot showing that treatment of primary cardiomyocytes 
with 5jxM staurosporine for 24hr resulted in cleavage of the caspase 3 precursor protein that 
was not seen in control cells.
3.4.3 A Model of Necrosis in Primary Cardiomyocytes
T-butylhydroperoxide (t-BOOH) has been frequently used for the induction of oxidative stress 
and cell death in a wide variety of cell types. Application of 60-140jj.M t-BOOH for 1 hr caused 
a significant drop in MTT conversion by primary cardiomyocytes and a corresponding increase 
in LDH release (Figure 15a & b). Analysis by electron microscopy confirmed that the cells were 
undergoing necrotic cell death as shown in Figure 15c.
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Figure 15a: 1hr of treatment with 60-140p.M t-butylhydroperoxide (t-BOOH) produced a 
concentration dependent decrease in cell metabolism as measured by conversion of MTT 
reagent [***, p < 0.001 v. control].
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Figure 15b: the same cells assayed for release of LDH displayed a concentration dependent
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increase, showing loss of membrane integrity as a consequence of t-butylhydroperoxide (t- 
BBOH) treatment [*, p < 0.05; ***, p < 0.001 v. control].
Figure 15c: Primary cardiomyocytes following application of 100|iM t-butylhydroperoxide for 
1hr. The cell membranes have broken open and the contents spilled out. The cell organelles 
have suffered only minimal disruption, probably reflecting the short treatment time (Total 
magnification x 5,700).
3.4.4 A Model of Simulated Ischaemia-Reoerfusion Injury
Primary cardiomyocytes were subjected to treatment with ischaemic solution for up to 6 hours 
as described in Materials and Methods followed by simulated reperfusion consisting of 
incubation for up to 24hr in full maintenance media. Analysis of the primary cardiomyocytes by 
electron microscopy revealed that the predominant form of cell death was necrosis as shown in 
Figure 16i & j. Measurement of cellular metabolism by MTT showed a steady decline in 
metabolic activity during the selected time periods as shown. LDH release followed a similar 
trend except in the case of simulated ischaemia with no reperfusion in which case the LDH
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release was extremely low (Figure 16a -  h). As this is a direct contradiction of the MTT results 
and the LDH release was actually consistently significantly lower than the control, it is probable 
that some element of the ischaemic solution used inhibits LDH activity - the most likely 
candidate being the 20mM lactate. This also leads to the possibility that the increased LDH 
activity over reperfusion time could in fact be the effect of the solution wearing off rather than 
increased LDH release from the cells. However, this scenario can probably be discounted 
since the LDH release correlates with the death of the cells as measured by MTT conversion. 
Simulated reperfusion of cardiomyocytes following application of ischaemic solution resulted in 
a gradual decline in viability up to 18hr reperfusion followed by a sharp decrease between 18 
and 24hr. 3hr of simulated ischaemia with 18hr simulated reperfusion was selected for working 
experimental conditions. This produced a reduction in MTT conversion of approximately 60% 
and was therefore considered an appropriate level of cell death for the application of inhibitors. 
Additionally, an 18hr period of simulated reperfosion preceded the sharp decline that would 
suggest the sudden and irreversible death of the majority of the cells.
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Figure 16a: Metabolic activity of primary cardiomyocytes as measured by conversion of MTT 
reagent, showed a time-dependent decrease during 6hr application of the simulated ischaemia 
solution [**, p < 0.01 v. control; ***, p < 0.001 v. control].
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Figure 16b: LDH activity during treatment with the simulated ischaemia solution was 
significantly lower than control suggesting that LDH activity was severely inhibited by the 
solution used [***, p < 0.001 v. control].
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Figure 16c: A further time-dependent decrease in cardiomyocyte metabolic activity was seen 
during 24hr of simulated reperfusion following 1 hr of treatment with the simulated ischaemia 
solution. A slight decrease was observed during the first 18hr with a sharp decline from 18 to 
24hr [*, p < 0.05 v. Control; **, p < 0.01 v. Control; ***, p < 0.001 v. Control].
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Figure 16d: A time-dependent increase in LDH release was observed during 24hr of simulated 
reperfusion following 1 hr of treatment with the simulated ischaemia solution. A slight increase 
was seen during the first 18hr with a sharply increased release evident from 18 to 24hr [*, p < 
0.05 v. Control; ***, p < 0.001 v. Control].
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Figure 16e: A further time-dependent decrease in cardiomyocyte metabolic activity was seen 
during 24hr of simulated reperfusion following 2hr of treatment with the simulated ischaemia 
solution. A slight decrease was observed during the first 18hr with a sharp decline from 18 to 
24hr [***, p < 0.001 v. Control].
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Figure 16f: A time-dependent increase in LDH release was observed during 24hr of simulated 
reperfusion following 2hr of treatment with the simulated ischaemia solution. A slight increase 
was seen during the first 18hr with a sharply increased release evident from 18 to 24hr [*, p < 
0.05 v. Control; ***, p < 0.001 v. Control].
* * *
Figure 16g: A further time-dependent decrease in cardiomyocyte metabolic activity was seen 
during 24hr of simulated reperfusion following 3hr of treatment with the simulated ischaemia 
solution. Significant reduction of activity was observed during the first 18hr of simulated 
reperfusion, with a further sharp decline over the final 6 hours [***, p < 0.001 v. Control].
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Figure 16h: Significant, time-dependent release of LDH from primary cardiomyocytes was seen 
during simulated reperfusion following 3hr of treatment with the simulated ischaemia solution. 
Significant release of LDH was observed during the first 18hr of simulated reperfusion, with a 
further sharp increase over the final 6 hours [*, p < 0.05 v. control; ***, p < 0.001 v. control].
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Figure 16i: primary cardiomyocytes subjected to 3hr application of simulated ischaemia 
solution displayed characteristics of necrosis. The cells in this EM photograph have
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marginalized chromatin, disrupted mitochondria and distended ER. Some cells were observed 
to have intact plasma membranes whereas other cells had burst open (Total magnification x
5,700).
Figure 16j: 24hr simulated reperfusion (following 3hr simulated ischaemia solution treatment) 
killed the majority of the cells, also by necrotic death. The cells in this image show completely 
irreversible damage. They have disintegrated and unrecognisable organelles, the chromatin 
has also disintegrated and the plasma membranes are broken in places (Total magnification x
5,700).
3.4.5 The Effect of MPTP Inhibition on Apoptosis
CsA was applied to the primary cardiomyocytes for 2hr at a concentration range of 10nM-1piM. 
Analysis of MTT conversion and LDH activity both revealed that CsA became toxic between 
400 and 600nM (Figure 17a & b).
- 9 8 -
Chapter 3 Cell Death and MPTP Inhibition
0 . 2 -]
j f  o .n
0.0
i I
*
r C^  r C^ r <^ r <^vCr vCr X r vCr
°  < #  c #  < #  < #  c #  #
^  ^
Figure 17a: Primary cardiomyocytes were treated with cyclosporin A (CsA) 100nM-1^iM for 
2hr. Analysis of metabolic activity by conversion of MTT reagent showed that CsA attained 
toxicity between 400 and 600nM [*, p<0.05; ***, p<0.001 v control].
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Figure 17b: Prior to MTT analysis, an aliquot of culture media was removed for analysis of LDH 
activity. This showed that cyclosporin A (CsA) became significantly toxic between 600 and
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800nM although there was a notable increase in LDH release between 400 and 600nM [***, p 
< 0.001 v control].
CsA was applied to the cardiomyocytes for 1 hr in a range of non-toxic concentrations and then 
washed off prior to 20hr of SSP treatment. However, analysis of both metabolism and LDH 
release showed that the application of 100-400nM CsA followed by 5jliM SSP for 20hr was in 
fact more toxic to the primary cardiomyocytes than the SSP alone (see Figure 18a & b).
1.00 -i
0 .75 -
Ecor--m 0 .5 0 -<
0 .2 5 -
0 .0 0 -
++ ++
&
O r< ^  r< ^  ^
^  ^  #  wrST rST rKT cST ^  ^  ^  ^
Figure 18a: Primary cardiomyocytes were treated with cyclosporin A (CsA) at concentrations 
ranging from 100-400nM followed by 5|iM staurosporine (SSP) for 20hr. Assessment of 
metabolic activity showed that pre-treatment with CsA led to a further reduction in of activity 
compared to SSP alone [***, p < 0.001 v control; ++, p < 0.01 v 5|iM SSP].
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Figure 18b: The same cells assayed for LDH release showed that all concentrations of 
cyclosporin A (CsA) used caused an increased loss of membrane integrity compared to 
staurosporine (SSP) [***, p < 0.001 v control; ++, p < 0.01 v 5|iM SSP].
To determine whether the length of treatment was instrumental in the toxicity of the CsA, it was 
applied to primary cardiomyocytes for 1 hr at the same concentration range. The cells were 
then washed and fresh media was replaced for 20hr. Analysis of MTT conversion and LDH 
release after this time period showed no evidence of toxicity (Figure 19a & b).
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Figure 19a: Cardiomyocytes were treated with cyclosporin A (CsA) at concentrations of 100- 
400nM for 1 hr and then reperfused for 20hr. Analysis of MTT conversion showed no significant 
variation in metabolic activity compared to the control.
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Figure 19b: Assessment of LDH activity in the same cells showed no additional loss of 
membrane integrity in the cyclosporin A (CsA) treated cardiomyocytes.
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Therefore CsA was tested at a lower range of concentrations. Cardiomyocytes were treated 
with 1 -1 OOnM CsA, which was washed off after 1 hr and replaced with 5^iM SSP. Although 
there was no evidence of CsA toxicity below 80nM, no indication of protection against SSP- 
induced apoptosis could be seen by either MTT (Figure 20a), LDH assay (Figure 20b) or by 
assessment of DNA content in permeablised cells (Figure 20c).
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Figure 20a: Primary cardiomyocytes were treated with cyclosporin A (CsA) at concentrations 
ranging from 1-60nM followed by 5jliM staurosporine (SSP) for 20hr. The reduction of 
metabolic activity (conversion of MTT reagent) proved to be unaffected by CsA pre-treatment 
[***, p < 0.001 v control].
- 103 -
Chapter 3 Cell Death and MPTP Inhibition
Figure 20b: The same cardiomyocytes assayed for LDH release showed that pre-treatment 
with cyclosporin A (CsA) at 1-60nM did not inhibit the staurosporine (SSP)-induced loss of 
membrane integrity [***, p < 0.001 v. control].
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Figure 20c: the number of viable cells according to size and DNA content was expressed as a 
percentage of the control. This showed that 50nM cyclosporin A (CsA) was unable to inhibit 
staurosporine (SSP)-induced loss of cell viability [***, p<0.001 v. control].
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Primary cardiomyocytes were treated for 1 hr with CsA and 5^iM SSP concurrently. 
Measurement of metabolic activity and membrane integrity after 20hr showed that the 
combination of CsA and SSP was significantly toxic to the cardiomyocytes (Figure 21a & b).
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Figure 21a: Primary cardiomyocytes were treated with 50nM cyclosporin A (CsA) concurrently 
with 5p.M staurosporine (SSP) for 1hr. The combination of CsA and SSP induced a 
significantly greater reduction of metabolic activity (quantified by conversion of MTT reagent) 
than SSP alone [***, p < 0.001 v. control; ++, p < 0.01 v. SSP].
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Figure 21b: The same cardiomyocytes assayed for LDH release showed that the combination 
of cyclosporin A (CsA) and staurosporine (SSP) induced a significantly greater release of LDH 
than SSP alone [***, p < 0.001 v. control; +++, p < 0.001 v. SSP],
1-25jiM Bongkrekic acid (BA) (Figure 22) was applied to primary cardiomyocytes for 2hr. 
Analysis of MTT conversion and LDH release after this time showed a significant toxic effect 
from between 10 and 15|iM (Figure 23a & b).
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Figure 22: Structure of bongkrekic acid (molecular formula: C28H38O7)
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Figure 23a: Primary cardiomyocytes treated with bongkrekic acid (BA) for 2hr showed a 
significant decrease in metabolic activity (quantified by conversion of MTT reagent) between 
10 and 15jiM [***, p < 0.001 v. control].
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Figure 23b: the same cardiomyocytes assayed for LDH release showed a significant loss of 
membrane integrity between 10 and 15)iM bongkrekic acid (BA) [***, p < 0.001 v. control].
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BA was applied to primary cardiomyocytes for 1 hr at a concentration range of 1-10jnM. The 
cells were then washed with PBS and 5|iM SSP was applied for 20hr. Analysis of metabolic 
activity and membrane integrity showed that BA was unable to inhibit apoptosis as shown in 
figure 24a & b.
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Figure 24a: Primary cardiomyocytes were treated with bongkrekic acid (BA) at concentrations 
ranging from 1-1 OjnM followed by 5|liM staurosporine (SSP) for 20hr. The reduction of 
metabolic activity (quantified by conversion of MTT reagent) proved to be uninhibited by BA 
pre-treatment [***, p < 0.001 v. control].
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Figure 24b: The same cardiomyocytes assayed for LDH release showed that pre-treatment 
with bongkrekic acid (BA) at 1-10|iM did not inhibit the loss of membrane integrity caused by 
staurosporine (SSP) [***, p < 0.001 v. control].
Therefore 5 & 10^iM BA was applied to the cardiomyocytes concurrently with SSP. Analysis of 
MTT conversion and LDH release after 20hr showed that BA was unable to inhibit cell death 
(Figure 25a & b).
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Figure 25a: Bongkrekic acid (BA) was applied concurrently with staurosporine (SSP) for 20hr. 
The reduction of metabolic activity (quantified by conversion of MTT reagent) was unaffected 
by BA [***, p < 0.001 v. control].
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Figure 25b: The same cardiomyocytes assayed for LDH release showed that bongkrekic acid 
(BA) was unable to prevent the loss of membrane integrity caused by staurosporine (SSP) [***, 
p < 0.001 v. control].
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3.4.6 The Effect of MPTP Inhibition on Necrosis
CsA at concentrations of 50-400nM was applied to primary cardiomyocytes for 1hr prior to 
treatment with 100piM t-BOOH. No inhibition of cell death could be seen by analysis of 
metabolic activity but 40-50nM CsA caused a slight inhibition in loss of plasma membrane 
integrity (Figure 26a & b).
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Figure 26a: Primary cardiomyocytes were treated with cyclosporin A (CsA) at concentrations 
ranging from 40-400nM followed by 1 0 0 j i M  t-butylhydroperoxide (t-BOOH) for 1 hr. The 
reduction of metabolic activity (quantified by conversion of MTT reagent) proved to be 
unaffected by CsA pre-treatment [***, p < 0.001 v. control].
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Figure 26b: The same cardiomyocytes assayed for LDH activity showed that cyclosporin A 
(CsA) slightly prevented loss of t-butylhydroperoxide (t-BOOH) caused membrane integrity at 
40-50nM [***, p < 0.001 v. control; +, p < 0.05 v. t-BOOH].
As the effect of CsA pre-treatment remained undetermined, CsA was instead applied to the 
primary cardiomyocytes concurrently with t-BOOH. Analysis of metabolic activity and plasma 
membrane integrity showed that 40-50nM CsA significantly inhibited cell death (Figure 27a & 
b).
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Figure 27a: Primary cardiomyocytes were treated with Cyclosporin A (CsA) at concentrations 
ranging from 40-400nM concurrently with 100jllM t-butylhydroperoxide (t-BOOH) for 1 hr. 40 & 
50nM CsA significantly inhibited the reduction in metabolic activity as quantified by conversion 
of MTT reagent [***, p < 0.001 v. control; +++, p < 0.001 v. t-BOOH].
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Figure 27b: The same cardiomyocytes assayed for LDH activity showed that 40-1 OOnM 
cyclosporin A (CsA) significantly prevented the loss of membrane integrity caused by t-
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butylhydroperoxide (t-BOOH) [***, p < 0.001 v. control; ++, p < 0.01 v. t-BOOH; +, p < 0.05 v. t- 
BOOH].
Primary cardiomyocytes were treated with 5|iM BA prior to application of 10OpiM t-BOOH. In 
about half of the experiments carried out, the combination of BA and t-BOOH killed the cells 
and in the remainder of the experiments no inhibitory effect of BA could be seen (Figure 28a &
b).
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Figure 28a: Primary cardiomyocytes were treated with 5(iM bongkrekic acid (BA) for 1 hr 
followed by 100|iM t-butylhydroperoxide (t-BOOH) for 1 hr. The effect of BA on t-BOOH 
induced reduction of metabolic activity (quantified by conversion of MTT reagent) was 
extremely variable and inconsistent [***, p < 0.001 v. control].
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Figure 28b: The same bongkrekic acid (BA) and t-butylhydroperoxide (t-BOOH) treated 
cardiomyocytes assayed for LDH release showed the same inconsistency [***, p<0.001 v 
control].
Primary cardiomyocytes were then treated with BA and t-BOOH concurrently for 1 hr. Analysis 
of both metabolic activity and plasma membrane integrity showed that the combination of BA 
and t-BOOH was effectively killing the cells (Figure 29a & b).
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Figure 29a: Primary cardiomyocytes were treated with 5jiM bongkrekic acid (BA) concurrently 
with 10OjuM t-butylhydroperoxide (t-BOOH) for 1 hr. The combination of BA and t-BOOH 
induced a significantly greater reduction of metabolic activity (quantified by conversion of MTT 
reagent) than t-BOOH alone [***, p < 0.001 v. control; +++, p < 0.001 v. t-BOOH],
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Figure 29b: The same cells assayed for LDH release showed that the combination of 
bongkrekic acid (BA) and t-butylhydroperoxide (t-BOOH) induced a significantly greater 
release of LDH than t-BOOH alone [***, p < 0.001 v. control; +++, p < 0.001 v. t-BOOH],
3.4.7 The Effect of MPTP Inhibition on Simulated Ischaemia-Reperfusion Injury 
50nM CsA was applied to cardiomyocytes either, for 1 hr prior to the experiment, during 
treatment with the simulated ischaemia solution, or during the 18hr simulated reperfusion 
period. Analysis of metabolic activity and membrane integrity showed that CsA was unable to 
inhibit cell death (Figure 30a & b).
5jiM BA was applied in the same manner as CsA, either as a pre-treatment, during ischaemic 
solution application, or during simulated reperfusion. After the 18hr of simulated reperfusion, 
the cells were analysed for metabolic activity and membrane integrity. As with t-BOOH, the 
effect of BA was extremely erratic, on some occasions it’s application was extremely toxic to 
the cells. However, only on rare occasions could any inhibitory effect be seen (Figure 31a & b)
- 117 -
Chapter 3 Cell Death and MPTP Inhibition
0.5-,
0.4-
I  0.3-CD1^ -to
<
0 .2 -
0.0
Figure 30a: 50nM cyclosporin A (CsA) was applied to primary cardiomyocytes, either for 1 hr 
prior to the experiment, during application of ischaemic solution, or during the 18hr simulated 
reperfusion period. Analysis of metabolic activity showed no inhibitory effect of CsA [***, p < 
0.001 v. control].
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Figure 30b: The same cardiomyocytes assayed for LDH release showed that cyclosporin A
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(CsA) was unable to inhibit the loss of membrane integrity induced by simulated ischaemia and 
reperfusion [***, p < 0.001 v. control].
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Figure 31a: 5|iM bongkrekic acid (BA) was applied to cardiomyocytes, either for 1 hr prior to 
the experiment, during treatment with the simulated ischaemia solution, or during the 18hr 
simulated reperfusion period. Analysis of metabolic activity quantified by conversion of MTT 
reagent showed no overall inhibitory effect of BA [***, p < 0.001 v. control].
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Figure 31b: The same cardiomyocytes assayed for LDH release showed that bongkrekic acid 
(BA) was unable to inhibit the loss of membrane integrity caused by 3hr simulated ischaemia 
solution treatment and 20hr simulated reperfusion [***, p < 0.001 v. control].
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3.5 Discussion
As stated in Chapter 1 the problem of quantifying apoptosis is a contentious issue, with many 
of the available methods of detection such as TUNEL staining being heavily disputed. 
Additionally, many different pathways of apoptosis have been reported. The classical apoptotic 
features are ubiquitous in physiological apoptosis, but it is difficult to think of any event that has 
been reported in all cases of pathological apoptosis. Therefore, it cannot be maintained with 
certainty that apoptosis is being accurately measured and any attempt to differentiate 
accurately between apoptosis and necrosis must be viewed with some scepticism.
In this study, SSP was used to induce apoptosis. SSP is widely recognised as an effective 
inducer of apoptosis and has been utilised by many researchers. It has previously been used 
in a wide range of cell types including primary cardiomyocytes and the resulting apoptotic cell 
death has been measured by a wide variety of methods (12,13,39, 59,233). As such it can 
be employed for the induction of apoptosis with relative confidence. In this study analysis by 
electron microscopy served to confirm that apoptosis was occurring in the cardiomyocyte 
cultures and also illustrated that high concentrations of SSP induced necrotic cell death 
instead of apoptosis.
For the quantification of apoptosis, three separate parameters were measured. Reduction of 
metabolic activity and plasma membrane integrity are features of all forms of cell death. In the 
case of apoptosis, metabolic activity must remain high in order to fully implement the process 
and loss of membrane integrity occurs only after the process is essentially complete. Both 
parameters must therefore be viewed as extreme endpoints. Fragmentation of nuclear DNA is 
commonly associated with apoptosis although it has also been reported in essentially necrotic 
cells (55). It occurs during the active process, prior to the formation of apoptotic bodies and 
should therefore be detectable before significant changes in metabolic activity and membrane 
integrity can be seen.
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This is borne out by the results obtained. No significant change in metabolic activity or 
membrane integrity could be observed until after 18-24hr of SSP treatment. However, analysis 
of DNA fragmentation through the quantification of DNA loss from permeablised cells showed 
significant changes from as early as 4hr. Taken together these data show that primary 
cardiomyocytes begin undergoing apoptosis within 4 hours of application of SSP. As apoptosis 
is an active process metabolic activity remains high and as the plasma membrane is not 
compromised the release of LDH is low. However, at a later stage in the process when over 
50% of the cells are dead and undergoing post-apoptotic necrotic changes, a corresponding 
decrease in metabolic activity and release of intracellular enzymes can be observed.
These data, combined with the known properties of SSP make it certain that apoptosis was the 
predominant form of cell death and subsequently, that the effects of the chosen interventions 
could be accurately measured. Finally, Western blotting of SSP-treated cells with an antibody 
against caspase 3 revealed cleavage of the 32kDa caspase 3 precursor protein that was not 
observed in the control cells. This finding is not in any way conclusive, since activation of 
caspases has been demonstrated in necrotic cell death as previously mentioned, and there 
could be other reasons for the disappearance of the caspase 3 precursor, such as a general 
breakdown of proteins in the dying cell. Although detection of the activated caspase 3 protein 
is a more direct means of showing caspase involvement, the available antibodies were not 
found to be reliable. However cleavage of the caspase 3 precursor protein serves as an extra 
piece of evidence for the activation of apoptotic pathways.
CsA, which binds to and inhibits cyclophilins, was applied to the cardiomyocytes as an aid to 
study the role of CyPD in cardiomyocyte cell death. The primary cardiomyocytes showed 
sensitivity to the toxic effects between 400 and 600nM CsA. This is in contrast with other cell 
types that are apparently resistant to much higher concentrations of CsA and reflects 
differences in cellular metabolism. For example primary rat hepatocytes do not show signs of
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compromised membrane integrity when treated with up to IOjlxM CsA (214) and 30jiM CsA 
was used without ill effect in human osteosarcoma cells (150). Long term CsA treatment is 
known to cause widespread tissue damage in vivo and causes apoptosis in cultured cells. The 
mechanisms underlying this toxicity appear to vary according to cell type. A number of studies 
have shown CsA induction of nitric oxide (213,234,235) and Esposito and colleagues 
reported CsA induced changes in cell proliferation, nitric oxide production and extra cellular 
matrix turnover, with the precise response to CsA being dependent upon the cell type (213).
When applied to primary cardiomyocytes prior to SSP treatment, CsA was toxic at a lower 
concentration than was observed without SSP. This is presumably due to interaction between 
CsA and SSP and is supported by the fact that when applied concurrently, CsA and SSP were 
toxic to the cells even at a CsA concentration as low as 50nM. When applied as a pre­
treatment, 50nM CsA had no detectable effect on the extent of apoptosis. However, in the light 
of the results above, it is possible that there was a slight toxic effect that was undetectable by 
the methodology chosen. An alternative possibility is that 50nM CsA was too low to be an 
effective dose. In this instance it may not be possible to apply an effective concentration that 
will not be toxic in combination with SSP. It must also be considered whether the CsA was 
successfully entering the mitochondria and binding to CyPD and if it did, then whether this was 
effectively inhibiting the collapse of the mitochondrial transmembrane potential. An additional 
possibility is that collapse of the transmembrane potential is a consequence of SSP-induced 
apoptosis as opposed to a cause. In which case, inhibiting the MPTP would not affect the 
extent of apoptosis.
In order to clarify these results, BA was selected as an alternative inhibitor to CsA. BA did not 
display any unexpected toxicity either when applied as a pre-treatment, or concurrently with 
SSP. However, it displayed no discernable influence on the extent of apoptosis by any of the
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measured parameters. BA directly inhibits the adenine nucleotide translocase (ANT) by binding 
to it and stabilising it in its closed ‘M’ conformation (236). Unlike CyPD, which is often 
described as a regulator of the MPTP, the ANT is believed to form at least part of the 
fundamental structure of the pore. Direct inhibition of the ANT, should therefore unquestionably 
inhibit formation of the MPTP and, theoretically, prevent the collapse of the transmembrane 
potential. However, stabilising the ANT in its closed conformation will also inevitably inhibit the 
passage of adenosine nucleotides across the mitochondrial membrane, thereby affecting cell 
metabolism. When applied for 2 hrs at a concentration of up to 10p,M, BA did not have any 
significant effect on metabolic activity as measured by the conversion of MTT reagent. Neither, 
however, did BA have any significant effect on the progression of apoptosis. This could mean 
that BA did not successfully enter the cells, and was therefore unable to influence either 
metabolism or the MPTP. Alternatively, it may be that the low concentrations of BA used, that 
did not noticeably inhibit ATP movement, were also unable to influence formation of the MPTP, 
that is, after all, a pathological event. A further possibility is that the MPTP did not play a 
significant role in this model of apoptosis, so that cell death could not be influenced by the 
presence of BA.
From the data obtained in this chapter, it is not possible to determine the precise reason for the 
failure of CsA to inhibit apoptosis. A further explanation is that inhibition of the pore by CsA 
and BA is a short-lived event. It is possible that over the course of the 18hr SSP treatment the 
inhibition is overcome and the cells undergo apoptosis. Further experiments are required to 
examine the process in further detail. Specifically, it must be determined whether CsA is 
successfully binding to CyPD and whether either inhibitor is capable of entering the cells and 
preventing the collapse of mitochondrial transmembrane potential.
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In order to establish a model of necrotic cell death, t-BOOH was applied to primary 
cardiomyocytes for 1hr. A short treatment period was chosen in part to address the question of 
whether MPTP inhibition by CsA and BA was only a transient event. Over the course of 1hr 
100p,M consistently produced significant but not total cell death and analysis by EM showed 
that the cells were dying by necrosis.
When applied either prior to or concurrently with t-BOOH, CsA did not display any unexpected 
toxicity. Effective inhibition of cell death could only be seen when CsA was applied 
concurrently with t-BOOH and at the low concentration of 50nM. This is contradictory to other 
studies that have stated 200nM or greater to be the most effective CsA concentration in rat 
primary cardiomyocytes. However the cardiomyocytes used in these studies were from older 
animals, the youngest used were from 2-week-old pups. Other studies have shown that the 
effective dose of CsA in primary cardiomyocytes varies according to the age of the animals 
used (133,136,237). Therefore it is not surprising that the results obtained in this study 
differed from existing reports. Doyle and colleagues showed that 500nM was the most effective 
dose of CsA in cells taken from 2-week-old pups, a concentration that would probably have 
been toxic in cells from 1-3 day olds (significant toxicity was noted between 400 & 600nM). 
Additionally the group applied 500p,M t-BOOH to their cells for over 70min (237), a treatment 
that killed the entire population of our cells in less than 1hr. It is therefore probable that 
cardiomyocytes from 1-3 day old rats were more sensitive to the application of chemicals than 
those used in other studies. Thus a much lower effective dose of CsA was observed.
BA proved to be extremely toxic when applied in combination with t-BOOH. When applied as a 
pre-treatment it was not significantly toxic but no inhibition of cell death could be seen. It is 
probable that this toxicity was due to interaction between BA and t-BOOH and even the most 
rigorous washing prior to t-BOOH application could not completely prevent the reaction.
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Many previous studies have utilised solutions designed to mimic the in vivo conditions of 
ischaemia in vitro (238-242). Such a system has several advantages. A far greater range of 
parameters can be easily studied in a cell culture system than in vivo and a single cell type can 
be easily studied. A greater range of interventions can be applied without the ethical 
considerations encountered in animal work and in vitro work is invariably less expensive. 
However, there are also problems associated with in vitro simulations. There may be varying 
opinions of the precise conditions encountered during in vivo ischaemia leading to argument 
over the content of the simulation buffers used. Additionally there may be other factors 
involved in vivo which are as yet unknown and therefore cannot be accounted for in a 
simulation. Such simulations therefore are useful tools for studying the mechanisms behind 
ischaemia-reperfusion injury, allowing more detailed analysis than can be easily achieved in 
whole tissue. However they can only serve as a starting point and the results cannot 
necessarily be extrapolated to an in vivo situation.
The solution used in this instance is based upon a protocol of Esumi and colleagues (217) 
incorporating slight modifications by Dr. R. Heads (personal communication). The solution is 
based on Krebs buffer but includes 2-deoxyglucose to inhibit glycolysis and sodium dithionite 
to inhibit mitochondrial respiration and scavenge oxygen. The addition of lactate and KCI 
mimics the conditions present during ischaemia in vivo (see introduction). The oxygen 
scavenging effect of sodium dithionite decreases after approximately 1hr so the cells were 
placed in a hypoxic chamber to maintain the anoxic environment for the duration of the 
experiment.
This treatment caused a time-dependent decrease in cell viability as expected. Also as 
expected, subsequent incubation in full media caused a further decrease in viability, a gradual 
decline in metabolic activity over the first 18 hours followed by a sharp decrease between 18
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and 24 hours of simulated reperfusion. This coincided with a significant increase of LDH 
activity in the cell media showing that plasma membrane integrity was severely compromised. 
When the cells were examined by electron microscopy, it could be clearly seen that they were 
dying by necrosis and were in fact in a state of greater degradation than those treated by t- 
BOOH. This was certainly due to the longer treatment period.
These results would initially suggest that the system used was successfully simulating 
ischaemia-reperfusion injury at least to some degree.
Treatment with CsA and BA did not produce the expected results. It has been shown on many 
occasions that the MPTP opens during reperfusion. Therefore inhibitors of the MPTP would be 
expected to reduce the extent of cell death during the simulated reperfusion phase if not during 
application of the ischaemic solution. CsA and BA were applied during all phases of the 
experiment but no influence was observed. On some occasions BA was in fact toxic if applied 
as a pre-treatment or concurrently with the simulated ischaemia solution. Presumably BA was 
reacting with an element of the ischaemic solution, although if that is the case it is difficult to 
explain why it was not always toxic when applied together with the ischaemic solution. CsA did 
not display any obvious toxicity but nevertheless failed to inhibit the loss of cell viability. As 
CsA had a significant effect on t-BOOH induced necrosis, it is likely that CsA is successfully 
binding to CyPD and inhibiting induction of the MPTP. However it still failed to reduce cell 
death during application of the simulated ischaemia solution. One possibility, as with the SSP 
model is that the experimental time is too long and the effect of CsA is only transient. 
Alternatively, it may be that the model of simulated ischaemia is not an accurate representation 
of the in vivo situation and the importance of the MPTP is diminished. It is therefore important 
to directly assess the effect of CsA on the behaviour of the MPTP in this model.
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3.6 Conclusions
Models of apoptosis, necrosis and simulated ischaemia-reperfusion injury were successfully 
implemented in neonatal primary cardiomyocytes.
Application of MPTP inhibitors only slightly suppressed necrotic cell death and was ineffective 
in the cases of apoptosis and simulated ischaemia-reperfusion injury. Therefore further study is 
required to clarify the situation.
-128-
Chapter 4 m AV and MPTP Inhibition
4: Quantification of mA'F and the Effect of MPTP Inhibition
4.1 Introduction
Translocation of protons across the mitochondrial membranes down the electron transport 
chain creates an electrochemical gradient with a potential gradient of approximately -180mV. 
This mitochondrial transmembrane potential, generally referred to as the mA'F, is the driving 
force for ATP synthesis and therefore crucial to the health of the whole cell. Opening of the 
mitochondrial permeability transition pore (MPTP) for any prolonged period inevitably disrupts 
this gradient resulting in a decline in ATP synthesis. For this reason, induction of the MPTP is 
widely recognised as an important factor in many situations of cell injury and death.
In particular, its role in ischaemia-reperfusion injury has attracted attention as it has been 
shown that opening of the MPTP upon reperfusion may be in part responsible for the increase 
in cell injury. A large number of studies have pinpointed MPTP induction as a crucial point in 
cell death (7,118,243) but equally there have been studies reported that MPTP was not 
induced or its influence was unimportant (150,187). Although the methods for detecting MPTP 
induction are often disputed, there can now be little doubt that it’s function and relative 
importance varies widely according to the cell type and manner of death induction.
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4.2 Objective
In a study dealing with the influence of the MPTP of cell death it is crucial to measure induction 
of the pore directly, and if possible unambiguously. The aim of this study was to measure 
mA'F in primary cardiomyocytes using the 3 models of cell death described in the previous 
chapter.
Additionally the effect of inhibitors of the MPTP on mA'F was examined.
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4.3 Materials and Methods
Neonatal primary cardiomyocytes were isolated and cultured as described in chapter 2.2.1. 
Cell death was induced using staurosporine (SSP), t-butylhydroperoxide (t-BOOH) and a 
solution designed to replicate the extracellular conditions of ischaemia-reperfusion injury as 
detailed in chapter 2.2.2-4.
Mitochondrial transmembrane potential (mA'F) was measured using the fluorescent dye 
3,3’dihexyloxacarbocyanine iodide (DiOCe(3)) and analysed by flow cytometry as described in 
chapter 2.4.1 or by confocal microscopy as detailed in 2.4.2.
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4.4 Results
4.4.1 Measurement of mA'F in primary cardiomyocytes
Fluorescence of (DiOC6<3)) was measured by flow cytometry and plotted against cell size as 
measured by forward scatter. Brightly stained cells again correlated with normal size and 
granularity and although the pattern of staining with (DiOC6<3)) was more diffuse than the 
propidium iodide (PI) staining described in chapter 3.4.2,1 group of small, very poorly stained 
cells were seen as well as 2 groups of larger, brightly stained cells which were assumed to be 
the viable cell population (see Figure 32). This allowed quantification of the percentage of cells 
with viable mitochondria as well as separate assessment of the mA'F of the viable cell 
population.
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Figure 32: Control cardiomyocytes stained with (DiOC6<3)) were analysed on a flow cytometer 
and cell size (FSC-H) was plotted against fluorescence (FL1-H) in a scatter plot, an example of 
which is shown above. This revealed one group of small, unstained cells and 2 groups of large, 
brightly stained viable cells. The quadrant parameters were set to contain all of the apparently 
viable cells in the upper-right quadrant. These cells were then analysed either by number or by 
mean fluorescence intensity.
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In order to demonstrate that (DiOCe(3)) was genuinely measuring mA'F, primary 
cardiomyocytes were treated for 1hr with the mitochondrial uncoupler carbonyl cyanide m- 
chlorophenylhydrazone (CCCP). Fluorescence of (DiOCe(3)) was then measured as above 
and expressed as a percentage of the control. Analysis of the number of viable cells showed 
no variation between the control and treated cells, due to the fact that the cell size was 
unaffected by CCCP treatment (Figure 33a). Measurement of the geometric mean 
fluorescence of the total cell population (including a negative staining control) also failed to 
show any change in staining (Figure 33b). This was explained by the fact that the two groups 
of cells seen in Figure 32 created two main peaks of fluorescence when plotted in a histogram 
(Figure 33c). During treatment the cells moved from the brightly stained group into the poorly 
stained group without creating any significant changes in the geometric mean, which lies 
midway between the two groups. However, when the mean fluorescence intensity (MFI) of the 
total cell population was measured, a significant and concentration-dependent decrease was 
observed (Figure 33d) showing that fluorescence of (DiOCe(3)) was relative to mA'F. Quadrant 
markers were set on the control samples to exclude the unstained cells (as shown in figure 32) 
allowing independent measurement of the viable population. This proved to be a far more 
sensitive method of analysis. A highly significant concentration dependent reduction in both the 
geometric mean (Figure 33e) and the MFI (Figure 33f) was observed.
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Figure 33a: Cardiomyocytes treated with the mitochondrial uncoupler CCCP were stained with 
(DiOC6<3)) and the number of cells in the upper-right quadrant was counted (see Figure 32). 
This revealed no variation between control and treated cells.
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Figure 33b: Analysis of the geometric mean of the total cell population in the same samples 
also failed to show any significant changes in (DiOC6(3)) fluorescence after treatment with the 
mitochondrial uncoupler CCCP [***, p < 0.001 v. Control].
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Figure 33c: This representative histogram shows the (DiOCe(3)) fluorescence of control and 
CCCP-treated cells. This demonstrates that the geometric mean remains changes only slightly 
despite clear changes in the distribution of fluorescence.
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Figure 33d: Analysis of the mean fluorescence intensity (MFI) of the total cell population of the 
same cells treated with the mitochondrial uncoupler CCCP revealed a significant 
concentration-dependent decrease in (DiOCe(3)) fluorescence [**, p < 0.01 v. Control; ***, p < 
0.001 v. Control].
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Figure 33e: Analysis of the geometric mean of only the viable cell population after application 
of the mitochondrial uncoupler CCCP revealed a concentration-dependent decrease in 
(DiOC6(3)) fluorescence of greater significance than the in the total population [*, p < 0.05 v. 
Control; ***, p < 0.001 v. Control].
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Figure 33f: Analysis of the MFI of the viable cell population revealed a (DiOC6<3)) 
concentration-dependent decrease in fluorescence following application of the mitochondrial 
uncoupler CCCP that was more highly significant than the geometric mean [***, p < 0.001 v. 
Control].
Primary cardiomyocytes stained with (DiOC6(3)) were visualised by confocal microscopy.
When 20nM (DiOC6(3)) was used, staining of the nuclear membrane and some random diffuse 
fluorescence was seen in addition to discrete staining of small sub-cellular compartments 
(Figure 34a). However, when a concentration of less than 1nM was used (0.8nM) as 
recommended by Rottenberg and colleagues (222), no nuclear membrane staining was seen 
(Figure 34b). Upon application of 1pM of the mitochondrial uncoupler carbonyl cyanide p- 
trifluoromethoxyphenylhydrazone (FCCP), the discrete staining was abolished and the 
fluorescence became diffused throughout the cell as illustrated in Figures 35 & 36. This 
demonstrated that (DiOCe(3)) was specifically staining the mitochondria.
-  138 -
Chapter 4 mA'F and MPTP Inhibition
Figure 34a: Primary cardiomyocytes were stained with 20nM (DiOCe(3)) and visualised by 
confocal microscopy. Discrete staining of small sub-cellular compartments can be seen but 
additionally, the nuclear membrane is defined and some diffuse fluorescence can be observed
in the cytoplasm.
Figure 34b: Primary cardiomyocytes were stained with 0.8nM (DiOCe(3)) and visualised by 
confocal microscopy. Discrete staining of small sub-cellular compartments can be seen with no 
definition of the nuclear membrane or diffuse cytoplasmic fluorescence.
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Figure 35: (a) Primary cardiomyocytes were stained with 0.8nM (DiOC6(3)) and visualised by 
confocal microscopy, (b) in cardiomyocytes photographed 30 seconds after the addition of 
1(iM of the mitochondrial uncoupler FCCP the discrete staining was lost and the fluorescence
had diffused throughout the cell.
Figure 36: In a certain experiment (a, photographed prior to FCCP treatment) the three 
cardiomyocytes lost the discrete staining (b, photographed 30 seconds after addition of FCCP) 
and the middle cell of the three was then seen to undergo rigor (c, photographed after a further
30 seconds)
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4.4.2 Measurement of mA'F during apoptosis
The data presented above showed that (DiOC6(3)) was successfully detecting changes in 
mA'F. Therefore, mA'F was measured in primary cardiomyocytes (see Figure 32) subjected to 
treatment with the apoptosis inducer SSP and changes in the number of cells displaying a high 
mA'F (i.e. as control) were monitored.
Application of 5|uM SSP to primary cardiomyocytes caused a time-dependent reduction in the 
number of cells displaying high mitochondrial transmembrane potential as shown in Figure 
37a. However when the mean fluorescence of the viable population was measured, no 
decrease in staining was observed as shown in Figure 37b.
9"1
<
E
-C
0 5
"O
co
3
100 -I
★ ★ ★
* * *
o
- f ac=
o
o
o ''
★ * *
Figure 37a: Application of 5^iM staurosporine (SSP) over 24hr caused a time-dependent 
reduction in the number of cells displaying high mitochondrial transmembrane potential (mA'F) 
as quantified by uptake of (DiOC6(3)) [***, p < 0.001 v control].
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Figure 37b: The mean fluorescence intensity (MFI) of the viable cardiomyocyte population 
(upper-right quadrant, see Figure 32) remained comparatively high throughout the 
staurosporine (SSP) treatment period showing that mitochondria were taking up (DiOCe(3)) 
and transmembrane potential was therefore little affected [*, p < 0.05 v control].
4.4.3 Measurement of mAH1 during necrosis
Mitochondrial transmembrane potential was also assessed in primary cardiomyocytes following 
1hr application of 1 0 0 jllM  t-BOOH. This produced a significant drop in the number of cells 
displaying high fluorescence (Figure 38a) and furthermore, the uptake of (DiOCe(3)) by the 
remaining viable cells was significantly reduced (Figure 38b).
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Figure 38a: Application of 100jiM t-butylhydroperoxide (t-BOOH) for 1 hr caused a significant 
reduction in the number of cells displaying high mitochondrial transmembrane potential (mA'F) 
as quantified by uptake of (DiOCe(3)) [***, p < 0.001 v. control].
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Figure 38b: During the 1 hr of t-butylhydroperoxide (t-BOOH) treatment, the mean fluorescence 
intensity (MFI) of the viable cell population was significantly reduced showing that 
mitochondrial uptake of (DiOC6<3)) was reduced and transmembrane potential has therefore 
declined [***, p < 0.001 v. control].
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4.4.4 Measurement of mA'F during simulated ischaemia-reperfusion injury 
Primary cardiomyocytes subjected to simulated ischaemia and reperfusion as described 
previously were analysed for changes in mA'F. After 3 hours of treatment with the simulated 
ischaemia solution there was no reduction in fluorescence, and for up to 4hr of simulated 
reperfusion no significant decrease in mA'F was observed; however after 20hr there was a 
significant decrease in fluorescence (Figure 39a & b).
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Figure 39a: 3hr application of the simulated ischaemia solution did not affect the number of 
cells displaying high mitochondrial transmembrane potential (mA'F) as quantified by uptake of 
(DiOCe(3)) but after 20hr of simulated reperfusion the number was significantly reduced [***, p 
< 0.001 v. control].
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Figure 39b: After 3hr of simulated ischaemia, the mean fluorescence intensity (MFI) of the 
viable cell population was slightly higher than the control, but after 20hr of simulated 
reperfusion it was significantly reduced showing that mitochondrial uptake of (DiOCe(3)) was 
reduced and transmembrane potential has therefore declined [***, p < 0.001 v. control].
4.4.5 The effect of MPTP inhibition on m AT during apoptosis 
Primary cardiomyocytes were treated with 50nM cyclosporin A (CsA) for 1 hr prior to SSP 
application. Analysis of m AT showed that CsA significantly inhibited the reduction of the 
number of cells with high membrane potential and also caused an increase in the membrane 
potential of the viable cell population (Figure 40a & b).
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Figure 40a: 50nM cyclosporin A (CsA) application to cardiomyocytes prior to treatment with 
5jiM staurosporine (SSP) significantly inhibited the reduction of cells displaying high 
transmembrane potential (mA'F) as quantified by uptake of (DiOC6(3)) [***, p < 0.001 v. 
control; +++, p < 0.05 v. SSP].
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Figure 40b: Analysis of the viable population showed that cyclosporin A (CsA) pre-treatment 
caused a small but significant increase in the mean fluorescence intensity (MFI) of the viable 
cell population [***, p < 0.001 v. control; +, p < 0.05 v. SSP].
Primary cardiomyocytes were also treated with bongkrekic acid (BA) prior to SSP application. 
Analysis of m A ^  revealed that BA significantly inhibited the reduction of the number of cells 
with high membrane potential and also caused an increase in the membrane potential of the 
viable cell population (Figure 41a & b).
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Figure 41a: Application of 5^M bongkrekic acid (BA) to cardiomyocytes prior to treatment with 
5jiM staurosporine (SSP) significantly inhibited the reduction of cells displaying high 
transmembrane potential (mA'F) as quantified by uptake of (DiOC6(3)) [***, p < 0.001 v. 
control; +++, p < 0.05 v. SSP].
- 148 -
Chapter 4 mAH* and MPTP Inhibition
o■-!=>_ro
Q_O
Q_
"a3
o
JD
-Qcp
>
120 -I
80-
OO
40-
Figure 41b: Analysis of the viable population showed that 5jiM bongkrekic acid (BA) pre­
treatment also caused a small but significant increase in the mean fluorescence intensity (MFI) 
of the viable cell population [*, p > 0.05 v. control; +++, p < 0.001 v. SSP].
4.4.6 The effect of MPTP inhibition on mA^F during necrosis
50nM CsA was applied to primary cardiomyocytes prior to treatment with 100p.M t-BOOH and 
analysis of m A ^. Quantification of the reduction of viable cells with high m A ^  showed a slight 
but significant inhibition by CsA (Figure 42a), and analysis of the decrease in fluorescence in 
the viable population revealed highly significant inhibition by CsA (Figure 42b).
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Figure 42a: Application of cyclosporin A (CsA) to cardiomyocytes prior to treatment with t- 
butylhydroperoxide (t-BOOH) significantly inhibited the reduction of cells displaying high 
transmembrane potential (mAxF) as quantified by uptake of (DiOC6<3)) [***, p < 0.001 v. 
control; +, p < 0.05 v. t-BOOH].
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Figure 42b: Analysis of the viable population showed that cyclosporin A (CsA) significantly 
inhibited the reduction of the mean fluorescence intensity (MFI) caused by t- 
butylhydroperoxide (t-BOOH) showing that mitochondrial uptake of (DiOC6<3)) was improved 
and the decline in transmembrane potential had therefore been inhibited [***, p < 0.001 v. 
control; ++, p < 0.01 v. t-BOOH].
4.4.7 The effect of MPTP inhibition on m A ^  during simulated ischaemia-reperfusion injury 
50nM CsA was applied to primary cardiomyocytes for 1 hr prior to subjection to simulated 
ischaemia-reperfusion injury. CsA pre-treatment significantly inhibited both the reduction in the 
number of cells displaying high transmembrane potential and the decrease in the MFI of the 
viable population (Figure 43a & b).
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Figure 43a: Pre-treatment of cardiomyocytes with 50nM cyclosporin A (CsA) significantly 
inhibited the simulated ischaemia-reperfusion injury induced reduction in the number of 
cardiomyocytes displaying high transmembrane potential (mAT) as quantified by uptake of 
(DiOC6(3)) [***, p < 0.001 v. control; ++, p < 0.01 v. 20hr Reperfusion].
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Figure 43b: Analysis of the viable population showed that 50nM cyclosporin A (CsA) 
significantly inhibited the reduction of the mean fluorescence intensity (MFI) caused by 
simulated ischaemia-reperfusion injury showing that mitochondrial uptake of (DiOC6(3)) was 
improved and the decline in transmembrane potential had therefore been inhibited [***, p < 
0.001 v. control; ++, p < 0.01 v. 20hr Reperfusion].
BA was applied to primary cardiomyocytes for 1 hr prior to subjection to simulated ischaemia- 
reperfusion injury. BA pre-treatment significantly inhibited both the reduction in the number of 
cells displaying high transmembrane potential and the decrease in the MFI of the viable 
population (Figure 44a & b).
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Figure 44a: Pre-treatment of cardiomyocytes with 5 j lx M  bongkrekic acid (BA) significantly 
inhibited the simulated ischaemia-reperfusion injury induced reduction in the number of 
cardiomyocytes displaying high transmembrane potential (mA4/) as quantified by uptake of 
(DiOC6(3)) [***, p < 0.001 v. control; ++, p < 0.01 v. 20hr Reperfusion].
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Figure 44b: Analysis of the viable population showed that 5jiM bongkrekic acid (BA) 
significantly inhibited the reduction of the mean fluorescence intensity (MFI) caused by 
simulated ischaemia-reperfusion injury showing that mitochondrial uptake of (DiOCe(3)) was 
improved and the decline in transmembrane potential had therefore been inhibited [***, p < 
0.001 v. control; ++, p < 0.01 v. 20hr Reperfusion].
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4.5 Discussion
Although mA'F-sensitive dyes have been used in many studies for the detection of MPTP 
induction, it is nevertheless a contentious area. Studies of these dyes have produced 
contradictory results so there is little consensus regarding their experimental use. In this study, 
(DiOC6(3)) was chosen to evaluate mA'F in primary cardiomyocytes as this is one of the most 
widely utilised dyes and has previously been used in cardiomyocytes. Initial studies of this dye 
used a concentration of 40nM (221), a concentration which did not appear to be effective in 
cardiomyocytes (244). However, a more recent study by Rottenberg and Wu showed that an 
extremely low concentration of (DiOC6(3)) (<1nM) was necessary for the accurate 
measurement of mA'F (222).
Evaluation of the (DiOC6<3))-staining of primary cardiomyocytes by confocal microscopy 
showed bright staining of discrete areas of the cells. At 20nM (DiOC6(3)), nuclear membrane 
staining was seen which concurs with the findings of Rottenberg and colleagues. At 0.8nM 
(DiOC6(3)) no nuclear membrane was observed and the discrete staining that was seen 
disappeared upon application of FCCP. This showed that (DiOCe(3)) was being taken up into 
viable mitochondria and diffused out upon the collapse of mA'F. When this effect was 
quantified using CCCP and flow cytometric analysis, a concentration-dependent decrease in 
fluorescence was observed further supporting the relevance of (DiOC6(3)) as a quantitative 
marker of mA'F.
When mA'F was measured during SSP-induced apoptosis, a time-dependent reduction in the 
number of cells displaying high membrane potential was seen. However, when the 
fluorescence of the viable cells (those in the upper-right quadrant) was measured, there was 
no significant variation during the period of treatment. This may suggest that rather than being
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a central event in the process of apoptosis, the observed reduction in mA'F was merely a 
consequence of the cells dying and therefore occurred late in the process. Pre-treatment with 
CsA caused a significant inhibition in the loss of mA'F implicating opening of the MPTP as the 
cause of the loss of potential. However, the inhibition observed was only slight, supporting the 
theory that induction of the MPTP is a non-essential, end-point event in this model of 
apoptosis. As CsA was able to produce a significant increase in mA'F of untreated cells, the 
possibility that it was directly interacting with (DiOC6(3)) and influencing the staining must be 
considered. However, when the effect of BA was analysed, exactly the same results were 
obtained. This shows that both inhibitors successfully entered the cells and would suggest that 
they were able to influence mA'F by stabilising the MPTP as has been frequently reported. 
The slight inhibitory effect of BA also lends further weight to the theory that MPTP induction is 
not a crucial event of SSP-induced apoptosis in primary cardiomyocytes.
Measurement of mA'F following t-BOOH treatment revealed a significant decrease in both the 
number of cells displaying high membrane potential and in the mA'F of the remaining viable 
population. This suggests that loss of transmembrane potential could have been an important 
factor in necrotic cell death as the mitochondria were undergoing a reduction in potential prior 
to the cells undergoing a reduction in size. Pre-treatment with CsA resulted in a significant 
increase in the number of cells retaining high membrane potential following t-BOOH treatment 
and a highly significant increase in the mA'F of the remaining viable population. This showed 
that CsA was effectively inhibiting the reduction in transmembrane potential but due to the 
severity of the insult, it was only a transient inhibition.
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When mA'F was analysed following 3hr of simulated ischaemia, no variation was observed. 
Upon simulated reperfusion, no change could be seen for up to 4hr. It was only when the 
cardiomyocytes were reperfused overnight for 20hr that a significant reduction in 
transmembrane potential was observed. As with the t-BOOH-treated cells, a significant loss of 
potential was observed in the mitochondria prior to the cells undergoing a reduction in size 
suggesting that loss of mA'F was a significant factor in the process of cell death. The fact that 
pre-treatment with CsA significantly inhibited the loss of potential implicated involvement of the 
MPTP. Pre-treatment with BA delivered the same results, confirming the involvement of the 
pore. However neither inhibitor was able to completely prevent the decline of mA'F. This could 
be due to a number of factors. Although the inhibitory effect of CsA and BA shows induction of 
the MPTP, there is no certainty that this accounts for the total decrease of mA'F. There are 
known to be other agents that cause disruption of the mitochondria (CCCP being an obvious 
example) and many other damaging factors present during reperfusion, so there may be other 
reasons for the decline in mA'F. The possibility that an element in the simulated ischaemic 
solution was directly affecting the transmembrane potential can probably be discounted, since 
no effect was seen during the period of application. By the time any decrease was observable 
the simulated ischaemia solution had been washed off and the cardiomyocytes had been 
incubating in maintenance media for 20hr making this an extremely unlikely scenario. It is also 
possible that induction of MPTP did account for the total decline in mA'F but that the inhibitors 
used were nonetheless able to exert only a partial influence. Other studies have reported 
complete inhibition by both of these agents (118,149,245,246) but different cell types were 
used. Many different methods of inducing a loss of mA'F have also been applied to many 
different cells types so it is virtually impossible to judge the severity of the insult. If more 
convergent conditions or cell types had been used in these studies, results in closer
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agreement might have been obtained. Additionally, it has been demonstrated that under 
severe enough conditions such as high Ca2+ concentration, the inhibitory effect of CsA may be 
overcome allowing induction of the MPTP (151,187-189). It is also possible that the inhibitors 
were unable to bind with sufficient affinity or that they became detached during the course of 
the experiment so that their influence was only transient.
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4.6 Conclusions
In conclusion, a significant decline in mA'F could be seen in all 3 models of cell death. 
Inhibition of the MPTP produced a significant effect in all instances proving the involvement of 
the pore. However in the case of the model of SSP-induced apoptosis, induction of the MPTP 
did not appear to be playing a very significant role. In all models complete inhibition by CsA or 
BA was never observed showing that other factors were influencing the outcome.
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5: Expression and Activity of Cyclophilin D during Cardiomyocyte Death
5.1 Introduction
Peptide bonds within proteins can exist in both a c/'s and a trans form. During protein folding 
and refolding, the rate of reaction is frequently determined by the time required for the relevant 
peptide bond to shift from the c/'s to the trans state. Proteins known as peptidyl prolyl cis-trans- 
isomerases catalyse this shift thus speeding up the rate-limiting reaction. There are 3 
unrelated families of proteins displaying peptidyl prolyl c/s-fra/?s-isomerase (PPI-ase) activity, 
the FK506 binding proteins (FKBPs) and the cyclophilins (CyP) (reviewed in 169) and the 
parvulins (168). The cyclophilin family as found in mammalian tissues consists of cyclophilin A, 
an 18kDa protein found in the cytoplasm, cyclophilin B and C (21 kDa) found in the 
endoplasmic reticulum, and cyclophilin D (CyPD) an 18kDa protein localised to the 
mitochondria (162-165). Besides their PPI-ase activity, the cyclophilin family display 
endonuclease activity (166) and are stress-inducible (174). They bind cyclosporin A (CsA) and 
have been found in larger protein complexes such as the oestrogen receptor, (172) the nuclear 
pore complex (173) and the mitochondrial permeability transition pore (MPTP).
Many groups have now published evidence of the interaction of CyPD with the MPTP (140,
159,1611247). Much of this evidence is based on the effect of CsA on the pore since it is well 
known that CsA prevents the binding of CyPD to the inner mitochondrial membrane. One 
proposed mechanism for the opening of the MPTP is through the binding of CyPD to adenine 
nucleotide translocase (ANT), sensitising it to a calcium ion-induced conformational change 
(157). According to this theory, the interaction with CsA would prevent CyPD from binding to 
ANT and would render the pore less sensitive to the presence of calcium.
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It is therefore possible that CyPD could be targeted therapeutically in order to prevent 
pathological induction of the MPTP.
Chapter 5 Activity of CyPD
5.2 Objective
The aim of this chapter was to determine whether CyPD was undergoing any changes in 
activity or expression during cell death.
It was also intended to establish whether CsA was successfully binding to and inhibiting the 
activity of CyPD.
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5.3 Materials and Methods
Neonatal primary cardiomyocytes were isolated and cultured as described in chapter 2.2.1. 
Cell death was induced using staurosporine (SSP), t-butylhydroperoxide (t-BOOH) and a 
solution designed to replicate the extracellular conditions of ischaemia-reperfusion injury as 
detailed in chapter 2.2.2-4.
The mitochondrial fraction of the primary cardiomyocytes was harvested according to a 
standard method of centrifugation as described in chapter 2.5.1.
The PPI-ase activity of the mitochondrial sample was measured according to the kinetic 
method adapted by Kofron as detailed in chapter 2.5.2.
A modification of the peptide sequence used by Bergsma and co-workers was used to raise 
antibodies to rat CyPD in rabbits. These were then purified and utilised in a standard Western 
blotting procedure. For details see chapter 2.5.3 and 2.8.1-2.
-164-
Chapter 5 Activity of CyPD
5.4 Results
5.4.1 Measurement of PPI-ase activity
PPI-ase activity was quantified by measuring the ability of cyclophilins to catalyse the cleavage 
of a cyclophilin-specific peptide by shifting peptide bonds from a c/s to a trans form. When 
cyclophilin A at concentrations ranging from 5-30nM was added to the basic assay (8mg/ml a- 
chymotrypsin in 35mM HEPES buffer with 8mM peptide), a concentration-dependent increase 
in the rate of reaction was observed (Figure 45a). The rate of reaction was computed and the 
CyP-induced increase in rate was expressed as the percentage increase over the rate of the 
control assay (Figure 45b).
30nM CyP 
20nM CyP 
10nM CyP 
5nM CyP 
Control
Figure 45a: Cyclophilin (CyP) was added to the control reaction at a concentration range of 5- 
30nM and the absorbance at 390nm was recorded every 0.25 sec for 2 min. This 
representative graph shows the ability of cyclophilin A to catalyse the conversion of the peptide 
in a concentration dependent manner.
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Figure 45b: The increase in the reaction rate was calculated and expressed as the percentage 
increase over the basic reaction for statistical analysis, showing a significant increase from a 
cyclophilin (CyP) concentration of 15nM [**, p < 0.01; ***, p < 0.001].
To test the ability of CsA to inhibit the PPI-ase activity of CyP in this assay, CsA at 
concentrations ranging from 1nM - 5p,M was added to a reaction also containing 30nM CyPA. 
This clearly demonstrated that CsA was an extremely potent inhibitor of the CyP-induced 
increase in the reaction rate at all the concentrations tested, demonstrating that the ability of 
CyP to increase the rate of reaction was due to its PPI-ase activity (see Figure 46a).
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Figure 46a: When added to an assay containing 30nM cyclophilin (CyP), cyclosporin A (CsA) 
significantly inhibited the CyP-induced increase in the reaction rate at concentrations ranging 
from 1nM - p < 0.001 v. 30nM CyP].
FK506-binding proteins are well-established possessors of PPI-ase activity in the cell. To show 
that these were not affecting the reaction, FKBP was added to the basic assay at 
concentrations ranging from 250nM - 5|iM. This demonstrated that FKBP had a non-significant 
catalytic effect compared to cyclophilin as shown in Figure 46b.
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Figure 46b: When FK506-binding protein (FKBP) was added to the basic assay, analysis of 
reaction rates showed that it was unable to significantly increase the rate of reaction in 
comparison to 30nM cyclophilin (CyP) [***, p<0.001 v. basic assay].
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5.4.2 Mitochondrial PPI-ase activity in apoptotic primary cardiomyocytes
The data presented above shows that the assay of increased rate of peptide cleavage is a
suitable method for the quantification of CyP PPI-ase activity. Therefore, it was employed for
the measurement of CyP PPI-ase activity in neonatal primary cardiomyocytes as detailed
below.
The mitochondrial fraction was isolated from primary cardiomyocytes by a standard method of 
differential centrifugation to produce a preparation of pure mitochondria with normal 
ultrastructure.
Isolation of the mitochondrial fraction and quantification of the PPI-ase activity was utilised to 
directly examine the activity of CyPD following treatment with the apoptosis inducer 
staurosporine (SSP). No change in PPI-ase activity could be seen in the SSP-treated samples. 
However, pre-treatment with CsA significantly reduced PPI-ase activity as shown in Figure 47.
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Figure 47: The cyclophilin PPI-ase enzyme activity of the cardiomyocyte mitochondrial fraction 
was assayed over 2 min and expressed as the percentage increase over the assay without 
mitochondrial fraction. No change in activity was observed after 20hr of 5p.M staurosporine
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(SSP) treatment but 1hr pre-treatment with 50nM cyclosporin A (CsA) produced significant 
inhibition of PPI-ase activity [**, p < 0.01 v. control].
5.4.3 Mitochondrial PPI-ase activity in necrotic primary cardiomyocytes 
Primary cardiomyocytes were treated with t-BOOH for 1hr prior to isolation of the mitochondrial 
fraction and analysis of the PPI-ase activity. No change in PPI-ase activity could be seen 
following necrotic cell death. However, pre-treatment with CsA significantly reduced PPI-ase 
activity as shown in Figure 48.
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Figure 48: The cyclophilin PPI-ase enzyme activity of the cardiomyocyte mitochondrial fraction 
was assayed over 2 min and expressed as the percentage increase over the reaction without 
mitochondrial fraction. No change in activity was observed after 1hr of 100p,M t- 
butylhydroperoxide (t-BOOB) treatment but 1hr pre-treatment with 50nM cyclosporin A (CsA) 
produced significant inhibition of PPI-ase activity [**, p<0.01 v. control].
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5.4.4 Mitochondrial PPI-ase activity following simulated ischaemia-reperfusion injury 
Primary cardiomyocytes were subjected to simulated ischaemia-reperfusion injury (according 
to Chapter 2.2.4) prior to isolation of the mitochondrial fraction and analysis of the PPI-ase 
activity. Although no change in activity was detectable, pre-treatment with CsA significantly 
reduced PPI-ase activity as shown in Figure 49.
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Figure 49: The cyclophilin PPI-ase enzyme activity of the cardiomyocyte mitochondrial fraction 
was assayed over 2 min and expressed as the percentage increase over the reaction without 
mitochondrial fraction. No change in activity was observed following 3hr of simulated 
ischaemia and 20hr simulated reperfusion but 1hr pre-treatment with 50nM cyclosporin A 
(CsA) produced significant inhibition of PPI-ase activity [**, p < 0.01 v. control].
5.4.5 Detection of Cyclophilin D protein in primary cardiomyocytes 
A specific antibody to CyPD was raised in rabbits according to the method of Bergsma and 
colleagues, and purified from whole serum as described in chapter 2.5.3. The efficiency of the 
purification was analysed by an ELISA detection of CyPD antibody. Comparison of CyPD
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antibody content of the purified antibody to both the original serum and the serum after affinity 
column binding showed that successful purification had been achieved (Figure 50).
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Figure 50: Cyclophilin D (CyPD) antibodies were detected using an ELISA assay. Comparison 
of antibody content in whole rabbit serum, serum after affinity column binding and purified 
antibody showed that the CyPD antibodies had been successfully isolated.
The purified antibody had a concentration of 15 i^g/ml and was used to detect CyPD in whole 
primary cardiomyocytes cell lysate by a standard Western blot protocol. The results obtained 
were extremely small bands at the limit of visibility but there was no obvious variation in CyPD 
following simulated ischaemia-reperfusion injury (Figure 51).
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Figure 51: Primary cardiomyocytes were subjected to 3hr of simulated ischaemia followed by 
20hr of simulated reperfusion and the cell lysates were probed with an antibody specific to 
cyclophilin D (CyPD). Although faint protein bands were seen at ~18kDa, no clear variation in
expression was observed.
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5.5 Discussion
CyPD is located in the mitochondrial matrix and its binding to the ANT on the inner 
mitochondrial membrane is believed to be an important part of MPTP induction. Analysis of the 
cyclophilin/CsA complex has shown that CsA physically blocks the cyclophilin site of PPI-ase 
activity (206). It is thought by some groups that this prevents CyPD from binding to the ANT 
thereby preventing formation of the pore complex.
In order to examine the activity of CyPD in the primary cardiomyocytes, the PPI-ase activity 
mitochondrial fraction was measured. No change in activity was seen in any of the models of 
cell death. However, pre-treatment with CsA resulted in a significant inhibition of PPI-ase 
activity in all instances. This shows that CsA was successfully entering the mitochondria and 
binding to the active site of CyPD for the duration of the experimental procedures.
Although the effect of CsA on PPI-ase activity was highly significant, complete inhibition was 
never observed. The concentration of CsA selected was the highest concentration that showed 
absolutely no toxic effect (see chapter 3.5.4), but it is possible that this was too little to bind to 
and inhibit all of the CyPD present.
Cyclophilin-like proteins and other molecules with PPI-ase activity are continually being 
discovered (180-182). A second possibility therefore, is that another as yet unidentified protein 
in the mitochondrial fraction was contributing to the detectable PPI-ase activity. However as 
the peptide used in the assay has extremely high affinity for cyclophilins and it has been 
demonstrated that CyPD is the only mitochondrial target of CsA (140), this option is not very 
probable.
A more likely possibility is that the presence of CsA resulted in a compensatory increase in 
CyPD production in the cardiomyocytes as a recent study has shown in human cancer cell 
lines (248).
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Western blotting with a specific CyPD antibody was intended to resolve this issue. The 
antibody in question was developed by Bergsma and colleagues and reported in a paper 
published in 1991 (162). In their paper the group showed specificity of the antibody and 
demonstrated that it did not cross-react with the other cyclophilins. Unfortunately the relevant 
protocols could not be replicated for this study, as only the CyPA protein is currently 
commercially available. However, Western blotting with the purified antibody revealed a protein 
band, which although faint, did appear at the correct position for CyPD.
This procedure was ultimately performed only on the model of ischaemia-reperfusion injury 
due to the huge number of cells required to obtain visible protein bands. Isolation of the 
mitochondrial fraction would have reduced the chances of cross-reaction with other 
cyclophilins and possibly improved the resolution of the CyPD protein bands. However, this 
proved unfeasible, as the amount of mitochondrial protein obtainable from the primary 
cardiomyocytes was too little to be successfully detected by Western blotting. Therefore whole 
cell lysates were used.
Although the protein bands resolved were too small and faint to effectively quantify, the PPI- 
ase activity seen in the CsA-treated samples could be accounted for by a protein increase of 
no more than 5-10% and would probably be difficult to detect by a technique such as Western 
blotting.
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5.6 Conclusions
The PPI-ase activity of CyPD was unaffected by the application of inducers of apoptosis and 
necrosis, or by the in vitro simulation of ischaemia-reperfusion injury. However pre-treatment 
with CsA produced a significant decrease in activity, showing that CsA enters the mitochondria 
and remains bound to CyPD for the duration of these experiments.
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6: ATP Production and Free Radical Activity: The Effect of MPTP Inhibition
6.1 Introduction
As inhibitors of the mitochondrial permeability transition pore (MPTP) had proved unable to 
exert more than a minimal influence over the progression of cell death in primary 
cardiomyocytes, it was assumed that other factors were affecting the ability of the cells to 
survive the insults.
Generation of ATP is one of the most crucial functions of the mitochondria, providing the cell 
with the energy that it needs to sustain itself. It has for some time been believed that the levels 
of ATP in the mitochondria can exert a major influence on the progression of cell death. 
Studies have suggested that the availability of ATP may act as an “intracellular switch” 
determining whether the cell proceeds to die through apoptosis or necrosis (61-63).
Another parameter of cellular injury that is frequently studied is the generation of free radicals. 
Increased free radical activity has been demonstrated during both ischaemia and reperfusion 
and many potential sources of free radical production within the cell have been proposed 
(reviewed in 249). The respiratory chain in the mitochondrial membranes has been proposed 
as a major source of free radical production during ischaemia-reperfusion injury. This site of 
injury is particularly relevant to this study due to the large number of mitochondria present in 
cardiomyocytes and the potential for MPTP induction to seriously affect the respiratory chain. 
Additionally, free radicals can destabilise lipid membranes and damage DNA, so the extent of 
their production in the cell may be an important factor in determining whether the cell will suffer 
irreversible damage.
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6.2 Objective
The aim of this study was to examine other important aspects of cell death and determine 
whether these were playing a major role in the primary cardiomyocytes.
The study aimed to quantify the production of ATP and the generation of free radicals during 
apoptosis, necrosis and simulated ischaemia-reperfusion injury and to determine whether 
inhibitors of the MPTP would affect these parameters.
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6.3 Materials & Methods
Neonatal primary cardiomyocytes were isolated and cultured as described in chapter 2.2.1.
Cell death was induced using staurosporine (SSP), t-butylhydroperoxide (t-BOOH) and a 
solution designed to replicate the extracellular conditions of ischaemia-reperfusion injury as 
detailed in chapter 2.2.2-4.
The ATP content of primary cardiomyocytes was measured using a standard bioluminescence 
assay (see Chapter 2.6).
Free radical production in primary cardiomyocytes was measured using the free radical 
sensitive fluorescent dye 2’,7’-dichlorodihydrofluoroscein diacetate (H2DCFDA) (see Chapter 
2.7).
-179-
Chapter 6 ATP and Free Radical Production
6.4 Results
6.4.1 Measurement of ATP in primary cardiomyocytes
The most reliable means of calculating ATP release from the samples was to include an 
internal standard in the bioluminescence based assay. Therefore, the ATP release from a 
sample of primary cardiomyocytes was measured and compared to the light emission data 
obtained when the sample was combined with a known range (1ng-10^g/ml) of ATP 
standards. The commercial assay used required an internal standard that produced a reading 
approximately double that of the sample alone (see chapter 2.6), a criterion that was met by 
the combination of 50pJ of 5|ig/ml ATP and a 50pJ sample of cell suspension (Figure 52a). 
Therefore, 5p.g/ml ATP was selected as an internal standard in all experiments in order to 
calculate the ATP content of each sample. Addition of cells in suspension and the kit 
component Somatic Cell ATP Releasing Reagent caused significant quenching as shown in 
Figure 52b, but as this was consistent throughout it did not alter the effectiveness of the assay. 
It was also noted that the emission of light rapidly reduced following initiation of the reaction 
(Figure 52c). However, this did not affect the results obtained as each sample was measured 
along with an internal standard ensuring that the ATP value could be accurately calculated in 
each instance, despite the declining light emission.
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Figure 52a: The ATP released by a control sample of cardiomyocytes in suspension was 
measured with a range of ATP standards from 1ng-10(ig/ml. 5jng/ml ATP was chosen for use 
as an internal control as it gave a reading of approximately double that of the sample alone.
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Figure 52b: Addition of cells in suspension and Somatic Cell ATP Releasing Reagent caused 
quenching of emitted light relative to the ATP standards (i.e. the combination of ATP and cell
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sample does not produce the same emitted light as the sum of the two separate readings).
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Figure 52c: The amount of light emitted by a sample of cells in suspension began to decrease 
in a linear fashion immediately following initiation of the reaction.
6.4.2 The effect of CsA on ATP content during apoptosis
Primary cardiomyocytes were treated with 50nM CsA for 1hr prior to SSP application for 20hr. 
Analysis of ATP content showed a significant decrease in ATP that was not inhibited by CsA 
(Figure 53).
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Figure 53: Compared to the control cells (ATP = 0.94jng/ml, SD = 0.23) the ATP content of the 
cardiomyocytes was reduced after 20hr of 5|uM staurosporine (SSP) application but pre­
treatment with 50nM cyclosporin A (CsA) did not show any significant influence [***, p < 0.001 
v. control].
6.4.2 The effect of CsA on ATP content during necrosis 
50nM CsA was applied to primary cardiomyocytes prior to treatment with 100jiM t- 
butylhydroperoxide and analysis of ATP content. The onset of necrosis resulted in the 
reduction of ATP content to virtually nothing. Pre-treatment with CsA resulted in a very slight, 
although significant inhibition (Figure 54).
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Figure 54: Compared to the control cells (ATP = 0.76|ig/ml, SD = 0.04), the ATP content of the 
cardiomyocytes was greatly reduced 1 hr after application of IO O jliM  t-butylhydroperoxide (t- 
BOOH) but pre-treatment with 50nM cyclosporin A (CsA) showed only a small, albeit 
significant influence [***, p < 0.001 v. control; +++, p < 0.001 v. t-BOOH].
6.4.3 The effect of CsA on ATP content during simulated ischaemia-reperfusion injury 
50nM CsA was applied to primary cardiomyocytes for 1 hr prior to subjection to simulated 
ischaemia-reperfusion injury. ATP content was analysed following the 3hr simulated ischaemia 
period and also after 20hr simulated reperfusion. Following 3hr simulated ischaemia the ATP 
content of the cells was greatly reduced but after the period of simulated reperfusion this had 
recovered an appreciable amount although the ATP content was still significantly less than the 
control cells. CsA pre-treatment did not show any significant influence on ATP during either 
simulated ischaemia or simulated reperfusion although a slight insignificant inhibition was 
reliably observed following reperfusion (Figure 55).
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Figure 55: Compared to the control cells (ATP = 0.935|ng/ml, SD = 0.10), 3hr of simulated 
ischaemia resulted in a large decrease in ATP content that was not inhibited by cyclosporin A 
(CsA) pre-treatment. After 20hr simulated reperfusion much of the ATP content was recovered 
and was again not significantly influenced by CsA pre-treatment [***, p < 0.001 v. Control; +++, 
p < 0.001 v. Ischaemia].
6.4.4 Toxicity of 2,.7’-dichlorodihvdrofluoroscein diacetate in primary cardiomyocytes 
The free radical sensitive dye 2’,7’-dichlorodihydrofluoroscein diacetate (H2DCFDA) was 
applied to primary cardiomyocytes at a wide range of concentrations designed to determine 
toxicity (500nM-5jLtM). Analysis of LDH release showed a slight increase at 3p.M with 
significant toxicity at 5}iM as shown in Figure 56.
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Figure 56: H2DCFDA attained significant toxicity to primary cardiomyocytes from 5|iM as 
determined by release of LDH [***, p < 0.001 v. Control].
6.4.5 The effect of CsA on free radical activity during apoptosis
Primary cardiomyocytes were treated with 50nM CsA before 500nM H2DCFDA was added to 
the media simultaneously with 5|iM SSP. The cells were then incubated in the dark for 20hr 
prior to measurement of fluorescence on a flow cytometer. A negative control was initially 
analysed and in subsequent samples, the number of cells displaying fluorescence greater than 
the parameters of the negative control were counted. Analysis showed that all samples 
displayed an extremely low level of free radical activity with no discernible difference between 
control and apoptotic samples (Figure 57).
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Figure 57: Neither 24hr of 5^iM staurosporine (SSP) treatment nor 1hr pre-application of 50nM 
cyclosporin A (CsA) had any effect on the generation of free radicals in primary 
cardiomyocytes (determined by free radical conversion of H2DCF to fluorescent form).
6.4.6 The effect of CsA on free radical activity during necrosis
Primary cardiomyocytes were treated with 50nM CsA before 500nM H2DCFDA was added to 
the media simultaneously with t-BOOH. The cells were then incubated in the dark for 1hr prior 
to measurement of fluorescence on a flow cytometer. Analysis showed that there was a highly 
significant increase in cells displaying free radical activity following t-BOOH treatment. Pre­
treatment with CsA did not influence the level of activity (see Figure 58).
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Figure 58: Treatment of primary cardiomyocytes with t-butylhydroperoxide (t-BOOH) for 1 hr 
resulted in a highly significant increase in free radical activity (determined by free radical 
conversion of H2DCF to fluorescent form) that was unaffected by cyclosporin A (CsA) [***, p < 
0.001 v. Control].
6.4.7 The effect of CsA on free radical activity during simulated ischaemia-reperfusion 
Primary cardiomyocytes were treated with 50nM CsA prior to subjection to simulated 
ischaemia and reperfusion in the dark. If the cardiomyocytes were subjected to simulated 
ischaemia only, then 500nM H2DCFDA was added to both samples and controls for the 
duration of the simulated ischaemia. If the cardiomyocytes were subjected to a subsequent 
period of simulated reperfusion, then H2DCFDA was added to samples and controls during the 
simulated reperfusion period only. Following treatment, the fluorescence of all samples was 
measured on a flow cytometer. Analysis showed a significant increase in cells displaying free 
radical activity following simulated ischaemia. However, pre-treatment with CsA did not inhibit 
the level of activity and appeared to cause a slight increase in comparison with simulated
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ischaemia although this was not significant. Following simulated ischaemia and reperfusion, 
there was a highly significant increase in free radical activity which was unaffected by CsA 
(see Figure 59).
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Figure 59: Primary cardiomyocytes subjected to 3hr of simulated ischaemia displayed a 
significant increase in free radical activity (determined by free radical conversion of H2DCF to 
fluorescent form) that was not inhibited by pre-treatment with 50nM cyclosporin A (CsA). 20hr 
of simulated reperfusion resulted in a significantly raised level of activity that was unaffected by 
CsA [**, p < 0.01 v. Control; ***, p < 0.001 v. Control].
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6.5 Discussion
The production of ATP by the respiratory chain is an essential process in all mammalian cells. 
ATP powers some of the most important intracellular reactions and is therefore essential to the 
survival of the cell. In the absence of oxygen, ATP production can continue for a time through 
glycolysis, but even this is eventually inhibited by the conditions present during ischaemia (74). 
The transfer of electrons across the virtually impermeable inner mitochondrial membrane by 
the complexes of the respiratory chain creates an electrochemical gradient, which drives ATP 
synthesis. Opening of the MPTP destroys this gradient, thus halting production of ATP and 
threatening the survival of the cell.
Apoptotic cell death is an active process that requires ATP to go to completion. Analysis of 
ATP levels in the primary cardiomyocytes following application of the apoptosis inducer SSP 
revealed a decrease of around 50%. This drop may represent cardiomyocytes in the post- 
apoptotic stage where all energy production has ceased. Pre-treatment with CsA did not 
influence the levels of ATP after 20hr, suggesting that inhibition of the MPTP has only a 
transient effect on ATP production, or no effect at all.
Induction of necrosis in cardiomyocytes caused an almost complete abolition of ATP 
production. Despite this, CsA pre-treatment slightly, but significantly inhibited this decline 
suggesting inhibition of the MPTP could have helped to preserve ATP production. However, 
levels of ATP were extremely low even in the CsA treated cells suggesting that the severity of 
the insult was able to overcome the inhibition resulting in only a partial inhibition. ATP 
production may have also declined due to direct inhibition of the respiratory chain that was 
unrelated to MPTP induction.
Inhibition of the respiratory chain during ischaemia-reperfusion injury has been demonstrated 
in many studies, predominantly the inhibition of respiration in complex I, which has been
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demonstrated up to 2 hr after reperfusion (250). Following 3hr of simulated ischaemia in the 
primary cardiomyocytes, levels of ATP were extremely low. The fact that CsA was unable to 
preserve ATP production was fully expected as it has been shown on many occasions that the 
MPTP does not open during ischaemia.
After 20hr of simulated reperfusion, ATP production had significantly recovered although it was 
still significantly lower than in the control cardiomyocytes. CsA did not have a significant effect 
on recovery although a slight positive effect was consistently observed. Although many studies 
have shown direct inhibition of the respiratory chain complexes during ischaemia-reperfusion, 
the length of simulated reperfusion in this study probably allowed complete recovery. 
Therefore, the most probable explanation is that the majority of cell death occurring was not 
related to MPTP induction. The slight inhibition that was observed probably accounted for a 
sub-population of cells that were dying due to the induction of MPTP. This may again indicate 
that in this specific model, MPTP is largely a consequence of cell death rather than a cause.
It was noted that addition of cell suspension to the ATP assay caused some quenching of the 
light emitted. However, this level of quenching was consistent throughout so did not affect the 
results of the experiment since an internal control was present, and the intent was to examine 
the variation between samples rather than to obtain an accurate quantification of ATP in 
primary cardiomyocytes.
The generation of free radicals has been identified as a major factor in ischaemia-reperfusion 
injury with a number of studies also showing the protective effect of various free radical 
scavengers (108,110,111). The mitochondrial respiratory chain has been pinpointed as a 
major source of free radical production during ischaemia-reperfusion injury (93,250,251). As 
cardiomyocytes have a comparatively large quantity of mitochondria it is anticipated that they 
may be the major source of free radical production during cardiac ischaemia-reperfusion injury.
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Following induction of apoptosis in primary cardiomyocytes for 20hr, no increase in free radical 
activity was observed. This result is as expected as it is known that SSP induces apoptosis 
without causing production of free radicals.
The inability of CsA to inhibit the increase in free radical production during necrosis shows that 
free radical generation most likely occurs throughout the cell, independently of MPTP 
induction. This may be due in part to direct generation of free radicals by the oxidant chemical 
t-BOOH. Although t-BOOH application did not appear to result in the large-scale generation of 
free radicals, it should be noted that the acetate group is cleaved from H2DCFDA inside the 
cell and the product is largely sensitive to hydrogen peroxide (H2O2) and hydroxyl radicals 
(100). It is therefore possible that application of t-BOOH resulted in large-scale production of 
superoxide radicals that could directly cause damage to the cells. However, the fact that no 
effect of CsA was observed shows that free radical production is not significantly linked to 
MPTP induction.
Simulated ischaemia produced a significant increase in free radical production in the 
cardiomyocytes. However, when they were pre-treated with CsA, a slight although non­
significant increase in free radicals over ischaemic cells was observed. As there was no 
change in activity when the cells were treated with CsA alone, the most likely explanation is 
that CsA was interacting with elements of the ischaemic solution. This issue could be settled 
using an alternative MPTP inhibitor. However, cell viability results obtained using the adenine 
nucleotide transporter inhibitor bongkrekic acid (BA) in this system were extremely erratic (see 
Chapter 3) and other MPTP inhibitors are not as readily available.
Many studies have shown an accumulation of superoxide radicals during ischaemia followed 
by a burst of hydroxyl radicals upon reperfusion that are proposed to originate from the 
degradation of superoxide radicals (reviewed in 249). The dye used in this study is known to 
detect hydroxyl radicals and H2O2 whilst being largely insensitive to superoxide radicals. The
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fact that significant production of free radicals was observed during ischaemia is probably due 
to the fact that analysis by flow cytometry required the cardiomyocytes to be suspended in 
PBS. Although the time between harvesting and analysing the cells was as short as possible, 
some degradation of superoxide to H2O2 and hydroxyl radicals may have been encouraged. 
Following simulated reperfusion of the primary cardiomyocytes, there was a highly significant 
increase in free radical production that was not inhibited by CsA. This production is a 
cumulative effect over 20hr that does not reveal the period of greatest free radical generation, 
as the intent was to monitor the effect of CsA following a long period of simulated reperfusion. 
The inability of CsA to affect the generation of free radicals shows that they are produced 
independently of MPTP induction. Xanthine oxidase is a possible source of free radicals in this 
model but significantly greater contribution from the respiratory chain would be expected due 
to the large number of mitochondria present in cardiomyocytes. During ischaemia the 
respiratory chain complexes become highly reduced leading to donation of electrons to 
residual oxygen molecules, thus forming superoxide radicals. Upon reperfusion, these are 
converted to the even more damaging hydroxyl radicals for which, unlike superoxide and H2O2 , 
the cell does not produce any dedicated enzymatic scavengers. As the chain of events is 
initiated during ischaemia, and MPTP induction is only observed upon reperfusion, CsA would 
not be expected to influence free radical production by the respiratory chain complexes. As 
CsA had no discernable effect on the generation of free radicals, this shows that all production 
of free radicals in this model is independent of MPTP induction. This is consistent with current 
theories of free radical production during ischaemia-reperfusion injury. This also means that 
inhibiting the MPTP in an in vivo situation would not attenuate free radical mediated damage.
Free radical production during ischaemia and reperfusion cannot be directly compared due to 
the differing application times of H2DCFDA. However, the intent in this instance was to
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determine the effect of CsA application in each case. H2DCFDA is a widely used dye that was 
ideal for this study as it is sensitive to H2O2 and hydroxyl radicals, which are generated during 
reperfusion when the MPTP is presumed to open. The free radical-sensitive dye 
dihydrorhodamine 1,2,3 is known to localise to the mitochondria. However, this dye is related 
to rhodamine 1,2,3 which is utilised for measurements of mA'P so would probably not be a 
reliable probe in this instance of both energised and de-energised mitochondria.
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6.6 Conclusions
In conclusion, apoptosis proceeded with no extra production of free radicals, but the failure of 
CsA to inhibit the decline in ATP production again implied that the MPTP was not playing a 
significant role.
During necrosis, CsA had a slight inhibitory effect on the decline of ATP production showing 
that lack of ATP was a contributing factor towards cell death. However, CsA had no influence 
over free radical production during necrosis suggesting that the majority of free radical 
production may be outside the confines of the mitochondria or unrelated to the respiratory 
chain.
CsA was unable to significantly effect the generation of free radicals during simulated 
ischaemia-reperfusion injury. This shows that inhibition of the MPTP cannot influence this 
parameter in this particular model. However, the failure of CsA to inhibit the decline in ATP 
production may suggest that the MPTP does not significantly contribute to cell death in this 
model of ischaemia-reperfusion injury.
-195-
Chapter 7 In Vivo Cardiac Ischaemia Reperfusion Injury
7: The MPTP and CyPD in an In Vivo Model of Cardiac Ischaemia- 
Reperfusion Injury
7.1 Introduction
Although numerous studies have examined mitochondrial permeability transition pore (MPTP) 
induction in isolated cardiomyocytes, substantially less work has been done using intact 
cardiac tissue. The major difficulty with studies using intact myocardium is that the techniques 
commonly employed for measuring mitochondrial parameters in vitro cannot be easily adapted 
to an in vivo situation. This means that some question remains as to whether the process 
under examination is merely an in vitro artefact.
Studies by Halestrap and colleagues have examined the behaviour of the MPTP in isolated 
perfused hearts. This work has shown that the MPTP opens during reperfusion only (130) and 
that inhibition by cyclosporin A (CsA), results in increased survival of the heart (136). This 
immediately suggests a potential role for MPTP inhibiting drugs in situations such as cardiac 
operations.
However, no study has yet attempted to examine the MPTP in myocardium subjected to 
ischaemia-reperfusion injury in situ. Although there is no obvious method of analysing the 
MPTP in vivo, a significant decline in mA'F is frequently cited as a strong implication of MPTP 
induction.
Therefore the purpose of this chapter was to attempt to directly measure the mA'F of 
mitochondria isolated from rat hearts subjected to in vivo ischaemia and reperfusion. This 
could be a useful indicator as to whether opening of the MPTP is truly a pathological event. It 
was also intended to examine the activity of cyclophilin D (CyPD), which is usually studied only 
by indirect means such as the action of CsA.
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7.2 Objective
The aim of this study was to attempt to examine the mA'F of mitochondria isolated from hearts 
subjected to in vivo ischaemia-reperfusion injury and to explore the potential action of CyPD.
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7.3 Materials and Methods
A model of cardiac ischaemia-reperfusion was set up in adult Sprague-Dawley rats and was 
assessed morphologically and by plasma creatine kinase (CK) activity. The mA'F was 
analysed in subsequently isolated mitochondria using a TPP+ sensitive electrode. For details 
please see chapter 2.10.
PPI-ase activity of the isolated mitochondrial fraction was measured by spectrophotometric 
assays as described in chapter 2.5.2 and CyPD protein was identified by Western blotting with 
a specific CyPD antibody as detailed in 2.8 and 2.5.3 respectively.
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7.4 Results
7.4.1 Ultrastructural changes in cardiac tissue during ischaemia and reperfusion 
Adult Sprague-Dawley rat hearts were subjected to left ventricular ischaemia by occlusion of 
the left anterior descending (LAD) branch of the left coronary artery for up to 1 hr, followed by 
15 min of reperfusion. After 1 hr of ischaemia muscle fibre ultrastructure appeared normal, but 
some mitochondria were swollen and disrupted. Following 15 min reperfusion the vast majority 
of the mitochondria were swollen and disrupted compared to those seen in sham-operated 
hearts as shown below in Figure 60 a-f.
Figure 60a: Electron micrograph illustrating a section of a cardiac myocyte from the left 
ventricle of a sham-operated heart at total magnification x 6,000. Of interest is the muscle fibre 
network branching throughout the cytoplasm and the numerous mitochondria with densely 
packed cristae. A fibroblast may also be observed in the bottom left-hand corner.
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60b: A section from the left ventricle of a sham-operated heart at total magnification x 24,000. 
The mitochondria display normal morphology with double membranes and parallel cristae.
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60c & d: Showing sections from the left ventricle of a heart following 60min ischaemia. Normal 
muscle fibre structure can be observed, but at least 50% of the mitochondria appear swollen 
and disrupted. (Total magnification x 6,000)
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60e: A section from the left ventricle of a heart following 60 min ischaemia and 15 min 
reperfusion. Normal structure of muscle fibres was consistently seen but almost all of the 
mitochondria observed were swollen and disrupted. (Total magnification x 6,000)
60f: A section from the left ventricle of a heart following 60min ischaemia and 15 min 
reperfusion at total magnification x 24,000. This shows swollen mitochondria with disrupted
cristae.
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7.4.2 Creatine kinase activity in the blood of post-operative rats 
LAD occlusion results in damage to the cardiac tissue of the left ventricle as can be seen in 
Figure 60a-d. This should result in the release of creatine kinase (CK) from the damaged cells 
that may be observed as an increased level of CK activity in the blood. However as shown 
below the sham operation, which involved cutting through the intercostal muscles, produced a 
high background level of CK activity which obscured any small increases caused by the 
cardiac ischaemia (see Figure 61).
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Figure 61: Creatine kinase (CK) activity was measured in the blood of sham-operated rats and 
those subjected to left ventricular ischaemia and reperfusion. However, the surgical procedure 
followed in order to expose the heart produced a large cumulative increase in CK activity over 
the 3-hour period. This obscured any change in CK activity that may have resulted from the 
LAD occlusion and reperfusion [***, p < 0.001 v. pre-ischaemia; n=3 for all groups].
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7.4.3 Measurement of m A ^  in mitochondria isolated from adult rat hearts 
The mitochondrial fraction was isolated from 2 sham-operated Sprague-Dawley rat hearts and 
the ability of the mitochondria to retain tetraphenylphosphonium chloride (TPP+) was measured 
using a TPP+ sensitive electrode. This information was then used to calculate mA1?. Upon 
repeated additions of 5}il of 10mM calcium, a steady decline in m AT was observed 
culminating in the complete loss of a negative transmembrane charge as shown in Figure 62. 
The amount of calcium that can be consumed and retained by the mitochondria prior to 
collapse of mA'F is known as the calcium retention capacity (CRC) and is also illustrated 
below in Figure 62.
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Figure 62: Repeated additions of calcium ions to cardiac mitochondria from sham-operated 
rats resulted in loss of the mAH* until the negative transmembrane charge was completely 
abolished [n=3 for all groups].
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7.4.4 CRC of post-operative and post sham-operative hearts
Mitochondrial fractions were isolated from the left ventricles of 2 rat hearts that had been 
subjected to either a 1hr sham operation, or 1hr LAD occlusion with or without 15 min
reperfusion. mA'F of the combined fractions was measured and the calcium retention capacity
calculated. Mitochondria from hearts that had been subjected to 15 min reperfusion displayed 
a lower CRC than those from either the LAD occluded or sham-operated hearts although this 
result did not attain statistical significance (see Figure 63).
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Figure 63: The calcium retention capacity (CRC) of isolated mitochondria was calculated using 
a TPP+ sensitive electrode. Mitochondria from hearts that had been subjected to 15 min 
reperfusion displayed a notable although non-significant reduction in CRC compared to those 
from either the 1 hr LAD occluded or sham-operated hearts [n=3 for all groups].
7.4.5 PPI-ase activity in the mitochondrial fraction of post-operative rat hearts
The mitochondrial fraction was isolated from post-operative rat hearts and the PPI-ase activity 
was measured. No variation in the activity of CyPD was observed between the occluded and
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reperfused or the sham-operated hearts (Figure 64).
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Figure 64: When the PPI-ase activity of the mitochondrial fraction was measured and 
expressed as the percentage increase in the rate of reaction over an assay with no 
mitochondria, no variation was seen between the occluded, reperfused and sham-operated 
hearts [n=3 for all groups].
7.4.6 Identification of Cyclophilin D protein in post-operative rat hearts 
The isolated mitochondrial fractions were subjected to Western blotting procedure in order to 
identify the CyPD protein. No variation in the expression of the CyPD protein was observed 
between the occluded, reperfused and sham-operated groups (Figure 65).
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Figure 65: Western blotting of the mitochondrial fraction with an antibody specific to Cyclophilin 
D (CyPD) revealed protein bands at approximately 18kDa, but no obvious variation in 
expression between the 1 hr LAD occluded, 15min reperfused and sham-operated groups.
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7.5 Discussion
Although there have been many convincing studies of the MPTP in isolated cardiomyocytes, 
the studies performed in intact tissue have been extremely limited. This is clearly due to the 
problems encountered in measuring the relevant in vitro parameters in an in vivo model.
The preceding experiments have addressed this issue by attempting to measure the 
parameters studied in the isolated primary cardiomyocytes in a model of in vivo ischaemia- 
reperfusion injury that has been previously utilised by other researchers.
Morphological analysis by EM was used to gain an overview of tissue damage and to assess 
mitochondrial swelling and ultrastructure. A quantitative assessment of damage by EM was not 
performed, as this technique may be considered rather subjective.
Analysis of plasma CK activity is frequently used as a marker of cardiac damage in clinical 
studies. However, the surgical procedure required to access the heart produced a large 
increase in plasma CK activity, which obscured any increase caused by the occlusion. The 
ideal solution would have been to analyse the activity of CK-MB, the cardiac isoform of CK. 
However, although a standard kit for the detection of human CK-MB is widely available this 
method proved ineffective for rat CK-MB.
In the primary cardiomyocytes, mA'F was measured by flow cytometry using a fluorescent dye 
that was taken up into energised mitochondria. Ideally, mA'F in mitochondria isolated from the 
reperfused hearts should have been measured using the same dye. However, the extremely 
small size of the isolated mitochondria was at the limits of detection on the equipment used 
and accurate readings could not be obtained. Therefore, mA'F in isolated mitochondria was 
calculated according to the ability of the mitochondria to retain TPP+. This is a method that has 
been used on numerous occasions by a number of groups (252-257) and has the advantage 
of being less controversial than mA'F-sensitive dyes. Measuring mitochondria isolated from 
the cultured primary cardiomyocytes using the TPP+ sensitive electrode would have provided a
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more direct comparison with reperfused hearts. However, isolating the necessary number of 
mitochondria for even one electrode measurement from cultured cells proved completely 
unfeasible. This aptly demonstrates the difficulties inherent in transferring in vitro protocols to 
in vivo models.
Analysis of mAY using the TPP+ sensitive electrode showed a decline in those mitochondria 
that were isolated from reperfused hearts in comparison to both control and ischaemic hearts. 
Each treatment group (containing 2 rat hearts) was repeated 3 times and the result was 
consistent throughout. Although the results obtained were not significant due to a large margin 
of error, it is anticipated that a larger sample size would produce significant results.
CyPD was analysed in ischaemic and reperfused hearts activity using the same methodology 
that was employed in the primary cardiomyocytes, allowing a more direct comparison. The 
PPI-ase activity of the mitochondrial fraction showed no variation between treatment groups 
and expression of CyPD protein was also unaffected by ischaemia and reperfusion. Thus, the 
results gained in this model of ischaemia-reperfusion injury are consistent with the results 
gained in the isolated primary cardiomyocytes.
Ideally the role of CyPD would have been further explored by analysing the effect of CsA on 
mA'F and CyPD activity and expression in reperfused hearts. This could have provided a 
clearer picture of the functioning of the MPTP in vivo and a means of comparison with the 
results in isolated cardiomyocytes. However, these experiments could unfortunately not be 
achieved due to pressure of time and resources.
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7.6 Conclusions
This preliminary study shows that in vivo ischaemia-reperfusion may result in a severe decline 
in mA'F that is not accompanied by any alteration of CyPD activity or expression. These early 
results are consistent with the data achieved in isolated primary cardiomyocytes but further 
work is required to provide a clearer picture.
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8.1 Analysis of methodology
8.1.1 Neonatal rat primary cardiomyocytes
Neonatal primary cardiomyocytes were used for all of the in vitro experiments performed in this 
project. These cells were selected as cultured primary cells are generally considered to provide 
a more accurate reflection of events in whole tissue than a cell line, which accumulates 
mutations over time. Neonatal cardiomyocytes were used, as obtaining viable cells from 
neonates is a more straightforward process than using adult rat hearts ensuring more 
consistent results. Also the implementation of a regular breeding programme ensures that 
sufficient neonatal myocytes are available on a regular basis. In addition, an original aim of the 
study was to attempt the transfection of CyPD into primary myocyte cultures, something that is 
significantly easier to achieve with neonatal cells than with those derived from adults. 
Unfortunately, unforeseen technical difficulties meant that this was ultimately not attempted. It 
is worth noting that even in cells derived from the same species, differences in the cellular 
metabolism can be observed according to the age of animal used, leading to varying 
experimental observations. For example, a difference in optimal cyclosporin A (CsA) 
concentration has been noted between neonatal and mature rat cardiomyocytes (133,136, 
237). If significant differences are observed even between different types of primary rat 
cardiomyocytes, then it is hardly surprising that vastly different results can be seen between 
different cell lines and primary cells. This is especially true in, for example, the field of 
apoptosis where the proposed existence of ‘mitochondrial’ and ‘non-mitochondrial’ pathways 
produced a number of conflicting reports and caused much lively discussion. The ideal type of 
cell to use is often a matter for personal opinion and convenience, but the examples cited 
above serve to highlight the danger of making generalisations.
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8.1.2 Detection of mitochondrial permeability transition pore induction 
The detection of mitochondrial permeability transition pore (MPTP) induction in intact cells is a 
rather problematic area that has attracted much controversy. The most common means of 
detection rely upon the fact that the opening of the MPTP increases the permeability of the 
inner mitochondrial membrane thus destroying the mitochondrial transmembrane potential 
(mA'F). Various fluorescent dyes have been utilised that are sensitive to mA'F. Some of the 
most commonly used are 3,3’dehexylocarbocyanine iodide (DiOC6(3)), tetramethylrhodamine 
methyl ester (TMRM) and Rhodamine 1,2,3, which are taken up into mitochondria 
proportionally to the mA'F. Thus any decrease in fluorescence is proportional to the decline in 
mA'F. Another frequently used dye is JC-1 that is incorporated into all mitochondria as a green 
fluorescent monomer, but only forms red fluorescing aggregates at high mA'F. All of the above 
mentioned dyes are widely used, but all have their detractors as well as supporters.
(DiOCe(3)), which was utilised in the present study was originally used at 40nM in a variety of 
intact cells by Zamzami and colleagues (221). Subsequently a study by Mathur and colleagues 
showed that this protocol was ineffective in cultured cardiomyocytes (244). However, their 
report failed to take into account the study published by Rottenberg and colleagues that 
showed that when used at 40nM, (DiOCe(3)) was affected by membrane quenching and they 
therefore advocated a concentration of less than 1nM (222).
Confocal microscopy results obtained in the primary cardiomyocytes used in this project fully 
support the work of Rottenberg since 20nM (DiOCe(3)) gave extremely ill-defined staining 
whereas 0.8nM stained only the mitochondria and diffused into the cytosol upon addition of the 
mitochondrial uncoupler carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP) (see 
Chapter 4.4.1).
Where dyes such as those described above can be proved to work, they are extremely
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powerful tools for the assessment of mA'F in cultured cells. However, they do only measure 
mA'F and therefore provide only an indirect analysis of the MPTP. One notable attempt to 
directly measure MPTP induction in cells has been made by the group of Lemasters. Isolated 
hepatocytes were loaded simultaneously with TMRM (tetramethylrhodamine methyl ester) and 
calcein. In cells with high mA'F, TMRM localised to the mitochondria whereas calcein stained 
only the cytosol. Upon induction of the MPTP, the situation was reversed as TMRM was lost 
from the de-energised mitochondria and calcein staining was observed in both cytosol and 
mitochondria (258). However, this technique has caused much controversy as Petronilli and 
colleagues have since published a number of studies disagreeing with the technique (246,
259,260). The group propose that calcein staining is not observed in the mitochondria only 
because it is quenched by the presence of TMRM and have put forward an alternative version 
of the technique. This involves co-staining with calcein and C0 CI2 to quench the cytosolic 
calcein signal so that upon induction of the MPTP C0 CI2 enters the mitochondria and the 
mitochondrial calcein staining is also lost (259). However, Lemasters and colleagues continue 
to support their original protocol and the issue remains unresolved (145).
During the course of this project, a brief attempt was made to investigate calcein staining. 
When calcein was loaded into viable, beating primary cardiomyocytes using the protocol of 
Lemasters, staining of both cytosol and mitochondria was observed. The matter was then not 
pursued further due to the complexity of the issue. However, if Petronilli and colleagues are 
correct in their assertion that calcein mitochondrial staining is quenched by TMRM, then the 
methods of both groups seem rather less straightforward and reliable than the exclusive use of 
TMRM or a similar dye. Both methods are also further complicated by the proposed 
physiological opening of the MPTP that could potentially allow the passage of some calcein or 
C0 CI2 .
The use of (DiOCe(3)) in this project consistently detected changes in mA'F, which as
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mentioned previously, only implies the involvement of the MPTP. However, the fact that CsA 
and bongkrekic acid (BA) invariably significantly inhibited the decline in mA'F makes it almost 
certain that at least the majority of the decline was due to induction of the MPTP.
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8.1.3 In vitro model of ischaemia-reperfusion injury
One of the major areas of difficulty with this study proved to be the model of simulated 
ischaemia-reperfusion injury, which did not produce the expected behaviour in the 
cardiomyocytes. The current consensus about ischaemia-reperfusion injury is that while the 
conditions present in ischaemia are detrimental to the cells, reperfusion can prove to be far 
more damaging. This is especially true of the initial moments of reperfusion when the MPTP is 
believed to open. However despite much experimentation with varying periods of simulated 
ischaemia and reperfusion in this in vitro model, results resembling the accepted scenario were 
never achieved.
The parameters that were relied upon were quantification of cell death and analysis of mA'F. 
Cell death was measured according to metabolic conversion of MTT reagent and release of 
lactate dehydrogenase (LDH) by compromised plasma membranes. Both of these are tried 
and trusted methods that produced consistent data and there was no reason to suspect that 
they could have inaccurately reflected the condition of the cells. The measurement of mA'F is 
a rather less certain area. However as discussed above, there is good reason to believe that 
mA'F was quantified with a reasonable degree of accuracy and that the decline in mA'F was 
largely due to the induction of the MPTP.
Assuming therefore that the results described were an accurate reflection of events in vitro, the 
conditions produced by the application of the simulated ischaemia solution followed by 
simulated reperfusion in culture media must have been at odds with true conditions in vivo. 
Incubation of the cardiomyocytes in the ischaemic solution produced a time-dependent 
deterioration in the condition of the cells with no accompanying decline in mA'F. The fact that 
the number of cells displaying normal mA'F remained unchanged after 3 hours of simulated
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ischaemia would seem to contradict the cell viability results which showed a distinct 
deterioration over this period. However, analysis of the fluorescence of the viable cells showed 
a significant increase in the mean. This would suggest that the least viable cells were dying 
during the period of simulated ischaemia causing an overall increase in the mean 
fluorescence. This slight increase could also be due to either CsA or the conditions of the 
simulated ischaemia such as low pH preventing physiological pore opening and therefore 
increasing the mean mA'F. These results correlate both with the cell viability data, which 
suggest that some cell death was taking place and with the established knowledge that the 
MPTP does not open during ischaemia. In addition to this, there was also significant 
suppression of ATP production and very little generation of hydroxyl radicals or hydrogen 
peroxide (H2O2) as expected.
So according to the parameters measured, incubation in the ischaemic solution produced 
results that were entirely consistent with current knowledge relating to ischaemia.
In contrast, the simulated reperfusion phase produced rather different results. Simulated 
reperfusion caused only a slight initial decrease in cell viability and no immediate decline of 
mA'F was observed. Induction of the MPTP would be expected to cause rapid cellular death 
partly due to an inability to generate ATP. Yet a consistent significant decrease in both was 
only seen after 20 hours of simulated reperfusion and production of ATP recovered 
significantly and remained surprisingly intact suggesting that the cells were dying gradually 
over an extended period of time. This could not have been due to the primary cardiomyocytes 
reaching the end of their natural lifespan since the control cells remained viable and analysis 
took place on the fourth day after initial plating whereas untreated cardiomyocytes often 
continued to beat vigorously for 6 days or more. Additionally, whilst application of CsA 
effectively inhibited the decline of mA'F, it had no influence over cell death. Taken together,
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these results would imply that the MPTP did not play a significant role in this model of 
ischaemia-reperfusion injury and opened only as a consequence of the death of the primary 
cardiomyocytes.
Therefore, it could reasonably be concluded that this model did not accurately replicate the 
conditions present during in vivo ischaemia-reperfusion injury that lead to induction of the 
MPTP. At present, the conditions that lead to opening of the MPTP are believed to include 
high matrix Ca2+ concentration, accumulation of free radicals, depleted ATP and accumulation 
of inorganic phosphates. In addition the inhibitory effect of the low pH present during 
ischaemia is removed, further encouraging MPTP induction.
The solution developed by Esumi and colleagues is designed to simulate the extracellular 
environment of myocardial ischaemia (217). It was extremely successful in the severe 
suppression of ATP production during simulated ischaemia, which also strongly implies the 
presence of an excess of inorganic phosphates in the mitochondria. These unfortunately could 
not be accurately measured due to the huge number of cardiomyocyte mitochondria required 
to gain an accurate reading in a standard assay. Incubation of primary cardiomyocytes in the 
ischaemic solution also resulted in significant generation of free radicals.
The only conditions that remain entirely unknown are the Ca2+ concentration in the 
mitochondrial matrix, and the intracellular pH. These parameters are dependent upon the 
Na+/Ca2+ antiporter and the Ca2+ ATPase, and the Na+/H+ antiporter respectively. It is therefore 
possible that a component of either the ischaemia solution or the maintenance media 
interfered with the normal functioning of one of these. Alternatively the Na+ concentration of the 
ischaemic solution may have been incorrect, especially in view of the fact that it incorporated 
sodium dithionite in place of the KCN of the original solution.
The pattern of cell injury over time does provide a clue to the nature of the injury. When 
cardiomyocytes were subjected to only 1 hr of treatment with the ischaemic solution, metabolic
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activity as measured by the conversion of MTT reagent did not show a significant decrease. 
However when the cells were subsequently incubated in full media for 24hr, the same pattern 
of cell death was observed as occurred following longer periods of simulated ischaemia. This 
could imply that elements of the ischaemic solution remained inside the cells causing a gradual 
and irreversible loss of viability, or were metabolised into a more damaging form. As the 
majority of the solution is based on Krebs buffer and consists purely of salts, the most likely 
candidates are the 2-deoxyglucose, the sodium lactate and the sodium dithionite.
Slight allowances must be made for the fact that these experiments were performed on 
neonatal primary cardiomyocytes whereas Esumi and colleagues were studying 
cardiomyocytes isolated from adult rats. As mentioned previously, the age of the animals used 
can have a major influence on the results obtained.
A number of other in vitro simulations of ischaemia have been inflicted upon isolated 
cardiomyocytes with a varying range of effects (133,239,241). Ideally some of these other 
simulations would have been applied to the neonatal primary cardiomyocytes. Unfortunately 
however, this was not feasible within the scale of this project.
Finally, it must be stressed that no in vitro simulation, regardless of how well researched can 
hope to be completely accurate. Although these simulations are very useful research tools that 
can substantially reduce the amount of necessary animal experimentation, they can never 
completely substitute for in vivo protocols.
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8.1.4 Use of staurosporine as an inducer of apoptosis
During the period in which the model of apoptosis in primary cardiomyocytes was set up, 
chemical induction was the most common method of initiating apoptosis. Frequently published 
examples included chemotherapeutic agents such as daunomycin and doxorubicin (36,261- 
263), nitric oxide (264,265) and staurosporine (SSP) (35,39,266). Two other methods of 
induction that were also employed were oxidative stress (29,267) and Fas ligand (14,268, 
269). Of these, oxidative stress was an inappropriate method for a study in which free radical 
activity was to be measured, but induction of apoptosis using anti-Fas antibody was briefly 
attempted. Although it reputedly induced the ‘mitochondrial’ pathway of apoptosis signalling, 
anti-Fas antibody application had no effect on the neonatal primary cardiomyocytes (data not 
shown). In fact, several recent publications seem to confirm that cardiac myocytes are resistant 
to Fas induced apoptosis and require a co-stimulant (270-272).
Of the chemical inducers of apoptosis that were available and appeared to successfully induce 
apoptosis in primary cardiomyocytes, SSP was selected for the following reasons.
Firstly, SSP was considered to induce ‘true’ apoptosis as it produced the generally accepted 
morphological features (43,273), with these changes occurring in a sequence typical for 
apoptosis (274). Additionally, the process usually required the involvement of the Ced-3/ICE 
family of proteins, now commonly known as caspases and considered to be one of the main 
hallmarks of apoptosis (39,275). A second advantage of the use of SSP was the fact that it 
was known to induce apoptosis in a number of cell types without the need for any protein 
synthesis (233), showing that it acted through a pathway involving proteins that were 
constitutively expressed in most types of cell. SSP is a broad-spectrum inhibitor of protein 
kinases and it is generally assumed that this inhibitory affect that gives SSP its ability to induce 
apoptosis. However, no study has as yet demonstrated this and it may not necessarily be the 
case as a detailed study of another protein kinase inhibitor, chelerythrine, showed that it
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induced apoptosis in primary cardiomyocytes through the generation of reactive oxygen 
species (276). Although some anucleate cells appear resistant to SSP induced apoptosis, 
experiments in cell free systems have shown that a component in the cytoplasm is essential for 
the induction of DNA fragmentation by SSP (43). This demonstrates that SSP could act upon a 
number of intracellular proteins in order to induce apoptosis. Finally, SSP had already been 
successfully utilised for the induction of apoptosis in primary cardiomyocytes (35,266) 
including those derived from neonatal rats (39) and the combination of these points made it a 
seemingly reliable option.
In more recent papers, serum deprivation appears to be the most frequently published method 
of apoptosis induction in a wide variety of cells (267,277-279) including cardiomyocytes (280, 
281). However, as nutrient deprivation is also a feature of ischaemia (40) it was not considered 
suitable for this project, where three separate and distinct models of cell death were sought. 
Currently, the accumulated evidence would suggest that apoptosis during ischaemia- 
reperfusion injury occurs mainly on the fringes of the affected area and its most important role 
may be during the remodelling that can transpire following the event. Whether apoptosis 
occurs via the ‘death receptor1 or the ‘mitochondrial’ pathway in these situations is as yet 
unknown.
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8.2 Overview and hypothesis
Cardiac disease, especially myocardial infarction, is one of the leading causes of human 
mortality in Western society. Ischaemia-reperfusion injury, which can result from myocardial 
infarction, is an important and extremely complex type of injury in solid tissues. Necrosis and 
potentially also apoptosis have an important role in ischaemia-reperfusion injury and induction 
of the MPTP has been observed during reperfusion as well as cited as a major factor in both 
forms of cell death.
Various aspects of the MPTP have been studied in many different in vitro models of cell death 
and, sparsely, in isolated perfused organs. This project aimed to bring together varying strands 
of research in the context of isolated primary cardiomyocytes, which arguably offer a more 
genuine insight than established cell lines. An additional aim was to attempt to reproduce 
some of the protocols in an in vivo model of ischaemia-reperfusion injury.
The focus of the project was the molecular chaperone protein cyclophilin D (CyPD) that has 
frequently been implicated in induction of the MPTP. The purpose of the project was to 
examine the importance of CyPD to MPTP induction in a variety of situations and to study the 
implications.
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8.3 General Discussion
Three models of cell death were set up in neonatal primary cardiomyocytes. Necrotic cell death 
was caused by both application of t-butyl hydroperoxide (t-BOOH) and subjection to simulated 
ischaemia-reperfusion injury and was measured by conventional, frequently used assays. 
Measurement of apoptotic cell death (induced using the established initiator SSP) is a more 
controversial area and was therefore analysed by a range of methods designed to assess 
different aspects of apoptosis. As pathological apoptosis can manifest itself in various forms, 
presumably according to the amount of intracellular energy available, measuring only one 
parameter can potentially produce unreliable results. Therefore the multi-stranded approach 
utilised was considered more suitable than a single method such as, for example, staining the 
condensed chromatin of apoptotic cells with Hoechst 33342.
In order to fully study the role of the MPTP and CyPD in cell death, the effects of 2 different 
inhibitors of the MPTP were studied. BA is a specific inhibitor of the adenine nucleotide 
translocase (ANT) that is not known to affect CyPD and was used as an aid to establishing the 
importance of the MPTP in each model. CsA is a well-characterised inhibitor of CyPD that was 
used to help establish both the importance of the MPTP and the role of CyPD in cardiomyocyte 
cell death. BA proved to give variable results and adversely affected cell viability in the models 
of necrosis and simulated ischaemia-reperfusion injury so reliable results were only obtained 
for apoptosis. It must be noted at this point that BA binding to ANT inevitably effects the 
movement of adenosine nucleotides in the cell. However, at the concentrations used it had no 
detectable influence on cellular metabolism in control cardiomyocytes. CsA showed no 
adverse affect on viability but was only able to inhibit t-BOOH induced necrotic cell death. An 
obvious explanation for this would be that the MPTP was induced only in the model of necrotic 
cell death. However when mA'F was measured, all models showed a marked decrease, which
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moreover was significantly inhibited by CsA. BA also successfully inhibited the decline in mA'F 
when tested in the model of apoptosis. This then would suggest either that blocking induction 
of the MPTP had an inhibitory effect on cell viability that was short-lived and easily overcome, 
or that induction of the MPTP was not a crucial event in these processes of cell death. In the 
case of apoptosis, loss of DNA fragments was seen earlier in the process than any decrease in 
mA'F. As DNA fragmentation is known to be one of the endpoints of apoptosis, it follows that 
induction of MPTP and the corresponding loss of mA'F is likely to be a consequence of cell 
death as opposed to a part of the active process of SSP-induced apoptosis. This is also 
supported by the fact that mA'F in the viable cell population remained high throughout the 
experiment. Therefore, application of CsA or any other inhibitor of the MPTP would be unable 
to aid cell survival. It must be stressed that many different versions of the process of apoptosis 
have been published and the relative importance of the MPTP may vary according to the 
inducer of apoptosis and the cell type. However, this does effectively demonstrate the 
complexity of the process and the problems inherent in finding an effective method of inhibition 
that would cover a wide range of situations.
In the model of necrotic cell death, CsA successfully inhibited both the decline in mA'F and the 
onset of cell death. The fact that CsA inhibition of cell death was only very partial is probably 
due to the extreme severity of the insult, suggesting that other factors beside MPTP induction 
were contributing to cell death. These results show that induction of the MPTP is an important 
event in this model of rapid necrosis due to severe oxidative stress and that CyPD may play an 
important role.
Cardiomyocyte death due to simulated ischaemia-reperfusion injury was completely unaffected 
by CsA application despite the fact that significant inhibition of the MPTP was observed. This 
result is contrary to other published studies including the results obtained by Griffiths and
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colleagues in isolated, perfused hearts (136) and may therefore suggest that the cellular model 
used in this project is not altogether accurate. This supposition is supported by the fact that 
mA*? remained high for several hours following simulated reperfusion whereas other groups 
have shown that induction of the MPTP occurs almost immediately upon reperfusion.
The majority of the direct evidence in the scientific literature for the importance of MPTP 
induction is provided by studies of inhibitors such as CsA and BA. This data must be treated 
with a certain amount of caution since these chemicals are known to have other effects in the 
cell. CsA is extremely toxic at higher concentrations and has been shown to induce apoptosis 
in a variety of cell types (212-214,235). It also has a multitude of other functions such as 
stimulation of tumour growth factor (TGF)-p production (282) and inhibition of the other 
members of the CyP family resulting in the well-characterised suppression of the immune 
response via calcineurin binding. In cardiac cells, this pathway is known to influence the 
cellular growth response. Although the potential role of CsA in this response is controversial 
and unclear, there is a distinct possibility that its application to cardiac myocytes could 
influence cell death, especially apoptosis, via interaction with calcineurin. In this study, 
inhibition of the MPTP was confirmed by confocal microscopy but other effects in the cell were 
not completely accounted for. Although CsA was not detectably toxic in the control 
cardiomyocytes, there is a possibility that its presence could have exacerbated cell death in 
any of the models used. One possible means of testing this could be the application of FK506, 
which is known to inhibit calcineurin by binding to FK-binding proteins, without affecting the 
MPTP. As it acts on the calcineurin pathway in much the same way as CsA it should, in theory, 
replicate any influence of CsA on cell death that is unrelated to the MPTP.
BA is less well studied but, in particular, allowances must be made for its effect on cell
-224-
metabolism through its ability to inhibit the activity of the ANT. The data in this project strongly 
suggests that it could have an uncertain effect on cell viability in some situations. As BA was 
used in extremely small volumes (less than 5jxl/ml) at concentrations that were shown to be 
completely non-toxic in control primary cardiomyocytes and did not appear to inhibit metabolic 
activity, it is presumed that BA was either influencing some other aspect of necrosis or 
attaining toxicity through interaction with t-BOOH and the ischaemic solution. It cannot then be 
stated with absolute confidence that the beneficial action of these inhibitors is due entirely to 
their effect on the MPTP. However since 2 such different MPTP inhibiting chemicals as CsA 
and BA can reduce cell death in such a wide variety of situations as are to be found in the 
literature as well as in this study, the importance of the MPTP is a near certainty.
In all the situations studied in this project CsA inhibition of mAvF was consistently observed, 
strongly implicating the involvement of CyPD. Analysis of CyPD activity and expression 
showed that both remained unaffected by cell death. However application of CsA resulted in a 
significant inhibition of CyPD peptidyl prolyl cis-trans-isomerase (PPI-ase) activity in correlation 
with CsA inhibition of mAvF. This would imply that the site of PPI-ase activity in CyPD is 
important for binding to the MPTP and influencing its induction despite that fact the onset of 
cell death did not result in any change in activity. The PPI-ase activity of the cyclophilin family 
has been shown to be essential for protein folding and it has been suggested that CyPD may 
induce a conformational change in ANT that sensitises it to the action of Ca2+ thus allowing 
induction of the MPTP (157). It is quite possible that no increase in PPI-ase activity is 
necessary for the implementation of this scenario or that the change in activity is too small or 
short lived to be detectable by this particular assay. Alternatively, it may be that the effect of 
CsA binding to the CyPD PPI-ase active site is to either inhibit its binding to ANT or to create a 
physical barrier obstructing the ANT Ca2+ binding site and PPI-ase activity is not necessary for
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MPTP induction.
In all models of cell death studied, it was found that CsA was binding to CyPD and resulting in 
inhibition of the MPTP. Despite this no inhibition of apoptosis or simulated ischaemia- 
reperfusion injury could be seen, and only a slight inhibition of necrosis was observed.
However, cell death is an extreme endpoint and therefore a rather crude indicator, so it was 
undertaken to measure other vital parameters that would precede and possibly be exclusive of, 
cell death. These experiments were also designed to provide an insight into the events 
surrounding MPTP induction in these models of cell death.
CsA proved unable to influence the generation of free radicals noted during necrosis and 
simulated ischaemia-reperfusion injury. These results are consistent with the theory that 
generation of free radicals in cardiomyocytes is initiated during ischaemia and will therefore 
remain unaffected by inhibition of MPTP induction during reperfusion. The fact that significant 
generation of free radicals was observed shows that there are potentially many important 
parameters of ischaemia-reperfusion injury that are independent of MPTP induction and 
therefore cannot be influenced by MPTP inhibition.
ATP production was significantly reduced during apoptosis and necrosis, but CsA was only 
able to affect the reduction observed during necrosis. As a high mA'F is known to be crucial 
for the production of ATP, these results are consistent with the probability that MPTP induction 
is an important element of t-BOOH initiated necrosis but only a consequence of SPP-induced 
apoptosis. ATP production was severely depressed during simulated ischaemia, but after 20hr 
of simulated reperfusion it had significantly recovered. Neither result was significantly affected 
by the application of CsA. Suppression of ATP production during simulated ischaemia was
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expected but such significant recovery after 20hr of simulated reperfusion is inconsistent with 
the drop in mA1?. This again suggests that MPTP was a late consequence of cell death and is 
most likely to be due to inaccuracies in the in vitro model of ischaemia-reperfusion injury as 
previously discussed.
In this project complete inhibition of the MPTP by either CsA or BA was never observed. It may 
be that the concentrations required for complete inhibition were toxic to the cardiomyocytes, or 
it may imply that MPTP induction was occurring despite the presence of the inhibitors. The 
precise manner by which the MPTP is formed is unknown as ANT individually displays pore­
like properties and other components of the pore remain disputed. If CsA acts to prevent CyPD 
binding, then the drop in m A^ that was independent of CsA or BA inhibition could have been 
due to the action of ANT alone. If, as has been proposed CyPD interacts physiologically with 
ANT (160,161), then logically not all CyPD binding could be prevented by CsA meaning some 
permeability will inevitably result. Alternatively, if CsA can interact with CyPD that is already 
bound to ANT providing mainly a physical block as has also been suggested (159), then this 
could also account for the partial inhibition observed.
It should be noted that, had complete inhibition of the MPTP been attained, this could have 
influenced other parameters, most notably the decline in ATP production where a positive 
inhibition could possibly have resulted.
The inability of CsA to attenuate to injury to primary cardiomyocytes during simulated 
reperfusion following simulated ischaemia disagrees with previous findings including those of 
Griffiths and colleagues in isolated perfused hearts (136). As previously stated, this is most 
likely to be due to failings of the in vitro model of ischaemia-reperfusion injury. However, even 
results obtained from isolated, perfused hearts cannot be as reliable as an equivalent study in
-227 -
vivo due to the extra stresses placed on a heart during isolation and the possibility of a lacking 
vital ingredient contained in circulating blood or surrounding tissue.
For that reason, the mA'F and CyPD expression and activity were analysed in rat hearts 
subjected to ischaemia-reperfusion injury whilst remaining in situ. The lack of any detectable 
change in CyPD activity or expression was consistent with the results obtained in isolated 
primary cardiomyocytes. However, analysis of mA'F showed a striking albeit non-significant 
decline in mitochondria isolated from reperfused hearts. Even in this situation mA'F 
measurements are undoubtedly influenced by the removal and isolation of the mitochondria. 
However, any deterioration will be consistent between the treatment groups and this method 
provides the means to keep the heart in its natural setting during the ischaemia and 
reperfusion. These initial measurements of mA'F although inconclusive broadly correlate both 
with the data obtained from the primary cardiomyocytes and with the published studies of other 
groups. As measurement of mA'F is acceptable by many as a means of studying MPTP 
induction, this method is well worth pursuing. In particular, analysing the effect of CsA could, 
firstly provide additional evidence that any observable decrease in mA'F is caused by the 
opening of the MPTP and secondly, give further information concerning the importance of 
CyPD in ischaemia-reperfusion injury.
In addition to this, the influence of CsA on parameters of cardiac function such as electrical 
activity and left ventricular blood pressure could be measured by standard techniques. Along 
with analysis of the ATP content of isolated mitochondria by a modification of the luciferase 
assay used in this project, or tissue ATP content by HPLC (high performance liquid 
chromatography) procedures, this would give a more complete picture of the functioning of the 
MPTP during ischaemia-reperfusion injury and the role of CyPD.
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8.4 Conclusions and future directions
Pathological induction of the MPTP has attracted a great deal of attention and funding over 
recent years. It is important to note that physiological induction of the MPTP has been 
demonstrated (127) but the cumulative evidence strongly suggests that induction of the MPTP 
is almost certainly an important pathological event.
Although many groups have pointed to evidence of apoptosis during ischaemia-reperfusion 
injury, necrotic cell death is still regarded as the predominant feature. The potential importance 
of the MPTP in reperfusion provoked necrosis is evidenced by the observation that 
mitochondrial swelling is one of the earliest changes seen in necrosis including that caused by 
reperfusion, whereas in apoptosis mitochondrial morphology remains unchanged (283).
As evidenced in this project, the MPTP may often be induced as a consequence of irreversible 
cell death. This highlights the fact that inhibition of the MPTP may not necessarily be beneficial 
even if induction is observed. Even where MPTP induction is an important occurrence there 
are ischaemic events such as generation of free radicals outside of the influence of the MPTP 
that could ultimately result in the death of the cell.
Although the influence of the MPTP was variable, the results of this project showed that CsA 
significantly inhibited induction of the MPTP in a wide variety of circumstances. This strongly 
supports the hypothesis that CyPD plays a vital role in the formation of the MPTP and is 
therefore of great significance in any situation where the MPTP is pathologically induced. It is 
thought that given severe enough conditions, especially in a situation of extremely high Ca2+, 
the MPTP will be induced irrespective of the action of CyPD (187-189). However under such 
circumstances, it is likely that irreversible cell death would occur regardless of MPTP induction.
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Ischaemia-reperfusion injury is a large and burgeoning field with a huge number of different 
focuses of study. Besides induction of the MPTP, numerous other intracellular events occur 
during ischaemia-reperfusion injury including activation of MAPK pathways (284), generation of 
free radicals (109,249,285) and movement of inorganic ions to mention but a few. The fact 
that injury has been attenuated by inhibitors as varied as Mg2+ (286), pyruvate (287), caspase 
inhibitors (38), the vitamin E analogue Trolox (288), the phytoestrogen genistein (289) and the 
gap junction uncoupler heptanol (290) demonstrates the huge complexity of interacting 
pathways occurring in ischaemic and reperfused cells. Some of these such as the generation 
of free radicals can in fact contribute to MPTP induction, an occurrence that is exacerbated by 
the inhibition of free radical scavengers such as SOD and catalase during ischaemia. This 
highlights the fact that there may be many effective methods of protecting patients from 
ischaemia-reperfusion injury. The remedies that eventually come into use may be determined 
more by ease of use, expense and marketing rather than purely by scientific and clinical merit. 
However, ischaemia-reperfusion injury occurs with varying severity according to factors such 
as the length of the ischaemic period and the general health of the affected tissue. In many 
instances the damage is irreversible regardless of drug interventions, in other cases rapid and 
appropriate treatment could save the life of a patient. In a situation of life-threatening cardiac 
ischaemia-reperfusion injury, inhibition of the MPTP is arguably the most important factor to 
attempt to control since without adequate production of ATP the cell would almost certainly die 
even if many other detrimental events were successfully contained.
In this scenario, the inhibition of CyPD has a distinct advantage. CsA is an extremely well 
characterised drug that is already widely used for immuno-suppression so the toxicity and side 
effects are well known. In the context of cardiac ischaemia-reperfusion injury, its influence 
could be tested during for example, bypass operations by measuring CK-MB in the blood of 
control and treated groups. This would be extremely straightforward, non-invasive and
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inexpensive and could eventually greatly ease one of the major dangers associated with heart 
surgery. In the case of myocardial infarctions, the majority of these are precipitated by 
thrombosis and patients are treated with fibrinolytic drugs to allow reperfusion to the affected 
area. CsA could be administered in combination with these drugs to prevent the reperfusion 
injury that can be potentially more serious than the infarction itself. In addition, there are 
analogues of CsA such as A/-methylVal-4-cyclosporin that bind CyPD and inhibit the MPTP 
without also causing immuno-suppression. In a patient undergoing and recovering from major 
surgery, this would be an important consideration. Although such analogues are not yet as well 
characterised as CsA, they may have potential for the attenuation of ischaemia-reperfusion 
injury without some of the side effects associated with CsA.
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